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1
INTRODUCTION
In this thesis, we focus on management options to reduce the risk of ovarian carcinoma related to 
BRCA1/2 germline mutations. Current guidelines recommend to remove both ovaries and fallopian 
tubes during risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 years. RRSO, 
however, is known to have several adverse effects due to acute onset of premature menopause. 
The magnitude of this problem in terms of how many women face premature menopause, to what 
extent quality of life is affected, and the residual chance to develop primary peritoneal carcinoma 
were evaluated in this thesis. This resulted in the need to explore the possibility and acceptability 
of an alternative risk-reductive strategy consisting of salpingectomy with delayed oophorectomy, 
of which results are also included in this thesis.
This chapter will first introduce some background knowledge on the function of BRCA genes, the 
epidemiology of BRCA mutations and organization of healthcare for female BRCA1/2 mutation 
carriers. Second, epidemiology, classification, and carcinogenesis of ovarian carcinoma are 
discussed. Third, we describe the options for ovarian carcinoma risk reduction in BRCA1/2 mutation 
carriers and their consequences with special attention to premature menopause. Finally, we outline 
the main objectives and content of this thesis.
BRCA1/2 genes
Pathogenic germline mutations in the two breast cancer (BRCA) susceptibility genes account for the 
majority of autosomal dominant inheritance of familial breast and ovarian cancer.1 The BRCA1 gene 
was localized to chromosome 17q in the early nineties of the 20th century and the BRCA2 gene was 
identified at chromosome 13q a couple of years later.2,3 Both genes are tumor suppressor genes 
and the proteins produced by these genes play a role in an error-free DNA damage repair pathway; 
more specifically, in the repair of double-stranded breaks through homologous recombination.4 
Thereby, functional BRCA1/2 genes help preserving the genomic integrity of the cell.4 BRCA1/2 
mutation carriers are heterozygous for the mutated gene and a second hit to the unaffected allele 
is mostly responsible for the eventual loss of BRCA1/2 functions. By this ‘loss of heterozygosity’, 
the cell is thrown back on other DNA repair mechanisms that are often more sensitive to errors. 
Consequently, cells with unrepaired DNA damage are prone to transform into cancer cells.
Prevalence of BRCA1/2 germline mutations varies from 0.2% to 0.3% in general populations to 2% 
among Ashkenazi Jewish people and 20% in high-risk families.5 Women carrying a BRCA1 mutation 
have a mean cumulative risk of 54% (95% confidence interval (CI) 46-63%) of developing breast 
carcinoma and 39% (95% CI 34-44%) of developing ovarian carcinoma before the age of 70 years.6 
Corresponding mean cumulative risks for BRCA2 mutation carriers are 45% (95% CI 38-53%) and 
16% (95% CI 12-20%) for breast and ovarian carcinoma, respectively.6 However, estimated risks vary 
widely by the method of analysis. For instance, point estimates of cumulative breast cancer risk to 
age 70 years for BRCA1 mutation carriers vary from 35% to 83% and for BRCA2 mutation carriers 
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from 41 to 86% in the same population depending on statistical method.7 Nevertheless, these risks 
are considerably higher than lifetime risks of women in the general population: 12.4% for breast 
carcinoma and 1.3% for ovarian carcinoma.8,9 Furthermore, both genes have been associated with 
other cancer types as well; elevated risks of pancreatic cancer and male breast and prostate cancer 
among BRCA2 mutation carriers are most pronounced.10 
Ovarian carcinoma related to BRCA1/2 germline mutations accounts for about 10-15% of all ovarian 
carcinomas.11-13 BRCA 1-related ovarian carcinoma is mostly diagnosed at earlier age (mean 51 to 53 
years) than BRCA2-related (mean 55 to 60 years) or sporadic disease (mean 58 to 61 years).14-17 
Current Dutch national guidelines suggest referral for genetic testing of every woman diagnosed 
with ovarian carcinoma, regardless of age, histology or family history.11,18
In the Netherlands, healthcare and supporting care for BRCA1/2 mutation carriers are mainly 
centralized in multidisciplinary Family Cancer Clinics with clinical geneticists, genetic counselors, 
(plastic) surgeons, medical oncologists, gynecologic oncologists, radiologists, pathologists, 
specialized nurses, and social workers involved. In the Radboudumc, weekly multidisciplinary team 
meetings are held since the year 2000 to discuss patients and their families to improve quality of 
care. Furthermore, nurses at our department of Obstetrics and Gynecology act as case managers 
and first contact person for BRCA1/2 mutation carriers to keep healthcare easily accessible. They 
are mainly involved in supportive care after RRSO with respect to vasomotor symptoms, sexuality, 
and hormone replacement therapy. Outside the hospital setting, BRCA1/2 mutation carriers seek 
peer support in patients’ associations, patient support groups and social media forums such as 
Facebook. 
Ovarian carcinoma 
Ovarian carcinoma was diagnosed in 1266 women in the Netherlands in 2015 and was with 2.6% 
the seventh most common cancer type diagnosed in women.19 However, it is the most lethal 
gynecologic malignancy accounting for about 1000 deaths each year.20 Ovarian carcinoma is 
particularly diagnosed in advanced stage, with intra- or extra-abdominal metastases in about 
80% of cases.9 Primary treatment typically consists of staging or cytoreductive surgery with (neo)
adjuvant platinum-based chemotherapy. However, relative 5-year survival rates remain poor and 
rapidly decrease with increased stage: 92% and 29% for women with localized and metastasized 
disease, respectively.9 BRCA1/2 mutation carriers have been shown to have better overall and 
progression-free survival rates compared to non-carriers.21,22 This might be best explained by a 
favorable response to platinum-based chemotherapy.12 Besides, beneficial effects of poly(ADP)-
ribose polymerase (PARP) inhibitors for recurrent ovarian carcinoma have been reported over 
the last years: a novel treatment option targeting the defective DNA repair pathway in BRCA1/2 
mutation carriers’ tumor cells.23 This new treatment option stresses the need to find all BRCA1/2 
mutation carriers among those with ovarian carcinoma.24,25 Within the group of BRCA1/2 mutation 
carriers, a personal history of breast cancer might worsen the prognosis of subsequent ovarian 
carcinoma, especially when breast cancer was treated by (adjuvant) chemotherapy.26
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1
It is of utmost importance to notice that the definition “ovarian carcinoma” is not limited to 
carcinoma of the ovary itself, but that it is rather a collective term for carcinomas of Müllerian 
origin of the ovaries, fallopian tubes and the peritoneum. These carcinomas were taken together 
as one entity because of great similarities in morphology, prognosis and treatment. Traditionally, 
these carcinomas were subdivided based on histology: serous (about 70%), endometrioid (about 
10%), clear cell (about 12%), mucinous (about 3%), transitional (i.e. malignant Brenner tumor, about 
1%) and undifferentiated/unclassifiable.27,28 Distribution of histological subtypes among BRCA1/2 
mutation carriers does not explicitly differ from the distribution in the general population.1,15,29 
Differentiation grade used to be classified according to Silverberg.30
The updated World Health Organisation classification (2014) discriminates between high-grade 
serous, low-grade serous, endometrioid, clear cell, mucinous, and undifferentiated carcinomas.31 
Furthermore, a dichotomy between type I and type II tumors was proposed by Kurman and Shih 
in 2011 based on morphologic and molecular genetic studies with supposed different pathways 
in the carcinogenesis for either type.32 Characteristics of type I and type II tumors are described in 
the last paragraph of this subsection. Unfortunately, the suggested pathways are still “supposed” 
because the carcinogenesis of ovarian carcinoma is still not fully elucidated.
Historically, carcinomas were thought to originate from a single cell type, i.e. ovarian surface 
epithelium, whether or not after invagination of this epithelium into so-called cortical inclusion 
cysts. The incessant ovulation theory proposed by Fathalla in the 1970s describes the malignant 
deterioration of ovarian surface epithelium that has become vulnerable through the repeated 
process of damage and repair during every ovulation.33 This theory is supported by the fact that 
high parity and the use of oral contraceptives (i.e. lower number of lifetime ovulations) are well-
established risk-reducing factors. However, early ovarian carcinomas or in situ lesions have been 
rarely identified in the ovarian surface epithelium.34,35 A second tissue type that was put forward 
as site of origin of ovarian carcinoma is the “secondary Müllerian system” that consists of the pelvic 
and lower abdominal mesothelium and the subjacent mesenchyma arising from the embryonic 
coelomic lining in close relation to Müllerian epithelium. It was supposed to have the ability to 
differentiate into Müllerian-type epithelium through a process that is called metaplasia.36  
More recently, the tubal-peritoneal junction and the fimbriated end of the fallopian tubes were 
proposed as origin of ovarian carcinoma, mainly of the serous subtype.37 The latter was first 
described by Piek et al.38 after the detection of dysplastic changes in the fimbriated ends of 
fallopian tubes that were removed during risk-reducing salpingo-oophorectomies in BRCA1/2 
mutation carriers. Many other study groups have focused on this particular site since then, and 
a potential cascade of p53-signatures, serous tubal intraepithelial lesions (STIL) and serous tubal 
intraepithelial carcinomas (STIC) has been suggested as the carcinogenic pathway of tubo-ovarian 
serous carcinoma (Figure 1).37,39 Nevertheless, tubal involvement including STIC is not found in all 
cases of serous carcinoma and although clonal relationships between STICs and concurrent high-
grade serous carcinomas have been identified in the vast majority of cases, it is still disputable 
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whether the STIC is a metastasis of the concurrent carcinoma rather than the primary occurrence.37 
The same train of thought of ovarian surface epithelium invaginated into cortical inclusion cysts 
applies to STIC cells that can exfoliate, be shed from the fallopian tube and nest at the ovarian 
surface, be entrapped in cortical inclusions cysts or nest at the peritoneum. 
All together, the idea that all ovarian carcinomas are derived from the same cell has been left 
and the dualistic model with classification into type I and type II tumors has been more and 
more adopted.32,40 Type I tumors are low-grade serous, endometrioid, clear cell, and mucinous 
carcinomas, are more often diagnosed in early stage and have a more favorable prognosis than type 
II tumors. Potential precursor lesions for type I tumors are endometriosis and borderline tumors. 
Although relatively genetically stable, the following genes are often mutated in these tumors: 
KRAS, BRAF, PTEN, PIK3CA, CTNNB1, ARID1A, and PPP2R1A. TP53 mutations are very rare in type I 
tumors as opposed to type II tumors that almost all harbor TP53 mutations, are genetically instable, 
and behave aggressively. High-grade serous, undifferentiated carcinomas, and carcinosarcomas 
are type II tumors and most likely originating from the fallopian tube through STICs. BRCA-related 
ovarian carcinomas are almost exclusively type II.32,40
Although the fallopian tube is thus particularly associated with type II tumors, the fallopian tube 
and type I tumors can be linked as well. Low-grade serous carcinomas may arise from papillary 
tubal hyperplasia; endometrioid and clear cell carcinomas through retrograde menstruation for 
which the fallopian tubes are needed; and mucinous carcinomas may develop through Walthard 
cell nests, paratubal cysts and Brenner tumors.41
Figure 1. A schematic representation of the hypothesized carcinogenic pathway of high-grade serous 
carcinoma originating in the fallopian tube. Eventuallly, STIC cells exfoliate and implant on ovarian surface. 
Abbreviations: STIL serous tubal intraepithelial lesion; STIC serous tubal intraepithelial carcinoma. Figure 
extracted and edited from: Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a 
proposed unifying theory. Am J Surg Pathol 2010; 34(3): 433-43.79
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1
Ovarian carcinoma risk management in BRCA1/2 mutation carriers
Initially, ovarian carcinoma surveillance, consisting of annual transvaginal ultrasonography and 
measurement of serum level of the tumor marker Cancer Antigen 125 (CA125), was offered 
to BRCA1/2 mutation carriers. However, both sensitivity and positive predictive value of this 
surveillance regimen turned out to be low leading to inability to detect early-stage ovarian 
carcinoma or improve prognosis.42-44
Therefore, most international guidelines recommend RRSO to BRCA1/2 mutation carriers from the 
age of 35 years and when childbearing is completed.18,41,45,46 Some guidelines distinguish BRCA2 
from BRCA1 mutation carriers in terms of recommended age for RRSO: 40-45 years versus 35-
40 years, respectively.18,46 This distinction is based on the risk of ovarian carcinoma increasing at 
older age in BRCA2 mutation carriers: their cumulative risk to develop ovarian carcinoma before 
the age of 50 years is only nearly 1%.47 In two meta-analyses, a hazard ratio of about 0.20 was 
calculated for ovarian carcinoma after RRSO, corresponding with 80% risk reduction.48,49 The best 
effect ever reported is 96% risk reduction.50 In other words, a residual risk of developing primary 
peritoneal carcinoma exists but widely varies in literature. This might be due to differences in 
follow-up time and mean age at RRSO and whether total salpingo-oophorectomy was performed 
or oophorectomy alone. In the 20 years following RRSO, the risk of primary peritoneal carcinomas 
is estimated about 3.9% for BRCA1 mutation carriers and 1.9% for BRCA2 mutation carriers.51 The 
origin, carcinogenesis, and characteristics of primary peritoneal carcinoma occurring after RRSO 
are still unclear. RRSO may also effect mortality: a 77% risk reduction in all-cause mortality to age 70 
after RRSO was calculated among BRCA1/2 mutation carriers without a previous cancer diagnosis 
at the time of RRSO.51 RRSO is mostly performed by a laparoscopic procedure and can be done in 
an outpatient setting. Serious surgical complications occur in only 1-2%.1,52-55 
The protocol for Sectioning and Extensively Examining the FIMbriated end (SEE-FIM) was introduced 
in 2006 in reaction to the detection of dysplastic cells in the fallopian tubes of RRSO specimens 
in 200138 and the subsequent attention that was increasingly paid to the fallopian tubes as the 
potential site of origin of most ovarian carcinomas.56 In this SEE-FIM protocol, the fallopian tube is 
entirely embedded and examined. Fimbriated ends are sectioned in longitudinal direction and the 
remainder of the fallopian tube is sectioned at 2- to 3-millimeter intervals. In RRSO specimens of 
BRCA1/2 mutation carriers, occult ovarian carcinomas are detected in approximately 2% to 9% and 
STIC without an invasive component in about 0 to 7% in recent studies where the SEE-FIM protocol 
was applied in most cases. Incidence of both occult carcinoma and STIC increases with age.51,54,57-64 
Premature menopause
Although RRSO at the currently recommended age is very effective in reducing the risk of 
developing ovarian carcinoma, acute onset of surgical premature menopause occurs after removal 
of the ovaries. This sudden estrogen deficiency is responsible for several short-term as well as long-
term health consequences on both physical and psychological domains that can significantly 
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affect quality of life. However, to what extent quality of life is affected and whether it concerns a 
temporary or permanent effect has not been crystallized. 
Vasomotor symptoms (i.e. hot flashes, night sweats), sleep disturbances, vaginal dryness, sexual 
dysfunction and mood swings are examples of short-term effects.1,65 Probably the most important 
long-term consequence is the 1.50 (95% CI 1.28-1.76) times increased risk of coronary heart 
disease, 1.19 (95% CI 1.08-1.31) times increase of cardiovascular mortality and 1.12 (95% CI 1.03-
1.21) times of all-cause mortality for women from the general population who enter menopause 
before the age of 45 years compared to women older than 45 years.66 In another study, the hazard 
ratio of developing ischemic heart disease was 8.7 (95% CI 2.0-38.1) in women who underwent 
bilateral oophorectomy under age 40 compared to those who underwent the same surgery 
after age 45.67 The risk of cognitive impairment has been found to be about 1.89 (95% CI 1.27-
2.83) times higher in women who were younger than 49 years at oophorectomy and did not 
receive hormone replacement therapy (HRT).68 Furthermore, increased risks of parkinsonism and 
depressive and anxiety symptoms have been reported.68,69 Lastly, studies on osteoporosis and 
fracture risk are contradictive: some described higher rates of osteoporosis after premenopausal 
RRSO,70 whereas others reported bone mineral density and fracture incidence comparable to an 
age-matched reference population.71 A third study reported a clear bone loss within 18 months 
after surgical menopause but lacked a control group.72 It must be taken into account that these 
studies were mostly not performed in the BRCA carrier population specifically, but mainly in the 
general population. More studies are needed to further elucidate long-term effects of RRSO in 
BRCA1/2 mutation carriers.
HRT is recommended between RRSO and the age of 48-50 years to alleviate climacteric symptoms 
and prevent long-term consequences, unless HRT is contra-indicated because of a personal history 
of breast cancer or thrombo-embolic events, for example. HRT partially relieves short-term effects 
of premature menopause.73-75 Evidence for the effect of HRT on long-term consequences is sparse, 
but it appears beneficial for most of them.67,68,71 Although HRT might affect breast cancer incidence 
in this high-risk population, current evidence suggests no adverse effect on oncologic outcomes 
in BRCA1/2 mutation carriers without previous breast cancer under the condition that its use is 
temporary and discontinued at the age of natural menopause.76
Non-hormonal treatments for menopausal symptoms consist of selective serotonin reuptake 
inhibitors (SSRI) and alpha-2 adnergic agonists like clonidine. Body-mind interventions like 
cognitive-behavioral therapy and mindfulness-based stress reduction have also been shown to 
reduce the bother of vasomotor symptoms.77,78 Furthermore, alternative medicine therapies exist 
but hardly any research data considering their effectiveness have been published.78
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1
AIM AND OUTLINE OF THIS THESIS 
As outlined in the first part of this chapter, two trends have been observed that are relevant 
to ovarian carcinoma risk management in BRCA1/2 mutation carriers. First, an important role 
in the development of most, mainly serous, ovarian carcinomas is attributed to the fallopian 
tubes. Second, evidence is growing on long-term health consequences of premature surgical 
menopause that may affect quality of life. The combination of those trends led to the proposal 
of an alternative to RRSO: risk-reducing salpingectomy (RRS) upon completion of childbearing 
with second-stage oophorectomy delayed beyond the currently recommended age for RRSO. This 
alternative strategy allows women to retain their ovaries towards the onset of natural menopause 
and therefore, it might improve their (menopause-related) quality of life. Removal of the fallopian 
tubes might take place before the currently recommended age for RRSO, depending on family 
planning, which might prevent (pre)malignant lesions from developing in the fallopian tubes. 
However, the risk of ovarian carcinoma under this alternative strategy is unknown. Besides, we do 
not know whether the alternative strategy will be accepted by both BRCA1/2 mutation carriers and 
healthcare providers. An optimally designed clinical trial is needed to point out efficacy and safety 
of such a strategy.  
Main objectives
- To evaluate the magnitude of adverse quality of life effects after RRSO 
- To gain insight into the number of BRCA1/2 mutation carriers that might face premature 
menopause due to RRSO in our region
- To explore the possibility of a risk-reducing strategy alternative to RRSO among both 
BRCA1/2 mutation carriers and professionals: salpingectomy upon completion of 
childbearing with delayed oophorectomy 
- To estimate the effect of the alternative strategy in terms of ovarian carcinoma risks 
- To optimally design a clinical trial comparing salpingectomy with delayed oophorectomy 
with standard RRSO
- To support BRCA1/2 mutation carriers who face the choice between salpingectomy with 
delayed oophorectomy and RRSO
- To evaluate clinical and pathological characteristics of peritoneal carcinomatosis 
occurring after RRSO in BRCA1/2 mutation carriers
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Thesis outline
In chapter 2, we review the literature on quality of life of unaffected BRCA1/2 mutation carriers 
and how quality of life is influenced by medical choices made regarding cancer risk management.
In chapter 3, we evaluated the number of women who undergo RRSO and at what age they 
undergo this surgery to get a better perception of how many BRCA1/2 mutation carriers face the 
consequences of RRSO performed before natural menopause at our institution. 
Because RRSO is known to prevent most but not all ovarian carcinomas, we collected international 
data on BRCA1/2 mutation carriers with ovarian carcinoma (peritoneal carcinomatosis) diagnosed 
several months or years after RRSO and described them in chapter 4.
We invited both BRCA1/2 mutation carriers and healthcare professionals to discuss the hypothesis 
of the fallopian tube as central player in ovarian carcinogenesis en how to embed these new 
insights into risk-reducing interventions. We presented them with the alternative risk-reducing 
strategy consisting of RRS with delayed oophorectomy and explored barriers and facilitators for 
the acceptance of this alternative strategy and a trial on this topic in chapter 5. The opinions of 
both BRCA1/2 mutation carriers and healthcare providers in the field are qualitatively studied in 
this chapter.
Since RRS with delayed oophorectomy has not been clinically studied yet, no data exist on its 
effect on the risk of ovarian carcinoma. However, an estimation of this risk is needed to properly 
counsel patients who consider this alternative strategy. These estimates are given in chapter 6 for 
BRCA1 and BRCA2 mutation carriers separately. We modeled the risk of ovarian carcinoma for the 
alternative strategy at various ages and compared this risk to RRSO using input parameters from 
literature. We estimated risks for best- and worst-case scenarios.
Chapter 7 presents the study protocol for a nationwide preference trial in which the alternative 
strategy of RRS with delayed oophorectomy will be compared to standard RRSO in premenopausal 
BRCA1/2 mutation carriers: the TUBA study. Primary outcome parameter is menopause-related 
quality of life. Healthcare providers are strongly discouraged to randomly perform RRS without 
close follow-up of its effectiveness and safety.
The development of a patient decision aid is described in chapter 8. Aim of this patient decision 
aid is to facilitate the complex decision-making process that participants of the TUBA study face: 
choosing between standard RRSO and RRS with delayed oophorectomy. 
Finally, a general discussion on the most important results is provided in chapter 9. Previous 
chapters are discussed in the light of the latest literature and suggestions and implications for 
future research are made.
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ABSTRACT
Germline mutations in BRCA1 and BRCA2 genes were discovered twenty years ago. Female BRCA 
mutation carriers have an increased risk of breast and ovarian cancer at a relatively young age. 
Several choices have to be made with respect to cancer risk management, and consequences of 
these choices may affect quality of life. A review of the literature was performed to evaluate quality 
of life in unaffected BRCA mutation carriers and the influence of these medical choices. Overall, 
general quality of life appears not to be permanently affected in BRCA mutation carriers or by their 
choices. Risk-reducing salpingo-oophorectomy and its subsequent premature menopause affect 
(menopause specific) quality of life most. Hormone replacement therapy does not fully alleviate 
climacteric symptoms and therefore, there is a strong need for alternative strategies to reduce 
ovarian cancer risk and/or for improvements in postoperative care. Future research should focus 
on these needs.
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INTRODUCTION 
Germline mutations in the two breast cancer (BRCA1/2) genes account for the majority of autosomal 
dominant inheritance of familial breast and ovarian cancer.1-3 Prevalence varies from about 0.2% in 
the general population to 20% in high-risk families.4 The mean cumulative risk for breast cancer by 
age 70 is 57-65% for BRCA1 and 45-49% for BRCA2 mutation carriers, compared to approximately 
12% lifetime risk in the general population.2-4 Corresponding risks for ovarian cancer are 39% for 
BRCA1 mutation carriers and 10-18% for BRCA2 mutation carriers, whereas lifetime ovarian cancer 
risk in the general population is about 1.5%.2-4 Breast and ovarian cancer in germline BRCA mutation 
carriers generally occur at younger age than in the general population.1,5,6
Female BRCA1/2 carriers have different options to handle their elevated cancer risk. Risk-reducing 
mastectomy (RRM) with or without breast reconstruction reduces breast cancer risk by 90-100% 
although it has not been proven yet to improve survival rates compared to intensive surveillance 
using mammography, MRI and/or ultrasound.7-10 Risk-reducing salpingo-oophorectomy (RRSO) is 
very effective, reducing ovarian cancer risk by circa 80% and disease-specific mortality by 79%.11-13 
However, removal of the ovaries at the currently recommended age of around 40 years results in 
acute onset of premature menopause which has short and long-term health consequences.1,14-19 
Hormone replacement therapy (HRT) has been shown to alleviate most but not all effects of 
surgical menopause to greater or lesser extent.17,18,20 Furthermore, in a substantial part of BRCA 
mutation carriers HRT is contraindicated because of a breast cancer history.
Women are more tended to choose for RRM and/or RRSO when they are younger, have children, 
have had breast cancer, have a strong family history, and when they overestimate their cancer risk 
or have high levels of cancer-related anxiety.21-24 All risk-reducing strategies and deciding on them 
may influence levels of anxiety, psychological distress, body image, sexual functioning, and physical 
health,25 all of which are considered domains contributing to quality of life (QoL). Although universal 
definitions of QoL lack, the term is often used to describe general health status.26,27 By influencing 
the above mentioned domains, the decision making process, and undergoing interventions to 
reduce cancer risks might affect QoL. Once a BRCA mutation carrier is diagnosed with cancer, QoL 
is influenced by the diagnosis “cancer” and by its possible treatments, as is commonly described for 
(sporadic) breast cancer patients.28,29 However, the extensive field of QoL in breast cancer patients 
and survivors has been left outside the scope of this review in order to focus on unaffected BRCA 
mutation carriers. 
The aim of this review is to evaluate QoL in female BRCA1/2 mutation carriers and to find out to 
what extent it is influenced by medical decisions and interventions in cancer risk management. 
We focused on BRCA mutation carriers without a history of breast or ovarian cancer. Knowledge 
about which factors influence QoL most will be the basis for future research on interventions to 
optimize QoL. 
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METHODS 
Literature search
We searched Pubmed and the Cochrane database of systematic reviews to identify possible relevant 
studies regarding QoL in BRCA mutation carriers published between the discovery of BRCA genes 
in 1993 and the last date of search, September 15th 2014. We searched for the following keywords: 
BRCA, hereditary breast and ovarian cancer, HBOC, familial ovarian cancer, familial breast cancer, 
family ovarian cancer, family breast cancer and quality of life, QoL, health, depression, anxiety, 
emotional, social, psychosocial, psychological, distress, well being, anxiousness, cancer worry. 
Eligibility criteria for studies
We identified relevant articles by screening titles and abstracts and subsequently by reading the 
full text. We manually screened reference lists and related articles to find additional relevant papers. 
We included articles published in English or Dutch, regardless of design. As additional criteria we 
formulated that at least five BRCA mutation carriers must be part of the study population. Studies 
were excluded when results of BRCA mutation carriers were indistinguishable from carriers of 
germline mutations in other genes or when the duration of follow-up and/or the number of 
(un)affected participants were unclear.  Furthermore, studies on both male and female mutation 
carriers were excluded when data on women alone could not be extracted. To distinguish between 
the effect on quality of life of being a mutation carrier and the effect on quality of life of the genetic 
test itself and its disclosure (which is outside the scope of this review), minimal follow-up had to be 
12 months after test disclosure. This interval was based on the experience with presymptomatic 
genetic testing for Huntington’s disease: most people appear to return to baseline levels after a 
temporary increase in depression and anxiety after test disclosure.30
Data extraction and comparison
We designed data extraction tables to systematically extract study characteristics and results from 
the selected studies, i.e. sample size, participants, design and aim of the study, main reported results 
relevant to this review and notable limitations and considerations. We clustered results by different 
aspects of QoL, i.e. general QoL; psychological distress, depression, anxiety, and cancer worry; body 
image and sexual functioning. For studies including surveillance visits or surgical procedures, QoL 
after these interventions was compared to baseline. In studies without any intervention, both 
comparisons over time and between BRCA mutation carriers and the general population were 
extracted. When applicable, differences between unaffected women and those with a history of 
(breast) cancer were reported as well. 
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RESULTS 
The Pubmed search yielded 514 articles. After applying all eligibility criteria, 33 articles were left to 
review. Eight articles were about BRCA mutation carriers 12 months after genetic test disclosure; 
five about QoL during breast cancer surveillance and seven about (considering) RRM. Another ten 
articles discussed QoL after RRSO with or without the effect of HRT. At last, QoL after both RRM and 
RRSO was evaluated in three other articles. A limited number of studies including only unaffected 
female BRCA mutation carriers were available. The majority included women with a personal 
(breast) cancer history as well and women at high risk for familial breast and ovarian cancer without 
a documented BRCA mutation. Therefore, specific data on unaffected BRCA mutation carriers were 
extracted from the original report and shown in this review when possible.
Carrying a germline BRCA mutation
We identified eight articles about QoL-related items in mainly unaffected women at high risk 
for hereditary breast and ovarian cancer who were genetically tested for BRCA mutations. All 
studies were prospective and observational with baseline measurements and follow-up at several 
time points after testing31-38 or focus group participation.38 Heterogeneity existed in used QoL 
questionnaires, with the Impact of Event Scale (IES) and Hospital Anxiety and Depression Scale 
(HADS) most commonly used. Number of participants varied between 32 and 201 women. Details 
on each study are shown in table 1.
General QoL
Little is reported about general QoL. Lower QoL was found in BRCA mutation carriers whose 
mother had deceased compared to BRCA mutation carriers whose mother was still alive, with 
FACT-G scores of about 75 versus 98 respectively (p0.003).38
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Psychological distress: anxiety, depression and cancer worry
Compared to women whose genetic test was negative, BRCA mutation carriers had significantly 
more definite or severe cancer worries (10-22% vs. 2-3%) and cancer related distress (IES 5.3-16.1 
vs. 4.3-12.3 and logIES-R score 0.28 vs. 0.11) after one year,32,34,35,37 but the difference in cancer worry 
was not found at 3 and 5 years after testing.33,36 For general distress and general mental health, no 
statistically significant differences were found between carriers and non-carriers.35,36 Nevertheless, 
BRCA mutation carriers had more sleeping problems (as a domain of SCL-90: 6.5 vs. 5.2 in the 
general population and ‘less’ in non-mutation carriers)35 and higher cancer risk perception after one 
year (47% of BRCA mutation carriers vs. 3% of non-carriers perceived their breast cancer risk more 
than 50%).35 Psychological symptoms like anxiety and depression were at or below baseline levels 
after one year.32,34,37 Long-term psychological distress was predicted by baseline values, including 
more distress at baseline,33,35 having young children,33 higher perceived cancer risk,33 and cancer 
deaths in the family.33,38 Women who had higher levels of anxiety and cancer worry at baseline 
were more likely to opt for risk-reducing surgery.31
Body image and sexual functioning
BRCA mutation carriers reported lower satisfaction rates on general and breast-related body image 
after 5 years (p0.05 and p<0.001 respectively; no effect sizes available).33
Breast cancer in germline BRCA mutation carriers
Surveillance
We identified five relevant articles about the influence of surveillance for breast cancer on QoL 
or related items.39-43 There were no randomized controlled trials in literature. All studies were 
prospective, included 55 to 357 women at high risk for breast and ovarian cancer, and the absolute 
number of BRCA mutation carriers varied from 17 to 55 women. Only three studies were limited 
to unaffected women,39,40 while 3% and 58% of the participants had a personal history of breast or 
ovarian cancer in the other two.41,42 Authors used different questionnaires at different time points, 
but at least before a surveillance visit and 1 month until 5-8 years thereafter. Details on each study 
can be found in table 2.
General QoL
Rijnsburger et al.39 found significantly higher QoL scores in high-risk women under surveillance 
than in the general population on validated QoL questionnaires (SF-36 physical subscale 52.5 
versus 50.0; EQ-5D utility 0.88 versus 0.85) and these scores did not change over time. However, 
they reported significantly lower scores on the EQ-5D Visual Analogue Scale (VAS) (81.9 versus 
86.9) suggesting lower QoL than in the general population, with a temporary decrease on the day 
of visit (79.0 versus 81.9 before the visit).39 Spiegel et al. reported no differences in QoL scores in 
women who were recalled after a surveillance visit compared to women who were not.42
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Psychological distress: anxiety, depression and cancer worry
In high-risk women adhering breast cancer surveillance, no changes in distress scores41 and anxiety 
and depression scores43 over time were found by some, whereas others described significantly 
higher cancer distress before the first visit (but within normal ranges, IES 9.6 versus 7.3 thereafter)40 
and a significant decrease of general distress (IES 7.9 to 6.8 and 7.3 to 6.6)40 after surveillance visits.
Recall visits after abnormal MRI results significantly increased levels of anxiety at 4-6 weeks after 
MRI compared to baseline (from HADS-Anxiety 7.8 (SD 4.7) to 8.8 (SD 5.2)) and breast cancer worry 
compared to non-recalled women (in 35% vs. 13% after 6 months), affecting mood in 6% and 
0% respectively.42 Another study found increased avoidance scores after abnormal MRI results 
compared to baseline (IES avoidance subscale from 6.5 (SD 7.6) to 9.5 (SD 8.4)), but this was found 
to be related to the overrepresentation of BRCA mutation carriers in this group rather than to MRI 
results. BRCA mutation carriers showed greater increase of distress scores between a first and 
second MRI versus BRCA negative or untested subjects (IES increase of 11.6 versus decrease of 0.86 
points) and carrying a BRCA mutation was the only predictor for increased distress levels.41
After long term adherence to breast cancer surveillance programs, intrusion and avoidance scores 
decreased (IES-Intrusion from 4.58 (SD 6.12) to 2.75 (SD 4.58) and IES-Avoidance from 4.07 (SD 
6.01) to 3.34 (SD 6.41)). Identified risk factors for higher distress levels were the loss of a first-degree 
relative to breast cancer, a passive or palliative coping strategy, risk overestimation and excessive 
breast self examination. Having a partner and coping through reassuring thoughts were predictors 
for lower distress levels.43
Risk-reducing mastectomy (RRM)
The only study about QoL in 56 women with increased risk of breast cancer considering prophylactic 
mastectomy is from Brandberg et al.44 Twenty-six were BRCA mutation carriers. Within two years 
prior to undergoing RRM, women’s concerns and expectations of an RRM were evaluated. In the 
study group, 30% reported anxiety and 7% depression above the ‘normal range’, without statistically 
significant differences between subjects with and without previous breast cancer and between 
the study group and existing data in the general population.
Six studies reported about QoL and related items like psychological symptoms, body image, 
sexuality and satisfaction after RRM.45-50 A cross-sectional design with measurements after a mean 
of 42 months48 and 52 months45,46 after RRM was used in three of them. The other three were 
prospective studies with baseline measurements before RRM and follow-up until 1 to 6-9 years after 
RRM.47,49,50 Number of included BRCA mutation carriers varied from 13 to 50 in study populations 
existing of 36 to 90 women at high risk for breast cancer. Four reports included unaffected women 
only,45-47,50 whereas the other two included 36% and 51% participants with a personal history of 
breast cancer.48,49 Various questionnaires were used. Study details are shown in table 2.
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General QoL
Women’s QoL scores after RRM were comparable or even above levels of age-matched women 
in the general population46,47 especially for women without previous breast cancer.48 Gopie et al. 
found a statistically significant improvement in general mental health (SF-36 mental: from 48 to 
51; p=0.02) and a statistically significant decline in physical health (SF-36 physical from 55 to 48; 
p<0.001) at six months after RRM compared to baseline.50 In contrast, Brandberg et al. did not find 
a change in QoL scores after RRM compared to baseline.47 Predictors for QoL were psychological 
distress and vulnerability.46
Psychological distress: anxiety, depression and cancer worry
General distress decreased after RRM (HADS from 9.91 (SD 5.98) to 7.45 (SD -0.41) at 6 months 
and to 6.58 (SD -0.15) at 6-9 years; p<0.03), as did cancer-related distress (IES from 23 at baseline 
to 12 at 6 months and to 13 at 12 months; p<0.001 and IES from 22.7 (SD 11.6) to 12.9 (SD -0.85) 
at 6 months and to 6.1 (SD -0.58) at 6-9 years; p=0.01).49,50 Cancer-related distress was found to 
be significantly higher in BRCA mutation carriers and in women with a strong family history of 
breast cancer compared to women without a BRCA mutation or strong family history (IES Intrusion 
10.20 (SD 8.28) versus 2.46 (SD 3.36) and IES Avoidance 10.40 (SD 3.46) versus 3.46 (SD 6.21)).45 
Anxiety levels were decreased one year after RRM (HADS-Anxiety from 5.59 (SE 0.55) to 3.83 (SE 
0.52); p<0.001), whereas the prevalence of depressive symptoms did not significantly change.47
Body image and sexual functioning
On sexual functioning, a decrease in the pleasure subscale was observed one year after RRM 
(Sexual Activity Questionnaire-Pleasure from 12.82 (SE 0.62) to 11.18 (SE 0.56); p=0.005).47 However, 
the general level of sexual functioning after RRM was comparable to the general population45 and 
satisfaction with sexual and partner relationship did not change from baseline.50 Body image did 
not change after RRM in one study,47 but was less positive at 6 months after RRM in two other 
studies (Body Image Scale (higher scores for worse body image) from 10.7 (SD 4.3) to 12.4 (SD 0.40); 
p=0.02 and from 3.8 to 3.3 on a study specific body image scale with higher scores for better body 
image; p<0.001),49,50 which was predicted by higher cancer distress, lower general physical health 
and lower body mass index at baseline.50 Better body image was predicted by better body image 
at baseline and active and support seeking coping strategies.49 
Women were highly satisfied with RRM in general (92-97%)45,48 and with aesthetic outcome (74%).48 
However, satisfaction is hard to measure objectively, since women will unconsciously enable 
everything to justify the previously made decision to reduce cognitive dissonance.51  
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Ovarian cancer in germline BRCA mutation carriers
Our literature search yielded eight articles concerning QoL of BRCA mutation carriers after RRSO, of 
which three were prospective with measurements before and until 12 months after surgery20,52,53 
and five cross-sectional54-58 of which one also retrospectively evaluated the presurgical status,57 
with mean follow-up durations of 6 months to 6 years. Number of subjects per study varied from 
75 to 846 women at high risk for breast and ovarian carcinoma with 26 to 364 BRCA mutation 
carriers amongst them. Three studies exclusively included BRCA mutation carriers.20,53,58 No studies 
included unaffected women only, resulting in 20-77% women with a personal history of breast 
cancer in each study. The proportion of women who were premenopausal at the time of RRSO 
varied between 38-75%. Different questionnaires were used, mainly evaluating (menopause-
related) QoL, sexual functioning and psychological symptoms. Details of included studies can be 
found in table 3.
General QoL
Levels of generic QoL after RRSO were generally high and equal to women adhering gynecologic 
surveillance and to reference populations (SF-12 Physical Component Summary 50.86 vs. 50 
(population norm) and Mental Component Summary 47.41 vs. 50 (population norm); EORTC-
QLQ-C30 global health score 74.9 (SD 19.0) vs. 76.1 (SD 19.4) in gynecologic surveillance and 68 
(SD 20.8) versus about 62 in EORTC standard).53,54,57 Only the physical component of QoL was found 
to be temporarily lower at 1 month after surgery compared to women in a surveillance group 
(Physical Component Summary β -5.61; p<0.02), but this difference was no more apparent after 
6 and 12 months.52 Women who were younger at the time of RRSO, had lower levels of social 
functioning at follow-up.57 QoL was significantly correlated with activity in sports, a better physical 
condition, absence of weight gain and lower levels of depression.56,57 The observation that QoL 
parameters did not differ between BRCA mutation carriers and high-risk non-mutation carriers was 
explicitly mentioned in two reports.56,57
Menopause-specific QoL
More endocrine symptoms were reported after RRSO compared to women adhering to surveillance 
(FACT-ES 56.0 (SD 9.5) vs. 59.7 (SD 9.6); p<0.001; lower scores indicating more endocrine symptoms).54 
Vasomotor symptoms (e.g. hot flashes) and vaginal dryness were most frequently reported: in 25% 
and 47% respectively57 and more than in women adhering to surveillance (55.3% versus 16.2% for 
hot flashes and 44.7% versus 10.8% for vaginal dryness after 6 months); however, these differences 
already existed at baseline in this particular study.52 Severe menopausal symptoms were more 
persisting when RRSO was performed at younger age (correlation R2 = 0.878; p=0.002).58
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Psychological distress: anxiety, depression and cancer worry
General distress was comparable in women after RRSO compared to age-matched controls from 
the general population (Brief Symptom Inventory Global score 50.1 versus 50).53 Cancer-specific 
distress significantly decreased (IES from 19.2 (range 0-57) to 10.4 (range 0-53)) after RRSO but was 
still moderately or severely present in 19% of participants.53
Levels of anxiety after RRSO were found to be equal to age-matched controls from the general 
population55 with mean anxiety levels being generally low (STAI-A 41.2 (range 20-73)), but high 
or very high in 17%.57 Being active in sports and absence of weight gain were correlated with 
lower anxiety levels at follow-up, whereas younger age at RRSO was associated with higher anxiety 
levels57. Finch et al. observed a decrease in anxiety scores (BSI t-score decrease of 2.43; p=0.04) and 
increase of somatization (BSI t-score increase of 4.04; p<0.001) after RRSO in women who were 
premenopausal (and thus relatively young) at the time of surgery.53 
Furthermore, cancer worry was less (Cancer Worry Scale 7.0 (SD 1.9) versus 7.9 (SD 2.2); p<0.001) 
and satisfaction with preventive strategy was higher (97% versus 82%) after RRSO compared to 
women adhering to gynecologic surveillance. However, levels of regret were equal (5% and 6% 
respectively).54 Levels of depression were found to be equal for RRSO and gynecologic surveillance52 
and lower after RRSO compared to age-matched controls from the general population (HADS-D 
2.0 versus 3.0; p<0.001).55
Body image and sexual functioning
Sexual functioning was worse after RRSO compared to women adhering to surveillance with more 
discomfort and less pleasure despite use of HRT after RRSO in 37% of participants (SAQ Pleasure 
9.6 (SD 3.5) vs. 10.7 (SD 3.2); p<0.05) and SAQ Discomfort 4.4 (SD 1.7) vs. 5.1 (SD 1.4); p<0.05).54 
Frequency of sexual encounters was temporarily decreased in 67% of women 1 month after RRSO 
compared to baseline but then returned to its usual level.52 In women who were premenopausal 
at the time of RRSO, a decrease in sexual functioning was observed compared to baseline 
although 39% used HRT (SAQ Pleasure from 13.48 at baseline to 11.35 at follow-up; p<0.001, SAQ 
Discomfort from 4.77 to 3.51; p<0.001 and SAQ Habit from 0.85 to 0.62; p=0.04).20 More severe or 
very severe sexual symptoms were reported in premenopausal women than in women who were 
yet postmenopausal at the time of RRSO (41 versus 25% respectively; p=0.021).58 However, the 
latter group still showed a small decrease in sexual functioning compared to baseline (MENQOL 
Sexual 3.43 to 3.87 (indicating more symptoms); p0.03).20 At last, 55% was sexually active after 
RRSO (mean age 48, range 35-74); sexual inactivity was mostly due to the lack of sexual interest 
in 42%.57 Differences in sexual functioning between pre- and postmenopausal women at time of 
RRSO were not confirmed by another study.54 Body image levels were similar for women after RRSO 
and women under gynecologic surveillance.52
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Influence of HRT on QoL after RRSO
In three from the above mentioned studies, a comparison was made between HRT users and non-
users.20,53,56 Finch et al. found fewer vasomotor symptoms (MENQOL Vasomotor 2.37 versus 4.07; 
p<0.001) and better sexual functioning (MENQOL Sexual 4.02 versus 2.80; p0.015) in HRT users 
compared to non-users with the most significant effect of HRT on discomfort; however, HRT users 
still had statistically significantly more vasomotor and sexual symptoms compared to baseline 
(2.37 versus 1.57; p<0.001 and 2.80 versus 1.77; p=0.004).20 HRT users also scored better on physical 
functioning (SF-12 Physical Component Summary 55.15 vs. 49.01), however it was unclear whether 
this difference was due to HRT, to baseline differences or to underlying reasons for women not to 
take HRT, e.g. personal history of breast cancer.53 In the study by Michelsen et al., HRT could not 
be significantly associated with any of the outcome variables.56 Two other cross-sectional studies 
focused on menopausal symptoms after almost 3 and 6 years after RRSO (see table 3 for details).59,60 
Madalinska et al. included 450 women at high risk for hereditary breast and ovarian cancer who 
were premenopausal at RRSO.59 About half of respondents were BRCA mutation carriers and about 
one third had undergone RRSO. Compared to women choosing for gynecologic surveillance, HRT 
users in the RRSO group reported more sexual discomfort (SAQ Discomfort RRSO 4.8 (SD 1.5) versus 
surveillance 5.5 (SD 1.0); p=0.003; lower scores indicate more symptoms) and more endocrine 
symptoms (FACT-ES RRSO 58.0 (SD 10.9) versus surveillance 61.7 (9.8); p=0.026; lower scores 
indicate more symptoms). HRT users had significantly less endocrine symptoms than women who 
did not use HRT after RRSO (FACT-ES 58.0 (SD 10.9) for HRT versus 54.6 (SD 9.7) for non-users; 
p0.034; lower scores indicate more symptoms). Chapman et al. did not find a statistically significant 
effect for HRT in 51 BRCA mutation carriers with respect to the number of menopause symptoms 
(p=0.06). However, it is unclear whether participants were pre- or postmenopausal at the time of 
RRSO and how many used HRT at the time of follow-up (mean follow-up 6 years after RRSO).60 
QoL after both RRM and RRSO
Three articles about psychosocial functioning after RRM, RRSO or both were identified (see table 
4 for details). Two of these were prospective, from the same author, and included largely the same 
study population (78 and 82 inclusions with 54 and 58 BRCA mutation carriers respectively).61,62 
About one third had previous cancer. Questionnaires about general and cancer-specific distress 
were filled in before risk-reducing surgery and at 6 and 12 months after surgery. The third study had 
a cross-sectional design including forty only unaffected women at high risk for hereditary breast 
and ovarian cancer, and used semi-structured interviews at a mean of 3 years after risk-reducing 
surgery.63 Twenty-five were BRCA mutation carriers. 
One year after RRM, levels of intrusion (IES from 11.6 (SD 9.3) to 7.2 (SD 7.2); p<0.001), avoidance 
(IES from 10.3 (SD 8.8) to 5.6 (SD 7.0); p<0.001) and anxiety (HADS-A from 7.0 (SD 4.5) to 4.5 (SD 3.1); 
p<0.001) all decreased from baseline,61 but unanticipated bodily sensations were present in about 
half of women after RRM and in some cases sexuality was permanently affected (no quantitive 
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data).63 After RRSO, no significant changes in intrusion, avoidance or anxiety were found in the 
prospective study,61 whereas women in the cross-sectional study reported emotional, sensational 
and physical impact of menopause and its effect on sexuality the most important changes (no 
quantitive data).63
After risk-reducing surgery in general, cancer worry and cancer-related and general distress 
decreased (IES from 20.3 (SD 15.2) to 13.1 (SD 11.8); p0.000 and HADS from 10.0 (7.3) to 7.8 (5.4); 
p0.000).62,63 However, negative emotions were present in half of the respondents either attributed 
to loss of their breasts or to onset of menopause.63 
Higher levels of distress at baseline were present in women who opt for risk-reducing surgery 
instead of surveillance (HADS 10.1 vs. 7.7; p<0.02 and IES 20.0 vs. 9.6; p<0.001)61 and were 
significantly correlated with higher levels of distress at follow-up.62 Carrying a BRCA germline 
mutation was predictive for higher cancer-related distress at 6 months (B 5.89; p=0.03), but for 
lower general distress at 12 months after risk-reducing surgery (B -3.53; p=0.001).62
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DISCUSSION
We reviewed the current literature about QoL in unaffected BRCA mutation carriers and how it is 
influenced by medical choices and interventions in cancer risk management. To the best of our 
knowledge, we are the first to report such a complete overview of different aspects of QoL in this 
particular population.
Most included studies are prospective cohort or cross-sectional studies with heterogeneity in study 
design, duration of follow-up and used questionnaires and with small sample sizes not limited to 
BRCA mutation carriers alone. In a single study, results were not adjusted for differences between 
subgroups that already existed at baseline. Furthermore, due to the use of questionnaires and the 
duration of follow-up, most studies had to deal with selection bias, survival bias, the disadvantages 
of patient-reported data and loss of follow-up.
This review has some limitations. We assumed that women with a high familial risk of breast 
and ovarian cancer who were not or negatively tested for a germline BRCA mutation experience 
largely the same uncertainties and levels of anxiety as it comes to breast and ovarian cancer risk 
management as BRCA mutation carriers and therefore may have a comparable QoL. However, this 
was not always supported by subanalyses in the included studies: BRCA mutation carriers sometimes 
had higher distress levels,32,34,35,37,45,62 lower body image,33 or greater increase of distress,41 whereas 
other studies stated that there were no differences in general QoL56,57 or even lower distress levels 
at some point.62 Moreover, studies were not always limited to unaffected women, especially in 
those on quality of life after RRSO. Some studies did not report subanalyses and we can imagine 
that women with a personal breast cancer history might score differently on health-related QoL 
items than unaffected women.28,64 Consequently, generalized results might not be applicable for 
the group of unaffected BRCA mutation carriers alone.
Conclusion
General QoL levels are comparable in unaffected BRCA mutation carriers and in the general 
population. Breast cancer surveillance visits, recalls after abnormal test results and RRM do not 
clearly affect overall QoL. No long-term effects on QoL were found after RRSO. Compared to 
women at high risk for breast and ovarian cancer without a BRCA mutation, BRCA mutation carriers 
had more cancer-specific distress, cancer worries, sleeping problems and higher cancer risk 
perception in the first year after genetic testing. Distress levels may fluctuate just before and after 
breast cancer surveillance visits. Recalls after abnormal MRI results temporarily increased levels 
of anxiety, avoidance and cancer worry. After risk-reducing surgery (both RRM and RRSO), levels 
of distress, anxiety and cancer worry decreased over time and women were highly satisfied with 
their decision. Levels of depression did not change. After RRSO, vasomotor symptoms and vaginal 
dryness were most frequently reported symptoms, bothering about a quarter to half of patients 
and being more persistent in women who were younger at the time of RRSO. BRCA mutation 
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carriers had worse body image five years after genetic testing compared to non-carriers. After RRM, 
body image generally decreased. Sexual functioning after RRM was comparable to the level in the 
general population, but a slight decrease in the pleasure domain was observed. Sexual symptoms 
were more common after RRSO, especially those from the discomfort and pleasure domains, with 
women who were premenopausal at the time of RRSO most affected. HRT could partially alleviate 
endocrine and sexual symptoms after RRSO, but significant differences with women under 
surveillance remained.
In conclusion, general QoL appears not to be permanently affected in unaffected BRCA mutation 
carriers or by their choices in breast and ovarian cancer risk management. However, endocrine and 
sexual symptoms are very common after RRSO, especially in young women, and the beneficial 
effect of HRT is limited. Future research must concentrate on improving menopause-specific QoL 
in ovarian cancer risk management for BRCA mutation carriers, either by improving HRT or by 
postponing premature menopause in an alternative risk-reducing strategy.
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ABSTRACT
Objective 
Risk-reducing salpingo-oophorectomy (RRSO) is the only effective surgical strategy to reduce the 
increased risk of epithelial ovarian cancer in BRCA1/2 mutation carriers. Given the long-term health 
consequences of premature surgical menopause, we need insight in uptake and timing of RRSO to 
guide us in improving healthcare.
Methods
A single-center retrospective cohort study of BRCA1/2 mutation carriers diagnosed and counseled 
at the multidisciplinary Family Cancer Clinic of the Radboud university medical center in Nijmegen, 
The Netherlands between 1999 and 2014. Descriptive statistics were used to analyze uptake and 
timing of RRSO.
Results 
Data of 580 BRCA1/2 were analyzed. The uptake of RRSO among mutation carriers who are currently 
above the upper limit of the recommended age for RRSO, is 98.5% and 97.5% for BRCA1 and BRCA2 
mutation carriers, respectively. The vast majority undergoes RRSO ≤40 (BRCA1) or ≤45 (BRCA2) years 
of age, provided that mutation status is known by that age: 90.8% and 97.3% of BRCA1 and BRCA2 
mutation carriers, respectively. 
Conclusions
The uptake of RRSO among BRCA1/2 mutation carriers who were counseled at our Family Cancer 
Clinic is extremely high. High uptake might be largely attributed to the directive and uniform 
way of counseling by professionals at our Family Cancer Clinic. Given the fact that RRSO is often 
undergone at premenopausal age in our population, future research should focus on minimizing 
long-term health consequences of premature surgical menopause either by optimization of 
hormone replacement therapy or by investigating alternative strategies to RRSO.
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INTRODUCTION
The cumulative risk of developing epithelial ovarian cancer (EOC) at age 70 in women harboring a 
germline BRCA1 or BRCA2 mutation is about 39% (95% confidence interval 34-44%) and 16% (95% 
confidence interval 12-20%), respectively.1 Most women with EOC present with advanced-stage 
disease leading to a poor five-year survival. Screening for ovarian cancer using ultrasound and 
serum levels of tumor marker Ca125 has been proven ineffective in BRCA1/2 mutation carriers.2 
Risk-reducing salpingo-oophorectomy (RRSO) is the only effective surgical intervention in the 
prevention of EOC, reducing the risk by at least 80%.3,4
EOC risk increases at the end of the fourth decade in BRCA1 mutation carriers, and from the beginning 
of the sixth decade in BRCA2 mutation carriers.5 Most international guidelines recommend RRSO 
to both BRCA1 and BRCA2 mutation carriers between age 35 and 40 if childbearing is completed.6,7 
The Dutch guideline, however, slightly differs from these international guidelines. Initially, it was 
recommended to undergo RRSO before the age of 40 or five years prior to the youngest age at 
which a relative was diagnosed with EOC to all BRCA mutation carriers. Since 2010, distinction is 
made in recommended age for RRSO between BRCA1 and BRCA2 in Dutch daily practice: between 
35 and 40 years for BRCA1 and between 40 and 45 years for BRCA2.8 This distinction is based on the 
risk of EOC increasing at older age in BRCA2 mutation carriers.
Uptake of RRSO varies from 17% to 89% worldwide.9 Research on uptake of risk-reducing surgery 
in BRCA1/2 mutation carriers has mainly been concentrated on demographic and psychosocial 
predictors.10,11 Main predictors for uptake of RRSO are family history of EOC, personal history of 
breast cancer, and age older than 40 years.12 However, a turning point with respect to age has been 
observed as well, i.e. women older than 60 years were less inclined to undergo RRSO.13,14
The objective of this study was to investigate the uptake of RRSO among BRCA1/2 mutation carriers 
in our tertiary hospital with a Family Cancer Clinic, and whether RRSO is usually performed within 
the recommended age range. 
MATERIALS AND METHODS
Study population
A retrospective single-center study was performed among all women diagnosed with a germline 
BRCA1/2 mutation at the laboratory of Human Genetics of the Radboud university medical center 
in Nijmegen, The Netherlands, between January 1999 and December 2012. Only BRCA1/2 mutation 
carriers who were subsequently counseled at the Family Cancer Clinic of the Radboud university 
medical center were included. The integrated care for BRCA1/2 mutation carriers at the Family 
Cancer Clinic is organized within the context of a multidisciplinary team including all professionals 
involved in prevention and management of either breast or ovarian cancer: clinical geneticists, 
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gynecologic oncologists, medical oncologists, (plastic) surgeons, pathologists, radiologists, and 
social workers. Mutation carriers and their families are discussed within this multidisciplinary team 
during a weekly session in order to coordinate care and to avoid mixed messages to these patients.
According to the Dutch law, no Institutional Board Review approval was needed for this retrospective 
study of medical records in which participants’ anonymity was guaranteed by assigning study-
specific, unique patient numbers.
Setting
For the 17 million inhabitants of The Netherlands, genetic counseling and germline BRCA1/2 
mutation testing is concentrated in eight university medical centers and one specialized cancer 
institute. The laboratory that identifies the first BRCA1/2 mutation within a family will test all following 
family members, independent of the center in which counseling takes place. After diagnosis of a 
germline BRCA1/2 mutation, women are generally referred for counseling on breast and ovarian 
cancer risk management by a specialist in breast surveillance and a gynecologic oncologist at the 
Family Cancer Clinic of one of the nine above-mentioned centers.
During counseling at the Radboud university medical center, BRCA1 and BRCA2 mutation carriers 
are told that estimated lifetime risks of EOC are 30-60% and 5-20%, respectively. Furthermore, it was 
emphasized that RRSO is the only evidence-based approach to reduce this elevated risk of EOC, and 
recommended ages for RRSO are mentioned. Until 2010, recommended ages for RRSO were equal 
for both BRCA1 and BRCA2 mutation carriers: between 35 and 40 years old, or five years before the 
age of onset of EOC in a relative if that relative was diagnosed with EOC before the recommended 
age of RRSO. In 2010, however, the recommended age for RRSO for BRCA2 mutation carriers was 
increased to 40-45 years. Use of hormone replacement therapy is recommended from RRSO until 
the age of 48-50, if not contra-indicated because of a breast cancer history. Additionally, breast 
cancer risk reduction by half when RRSO was performed before onset of natural menopause was 
communicated to all women in this cohort, based on the available evidence at that time. Lastly, 
BRCA1/2 mutation carriers in our hospital were offered annual ovarian cancer screening consisting 
of transvaginal ultrasounds and Ca125 testing until September 2011. Since then, patients have 
been counseled about the ineffectiveness of ovarian cancer screening in terms of prognosis 
and false positive findings, and ovarian screening have not routinely been offered anymore. An 
overview of key elements addressed in each counseling session by a gynecologic oncologist at our 
Family Cancer Clinic can be found in Box 1.
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Box 1. Key points emphasized by gynecologic oncologist during counseling sessions
•	 Cumulative risk of EOC 30-60% (BRCA1) and 5-20% (BRCA2)
•	 Poor survival of EOC
•	 Ovarian screening is ineffective (since September 2011)
•	 RRSO is the only evidence-based approach to reduce EOC risk
•	 Recommended age for RRSO: age 35-40 (and age 40-45 for BRCA2 since 2010)
•	 Breast cancer risk reduced by half if performed before natural menopause (until 2015)
•	 No need for prophylactic hysterectomy
•	 Use of hormone replacement therapy is recommended until the age of 48-50 if not contra-
indicated (e.g. breast cancer history)
Data collection
Information on demographics, clinical characteristics and risk-reducing surgeries was obtained 
from medical records, including age at BRCA1/2 mutation diagnosis, mutation status, parity, family 
history of breast and ovarian cancer, personal history of  breast and ovarian cancer, date of RRSO, 
and time from BRCA diagnosis to RRSO (time to surgery). Consultation of medical records took 
place in April 2014. Whenever medical records did not mention RRSO, the nationwide network and 
registry of histo- and cytopathology in the Netherlands (PALGA) was consulted to find out whether 
and when RRSO was possibly undergone in another Dutch hospital.
Analyses
All statistical analyses were performed using IBM SPSS Statistics version 22. Descriptive statistics 
were used to summarize patient characteristics and to present uptake and age at RRSO. RRSO 
within the recommended age is up to and including age 40 for BRCA1, and up to and including 
age 45 for BRCA2 mutation carriers. We determined the median time from diagnosis of the BRCA1/2 
mutation to RRSO in three groups classified by age at mutation diagnosis: before, at or after the 
recommended age for RRSO. Differences in time to surgery between women with and without 
a personal history of breast cancer at the time of mutation diagnosis were tested for statistical 
significance using the Mann-Whitney test for non-parametrically distributed data.
RESULTS
Population
A germline BRCA1/2 mutation was diagnosed in 1,038 women between January 1999 and December 
2012. Of these, 609 visited the Family Cancer Clinic at least once with first visits between April 1999 
and February 2014. Twelve women were excluded because they had already undergone bilateral 
salpingo-oophorectomy: eight as risk-reductive strategy because of their family history before 
they knew their mutation status and four for other non-oncological reasons. Sixteen women had 
already developed EOC before the BRCA1/2 mutation was diagnosed. One BRCA1 mutation carrier 
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was excluded because she died of metastatic breast cancer before she reached the recommended 
age for RRSO. The remaining 580 women were included in our analyses: 357 BRCA1, 222 BRCA2, 
and 1 BRCA1+2 mutation carriers. The woman who carried germline mutations in both BRCA1 and 
BRCA2 was counseled and analyzed as a BRCA1 mutation carrier. Patient characteristics of all 580 
included women are shown in Table 1. A flowchart can be found in Figure 1.
A total number of 209 BRCA1 mutation carriers were diagnosed with the mutation at ≤40 years 
(58.4%), and 149 women were diagnosed at a higher age (41.6%). A BRCA2 mutation was diagnosed 
at ≤45 years in 139 women (62.6%), and at higher age in 83 women (37.4%).
After BRCA1/2 mutation diagnosis, two women developed pelvic cancer: one 52-year-old BRCA1 
mutation carrier had primary peritoneal carcinoma four years after RRSO, and one 60-year-old 
BRCA2 mutation carrier was diagnosed with EOC at the time of RRS.
Table 1. Characteristics of study population
BRCA1 (or 1+2) BRCA2
N= 358 61.8% N=222 38.2%
Median Range Median Range
Age at mutation diagnosis (yr) 37.5 18-79 41.0 19-79
N % N %
Parity  
0 82 22.9% 46 20.7%
1-2 200 55.9% 114 51.3%
≥ 3 72 20.1% 60 27.1%
Missing 4 1.1% 2 0.9%
Menopausal status at 1st gynecologic consultation
Premenopausal 256 71.5% 148 66.7%
Postmenopausal 93 26.0% 69 31.1%
Missing 9 2.5% 5 2.2%
Personal history of breast cancer 84 23.5% 51 23.0%
At mutation diagnosis 54 15.1% 39 17.6%
Missing 2 0.6% 0 -
First degree family history 
Breast cancer            195 54.5% 111 50%
Missing 41 11.5% 33 14.9%
Ovarian cancer    88 24.6% 19 8.6%
Missing 37 10.3% 27 12.2%
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Figure 1. Flowchart
Uptake and timing of RRSO
Of all 358 BRCA1 mutation carriers 98 are still ≤40 years and have not yet undergone RRSO, probably 
because of age. Of the remaining 260 women, four have not undergone RRSO yet despite their 
current age of 41 years or older. Total uptake is 98.5%. 
A total number of 209 BRCA1 mutation carriers had their mutation diagnosed at age 40 or younger. 
Of them, 98 are still ≤40 years old and have not yet undergone RRSO, as described above. The other 
111 are currently 41 years or older of which 109 have already undergone RRSO: 99 before or at 40 
years of age. Eight women underwent RRSO at higher age: six were already 40 years old at the 
time of genetic test disclosure and underwent RRSO within one year from then, and two of them 
had other reasons to postpone RRSO (Table 2). Timing of RRSO of two BRCA1 mutation carriers is 
unknown. 
Sixty-four of a total of 222 BRCA2 mutation carriers are currently still 45 years old or younger and 
have not yet undergone RRSO, probably because of age. Of the remaining 158, four women have 
not undergone RRSO yet despite the fact that they are currently 46 years or older (Table 2). Total 
uptake of RRSO among BRCA2 mutation carriers is 97.5%. Of the 75 BRCA2 mutation carriers who are 
currently 46 years or older and had their mutation diagnosed at age 45 or younger, 74 underwent 
RRSO, of which 72 before or at the age of 45. Two women underwent RRSO at age 46 within one 
year after detection of their germline mutation at age 45. 
Only two of 149 BRCA1 mutation carriers who were older than 40 years at the time of mutation 
detection decided not to undergo RRSO. Of all 83 women who had their BRCA2 mutation diagnosed 
after the age of 45, three have not undergone RRSO yet. Reasons for reluctance can be found in 
Table 2. 
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BRCA2 mutation carriers before and after changing recommended age for RRSO
Hundred thirty-five BRCA2 mutation carriers visited the Family Cancer Clinic for the first time before 
January 2010 and 87 in 2010 or thereafter. Sixty-eight of 135 women were ≤40 years old at this 
first visit and were recommended to undergo RRSO ≤40 years of age, of which 34 (50%) have not 
undergone RRSO yet. They all are currently ≤44 years old, so they were ≤40 years old in 2010 when 
the recommended age was changed and they were acquainted about this new recommendation. 
Of the 34 BRCA2 mutation carriers who have already undergone RRSO (median age at RRSO 40 
years, range 32-44), 27 were 40 years old or younger at the time of surgery and seven were 41 years 
or older and thus crossed the upper limit of the previously recommended age. However, three of 
them had not reached the age of 40 by 2010 and adhered to the currently recommended age 
to undergo RRSO: they underwent RRSO at age 41. Two others were 40 years old at the time of 
mutation detection and subsequently underwent RRSO at age 41 as well. The only two women 
(5.9%) who really deviated from the previous guideline both underwent RRSO at age 44 in 2010. 
One of them initially preferred annual ovarian surveillance to RRSO, and the reason for the other 
woman is unknown because she did not have follow-up in our hospital. 
Of 87 BRCA2 mutation carriers who were recommended to undergo RRSO between 40 and 45 
years of age because they primarily visited the Family Cancer Clinic from January 2010 onwards, 34 
had their mutation diagnosed before or at 40 years of age. Thirty-one of them have not undergone 
RRSO yet because of age: only one is currently 42 years old and 30 are currently ≤37 years old. The 
other three did undergo RRSO: two at age 40 and one at age 39. Only the latter deviated from the 
recommended age by undergoing surgery 2.5 months before her 40th birthday. 
The number of BRCA2 mutation carriers who were diagnosed ≤40 years and visited our Family 
Cancer Clinic for the first time between January 2010 and September 2013 is too small to draw 
conclusions about implementation of this new recommendation, taken into account that 30 of 34 
patients have not reached the age of 40 yet.
Time to surgery
Time to surgery related to breast cancer status at the time of mutation diagnosis could be 
determined for 405 of 410 BRCA1/2 mutation carriers who underwent RRSO. Dates of RRSO were 
missing for two BRCA1 mutation carriers, and data on breast cancer status at mutation diagnosis 
were missing for three other BRCA1 mutation carriers. Box plots for these 405 women are presented 
in Figure 2 (BRCA1) and Figure 3 (BRCA2).
For BRCA1 mutation carriers, median time to surgery was only statistically significantly longer in 
women who were affected with breast cancer (median 5 months) compared to unaffected women 
(median 4 months) in the group of women 40 years and older at the time of mutation diagnosis 
(Mann-Whitney U=2,912.00, z=2.602, p=0.009). However, the difference of only one month does not 
seem clinically relevant. Among BRCA1 mutation carriers regardless of age at mutation diagnosis, 
median time to surgery was 5 months in unaffected and 6 months in affected women (p=0.807). 
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Figure 2. Time to surgery in BRCA1 mutation carriers given the age at mutation diagnosis and personal breast 
cancer history. #: statistically significant (Mann-Whitney test)
Figure 3. Time to surgery in BRCA2 mutation carriers given the age at mutation diagnosis and personal breast 
cancer history. #: statistically significant (Mann-Whitney test)
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For BRCA2 mutation carriers, the only statistically significant difference was found within women 
who were diagnosed with the mutation before the recommended age for RRSO (<40 years). 
Time to surgery was longer in affected (median 110 months) compared to unaffected women 
(median 24 months) (Mann-Whitney U=63.00, z=2.134, p=0.020). However, these results need to 
be interpreted with caution because only two women with a breast cancer history at the time 
of mutation diagnosis were included in this age group. Regardless of age at mutation diagnosis, 
median time to RRSO was 6 months both for unaffected and affected BRCA2 mutation carriers 
(p=0.532).
DISCUSSION
Among BRCA1/2 mutation carriers who visited our Family Cancer Clinic, uptake of RRSO is very 
high with 98.5% and 97.5% among BRCA1 and BRCA2 mutation carriers, respectively. Furthermore, 
the vast majority undergoes RRSO at the recommended age, provided, that the germline BRCA1/2 
mutation is diagnosed before the upper limit of the recommended age. Time to RRSO does not 
convincingly differ between women with and without a personal breast cancer history at the time 
of mutation diagnosis.
The best explanation for the extremely high uptake is probably the very directive way of counseling 
by all professionals working at the Family Cancer Clinic. Besides, no alternative in terms of ovarian 
cancer screening has been offered since September 2011; however, even before 2011, the option 
of annual screening seems to have contributed to postponement of only one RRSO beyond the 
age that was recommended at that time. For three others, reasons for postponing or refusing RRSO 
are unknown.
The reported uptake of RRSO among women at high risk of breast and ovarian cancer varies widely 
across the world: from 17 to 52.4% in Asia,9,15 from 17.3 to 38% in Australia,9 from 40-89.5% in North 
America,9,16,17 and from 21.4 to 75% across European countries outside the Netherlands.9,18 From 
other parts of the Netherlands, uptake rates of 64 to 87.2% have been reported.19-22 Several aspects 
can contribute to the differences in reported uptake rates.
Firstly, methodological differences are present across studies: uptake of RRSO can widely vary 
depending on the study population (e.g. older age, personal breast cancer history and BRCA1/2 
carrier status have been associated with higher uptake).12 We only included proven BRCA1/2 
mutation carriers and we included both carriers with and without a personal history of breast 
cancer. Furthermore, for women who have not yet undergone RRSO in our study, we only counted 
those who have already passed the recommended age for RRSO. In our opinion, it is only relevant 
to measure uptake in women above the recommended age because EOC risk slightly starts to 
increase at that age and thus they are at an actual risk. Also, it is very likely that women at or below 
the recommended age will still undergo RRSO within the recommended age range, given our 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 3
62
study data. Considering them reluctant to RRSO too early would be misleading. However, excluding 
women who have not yet exceeded the currently recommended age (i.e. ≤40 years for BRCA1 and 
≤45 years for BRCA2) might partially explain the high uptake in our population compared to other 
studies. In addition, uptake can also depend on determination of a certain time frame, e.g. uptake 
within the first 12 months after genetic test disclosure. We did not determine such a time frame. 
More than five years of follow-up in the majority of women in this study could contribute to our 
higher RRSO uptake, since women still elected RRSO several years after genetic test disclosure.
Secondly, physicians’ attitudes towards risk-reducing surgery diverge internationally, which may 
influence counseling of BRCA mutation carriers and thereby their uptake of RRSO.23-29 Counseling 
can be more or less directive: Laitman et al.30 found 51% uptake in an Israeli population in case 
the healthcare provider recommended RRSO versus 39% uptake in case the healthcare provider 
advised against RRSO. The authors suggested that counseling by physicians who were not members 
of the oncogenetics team may be a reason for low RRSO uptake. In addition to this, counseling by 
a gynecologic oncologist has been described to increase uptake: Kim et al.15 observed an uptake 
of 21/33 (66%) among Korean BRCA1/2 mutation carriers who were counseled by a gynecologic 
oncologist in contrast to an uptake of only 1/9 (11%) among those who were counseled by other 
professionals (not further specified). At last, recommending the use of hormone replacement 
therapy after RRSO until the age of 48-50 may increase its acceptance and uptake.31 Therefore, 
very unequivocal recommendations provided by gynecologic oncologists at our multidisciplinary 
Family Cancer Clinic may have contributed to the very high RRSO uptake in our study.
Thirdly, RRSO uptake can be affected by offering alternative options. Specifically, the possibility 
of less invasive ovarian cancer screening might reduce the uptake of RRSO, although proven 
ineffective. This is supported by a Dutch study:19 overall uptake of RRSO within one year after genetic 
test disclosure increased from 53% to 85% after stopping ovarian cancer screening, and from 77% 
to 91% among women who reached the recommended age for RRSO. Offering screening as part 
of a clinical trial was mentioned as a possible explanation for the low uptake of RRSO observed in 
women at risk of familial EOC in the United Kingdom (both BRCA mutation carriers and women 
with unknown BRCA status).18
Furthermore, taking into account the formerly assumed effect of premenopausal RRSO on breast 
cancer risk reduction might have increased uptake of RRSO:17 from our experience, BRCA1/2 
mutation carriers, especially in families with a high breast cancer incidence, preferred halving 
their breast cancer risk through RRSO over minimizing that risk by risk-reducing mastectomy, the 
latter being more effective but (experienced as) more invasive and mutilating on the other hand. 
However, a recent Dutch study found no beneficial effect of RRSO on breast cancer incidence after 
applying alternative analyses to earlier large cohort studies, thereby minimizing amounts of bias.32 
Therefore, breast cancer risk has not been part of counseling on RRSO anymore in our center since 
2015, of which the effect on RRSO uptake is unknown up to now.
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Lastly, differences in uptake of RRSO between continents might also be attributed to cultural 
differences, e.g. women’s devotion to retain fertility as long as possible, their attitude towards 
menopause, whether RRSO is considered as mutilation and whether paternalism is more common 
in healthcare instead of emphasis on patient’s autonomy.25,26,33 In the Netherlands specifically, 
several factors can also contribute to a high uptake of RRSO as was described for Denmark: free 
access to healthcare, costs of risk-reducing surgery covered by compulsory health insurance, 
small country with short distances to hospitals throughout the country, and existence of national 
guidelines.34
The overall median time to RRSO of five to six months in both women affected and unaffected 
with breast cancer is equal or even a bit shorter compared to other studies.13,17 We observed a 
statistically significantly longer time to surgery of one month among BRCA1 mutation carriers aged 
40 years or older. A possible explanation is that women who are diagnosed with a BRCA mutation 
after being tested because of a breast cancer diagnosis complete their breast cancer treatment first 
before undergoing RRSO.
We did not report on the uptake of risk-reducing mastectomy (RRM) in our study population 
because we decided to focus on RRSO. However, it is clear from our data that about 35% of 
unaffected BRCA1/2 mutation carriers underwent RRM, which lies well within the broad range of 
uptake rates previously reported.9 The best explanation for this moderate uptake rate compared 
to the extremely high RRSO uptake is our less directive way of counseling in breast cancer risk 
management compared to EOC risk management because breast surveillance is a more or less 
equal alternative to RRM in terms of survival.35
The main strength of our study is that we included a large cohort of consecutive women tested 
positively for a germline BRCA1/2 mutation in our center. By selection through our laboratory 
database, it is unlikely we missed any patients. Besides, our nationwide network and registry of 
histo- and cytopathology in the Netherlands (PALGA) allowed us to complete data on uptake of 
RRSO, regardless of in which Dutch hospital RRSO took place. We only might have missed a patient 
having undergone RRSO abroad. Therefore, the amounts of selection bias and missing data are 
very low in spite of the retrospective study design.
Some limitations have to be noted as well. At first, generalization may not be possible since our 
study is a single-center experience. Second, we did not discriminate between RRSO for purely 
preventive purposes and bilateral salpingo-oophorectomy possibly being part of breast cancer 
treatment and a preventive strategy for EOC at the same time. The latter might be even better 
accepted by BRCA1/2 mutation carriers and therefore it might have influenced the uptake of 
surgery. 
An interesting population that we did not include in this study, consists of women from families 
with high occurrence of breast and ovarian cancer in absence of germline BRCA1/2 mutations. 
Before 2011, they were offered annual ovarian screening but we are not aware of their choices for 
RRSO after screening had been stopped in our center. Currently, these women are offered RRSO 
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if they have at least two relatives with EOC: one first-degree and another first- or second-degree 
relative.
Future research should focus on long-term health consequences of (premenopausal) RRSO and 
how to minimize adverse effects, since the uptake of RRSO among BRCA1/2 mutation carriers at our 
Family Cancer Clinic is very high and, when possible, surgery is almost always undergone within the 
recommended age range. Minimizing long-term health consequences could be achieved by either 
optimizing hormone replacement therapy or by investigating alternative risk-reducing strategies 
in EOC risk management. A French study group is already investigating bilateral salpingectomy 
as alternative strategy restricted to women who are reluctant to standard RRSO (NCT01608074). 
However, this will not be feasible in our situation since our study shows that reluctance is highly 
exceptional in our population. Another study currently running in the U.S. compares ovarian 
cancer screening, RRSO, and salpingectomy with delayed oophorectomy (NCT01907789), which is 
neither applicable to our situation, since ovarian cancer screening is not routinely offered anymore. 
More applicable to our situation, we are currently comparing bilateral salpingectomy with delayed 
oophorectomy to RRSO in a preference trial (NCT02321228).36
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ABSTRACT
Background
Risk-reducing salpingo-oophorectomy (RRSO) is recommended to BRCA1/2 mutation carriers 
because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal 
carcinomatosis is occasionally diagnosed. Knowledge regarding occurrence and pathogenesis is 
necessary to improve gynecologic counseling on risk-reducing surgery.
Methods 
Literature was searched for publications describing BRCA1/2 mutation carriers with peritoneal 
carcinomatosis after risk-reducing surgery and authors were requested to provide additional data 
and cases. Descriptive statistics were used to analyze clinical and histopathological data and to 
compare cases with a single-institution control cohort.
Results 
Thirty-one of 36 collected cases (86.1%) concerned BRCA1 mutation carriers. Median age was 52 
years (range 30-71) at risk-reducing surgery and 60 years (range 37-75) at peritoneal carcinomatosis 
diagnosis, and median interval between those two was 54.5 months (range 11-292). The vast 
majority of peritoneal carcinomatosis was of the high-grade serous subtype. Histopathological 
details of RRSO specimens including the complete fallopian tubes were retrieved in 8 cases: 5 
(62.5%) with serous tubal intraepithelial carcinoma (STIC), one with epithelial atypia. Cases were 
statistically significantly older (p=0.025) at risk-reducing surgery and harbored more STICs (p<0.001) 
than women from the control cohort. 
Conclusion 
Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in 
BRCA1 mutation carriers, within 5 years. Data suggest that surgery at younger age might lower 
rates of peritoneal carcinomatosis. These data can be used in gynecologic counseling of BRCA1/2 
mutation carriers. RRSO should include complete salpingectomy, and detailed histopathological 
examination of specimens removed at the time of RRSO is essential. 
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INTRODUCTION
Women carrying a germline mutation in one of the BRCA1 or BRCA2 genes have an increased risk 
of developing ovarian carcinoma.1 Ovarian carcinoma is a collective term for carcinomas located in 
ovaries, fallopian tubes and/or peritoneum, and are of the high-grade serous histological subtype 
in about two thirds of reported BRCA-related cases.2,3 
Given the poor prognosis of (high-grade serous) ovarian carcinoma and the lack of effective 
screening modalities, risk-reducing salpingo-oophorectomy (RRSO) is recommended between ages 
35 and 40 years in BRCA1 mutation carriers and between ages 40 and 45 years in BRCA2 mutation 
carriers, prior to age-related increases in risk for this disease. This procedure reduces the risk of 
ovarian carcinoma by 80-96%.4-6 However, the residual cumulative risk of peritoneal carcinoma, 
i.e., “peritoneal carcinomatosis”, has been estimated to be 3.9% for BRCA1 mutation carriers and 
1.9% for BRCA2 mutation carriers in the 20 years following RRSO and might be lower when RRSO 
is performed at younger age.7 Currently, there are limited data that allow the prediction of which 
women will develop metachronous peritoneal carcinomatosis and when this cancer will occur.
Several sites have been postulated as possible origins of peritoneal carcinomatosis.8,9 Studies 
indicated that many or most cases originate from remnants of the embryonic Müllerian ducts, 
especially from fallopian tube epithelium, including the tubal-peritoneal junction.10-12 However, 
detection of precancerous lesions is not ubiquitous in completely sampled fallopian tubes of 
patients with peritoneal carcinomatosis, varying from 40-70% in reported cases,13 leading others 
to propose that endometrial epithelium, another Müllerian derivative, also may be the origin of 
some peritoneal carcinomatosis.14,15 Ovarian surface epithelium and the “secondary Müllerian 
system” of pelvic and lower abdominal mesothelium and mesenchyme also are proposed as 
possible primary sites of malignant transformation.8 The latter two hypotheses are less likely due 
to frequent expression of Müllerian-specific rather than coelomic-specific markers by these cancer 
cells,16 although malignant transformation of mesothelium through Müllerian metaplasia cannot 
be ruled out.
Peritoneal carcinomatosis occurring many months after removal of the adnexa with or without 
hysterectomy in BRCA1/2 mutation carriers may have arisen from fallopian tube or endometrial 
epithelium cells shed into the pelvic cavity before that surgery.  A similar mechanism is described 
for endometrial cells disseminated through retrograde menstruation.17 In like manner, ectopic 
cells from Müllerian epithelium may develop into a full-blown carcinoma, that may appear to be 
of peritoneal origin. If the interval is long between risk-reducing surgery and the presentation 
of peritoneal carcinoma, this hypothesis seems less plausible and another or at least a second 
pathway in the development of peritoneal carcinomatosis has to be considered.
The aim of our present study is to collect and analyze clinical and pathological data from cases 
of peritoneal carcinomatosis diagnosed after intended risk-reducing surgery accrued to several 
institutions across the world and transmit this information to inform gynecologic counseling of 
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BRCA1/2 mutation carriers. Some of these findings were compared with data gleaned from a recent 
single-institution cohort of BRCA1/2 mutation carriers who underwent RRSO at the Radboud 
university medical center, Nijmegen, The Netherlands. 
MATERIAL AND METHODS
Data collection
We performed a literature search in the Medline database to collect reported cases of peritoneal 
carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers with no pathological 
abnormalities in the ovaries and fallopian tubes. The following search terms were used: BRCA, 
BRCA1, BRCA2, HBOC, familial, or high risk; risk-reducing surgery, salpingo-oophorectomy or 
oophorectomy; peritoneum, peritoneal or intra-abdominal; and cancer, cancers, carcinoma, 
carcinomas or carcinomatosis. The last date of search was December 31st, 2016. Studies describing 
one or more case(s) of peritoneal carcinomatosis after risk-reducing surgery were identified by 
scrutinizing titles and abstracts and full-texts. Both reference lists and citations of relevant papers 
were also checked to find articles we missed in the initial search. Only studies in English were 
included. Cases were excluded if either initial or revised microscopic evaluation of the salpingo-
oophorectomy specimen revealed invasive carcinoma. Although we were only interested in 
BRCA1/2 mutation carriers, studies that did not mention BRCA status or were published before the 
BRCA genes had been identified were not excluded at this stage because of the possibility that the 
respective authors would have updated data on these cases.
Then, we contacted authors of the identified papers through email with the request to fill out a 
two-page case record form for each reported case and, if applicable, for other cases of peritoneal 
carcinomatosis after risk-reducing surgery from their experience. In the event they did not reply 
to our first request, we sent a reminder after four weeks and repeated if necessary. We also sent 
comparable emails to our national and international contacts who are experts in the field of 
hereditary breast and ovarian cancer. 
The two-page case record form consisted of several items: age, BRCA mutation status, breast cancer 
history including stage and histology, type of risk-reducing surgery and histopathologic outcomes, 
details on peritoneal carcinomatosis diagnosis, e.g., age, histology, grade, stage and treatment, 
and the patient’s vital status. All data were entirely anonymized before they were sent to us. We 
eliminated duplicates by comparing birth years and dates of surgeries. Local legal procedures of 
each contributing institution were followed to allow data sharing whenever required. Whenever 
BRCA mutation status was unclear or negative, cases were excluded.
These findings were compared with a single-institution cohort of all BRCA1/2 mutation carriers who 
underwent RRSO at the Radboud university medical center between 2014 and 2016 and did not 
have invasive carcinoma in their surgical specimen (N=113). All RRSO specimens were completely 
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embedded and sectioned according to the protocol for Sectioning and Extensively Examining 
the FIMbriated end (SEE-FIM),18 which has been adopted as institutional standard protocol. 
Precancerous lesions in the fallopian tube, including STICs, were classified using the algorithm 
published by Visvanathan et al.19 This cohort was used to analyze whether cases assembled from the 
literature of BRCA1/2 mutation carriers who developed metachronous peritoneal carcinomatosis 
after risk-reducing surgery had clinical characteristics different from this recent single-institution 
cohort of BRCA1/2 mutation carriers undergoing RRSO. It should be taken into account that all 
women from this recent cohort were recommended to undergo RRSO between 35 and 40 years of 
age for BRCA1 mutation carriers or between 40 and 45 years for BRCA2 mutation carriers, or as soon 
as possible in the event the germline mutation was detected at older age (41 years and older for 
BRCA1, 46 years and older for BRCA2).
The Medical Research Involving Human Subjects Act (Dutch: WMO) is not applicable to this study 
since it is a retrospective study using anonymized data from medical records. Therefore, the study 
was exempted from being approved by the Institutional Review Board.
Statistical analysis
We performed basic descriptive statistical analyses to summarize the retrieved set of international 
cases using the IBM SPSS Statistics version 22 software package. Median age at risk-reducing 
surgery, time interval between surgery and peritoneal carcinomatosis diagnosis, and survival were 
calculated. Distribution of histopathology, grade, and stage were summarized. The following tests 
were applied to compare cases with our single-institution cohort: Mann-Whitney test for non-
parametrically distributed continuous variables, Chi-square test for categorical variables, and 
Fisher’s Exact test for categorical variables in case of smaller subgroups. 
RESULTS
Our Medline search yielded 129 articles, of which 21 remained after screening titles, abstracts, and 
full texts. An additional 7 relevant reports were identified after reference lists and citations were 
checked (Table 1). Contact information on the authors of one study describing one possibly relevant 
case could not be retrieved.20 Because some of the papers had overlapping authors, we eventually 
sent 20 email inquiries. Two authors replied that they did not have access to the requested data 
anymore and referred us to others, who subsequently did not reply to our emails. After several 
reminders, 6 filled out a total of 36 case record forms, of which 8 could be recognized from previous 
publications.5,21-23 Six cases could be added from our own institution. From Dutch colleagues, we 
received two additional cases. Email requests to several other international connections in the 
United Kingdom, Israel, Canada, Germany and Norway yielded no additional cases. 
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In sum, we collected 44 cases of peritoneal carcinomatosis after risk-reducing surgery without 
invasive carcinoma in BRCA1/2 mutation carriers. Of these, 8 were excluded because essential data 
were missing. No duplicates were detected and data from 36 cases could eventually be analyzed 
(Table 2).
Table 2. Sources of assembled cases of BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-
reducing surgery 
Source Country Number of cases Previously published;
Number [ref ]
Creighton University School of Medicine NE, USA 16 (8 excluded) 323
Dana Farber Cancer Institute MA, USA 9 15
Radboud university medical center The Netherlands 6 0
University Medical Center Groningen The Netherlands 4 0
Antoni van Leeuwenhoek hospital The Netherlands 3 0
National Cancer Institute MD, USA 3 321
Maastricht University Medical Center The Netherlands 1 0
Elisabeth-TweeSteden Hospital The Netherlands 1 0
McGill university Quebec, Canada 1 122
Abbreviations: N/A not applicable;
Characteristics of assembled cases can be found in Table 3. Thirty-one of the 36 (86.1%) assembled 
cases were from women who carried a BRCA1 germline mutation. The other 5/36 patients harbored 
a germline mutation in BRCA2. Risk-reducing surgeries took place between 1961 and 2014. The 
median age at surgery was 52 years (range 30-71, see Figure 1) for the whole group and statistically 
significantly differed between BRCA1 and BRCA2 mutation carriers: 51 years (range 30-71) and 57 
years (range 56-65), respectively (p=0.006). The median age that peritoneal carcinomatosis was 
diagnosed is 60 years (range 37-75), and the median interval between risk-reducing surgery and 
diagnosis of peritoneal carcinomatosis was 54.5 months (range 11-292 months, see Figure 2). 
Interval between risk-reducing surgery and peritoneal carcinomatosis was not related to age at 
risk-reducing surgery (see Figure 3). Most patients had undergone salpingo-oophorectomy (31/35, 
86.1%), and 16 (44.4%) also had a hysterectomy. Three women underwent only oophorectomy, 
with most of the fallopian tubes left in situ according to the pathology report, although clinical 
notes suggested that total salpingo-oophorectomy was performed in two of them. In two other 
cases, it was unclear whether salpingectomy was performed. The complete surgical specimens 
including the fallopian tube of only 8 women from the assembled cases were known to be 
entirely embedded and examined. Five of these 8 women had STICs, and another showed tubal 
epithelial atypia. In most cases, however, ovaries and fallopian tubes were not entirely sampled so 
precancerous lesions and occult invasive cancers might have been missed. The median survival 
time was 24 months (range 2-80) after the diagnosis of peritoneal carcinomatosis in 19 patients 
known to have died of their disease. 
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Figure 1. Distribution of age at risk-reducing surgery
Figure 2. Distribution of interval between risk-reducing surgery and peritoneal carcinomatosis 
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Figure 3. Relationship between age at risk-reducing surgery and time to peritoneal carcinomatosis diagnosis 
for 36 cases
Further details and the clinical data from the single-institution cohort (N=113) that underwent RRSO 
in the Radboud university medical center between 2014 and 2016 and were not found to have 
invasive carcinoma at RRSO are shown in Table 3. The following variables statistically significantly 
differed between cases of metachronous peritoneal carcinomatosis after risk-reducing surgery and 
those from the consecutive, single-institution cohort of women who underwent RRSO: median 
age at risk-reducing surgery 52 years (range 30-71) versus 46 years (range 32-80) (p=0.025, Figure 
1), proportion of BRCA1 mutation carriers 86.1% versus 53.1% (p<0.001), proportion of STICs in the 
RRSO specimen 62.5% versus 0% (p<0.001) (Table 3).
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Table 3. Patient and tumor characteristics
PC after RR(S)O; 
cases; multicenter
Cohort RRSO; 
single institution
N=36 N=113 p-value
Germline mutation  <0.001**
BRCA1 31 (86.1%) 60 (53.1%)
BRCA2 5 (13.9%) 53 (46.9%)
Previous breast cancer NS**
Yes 14 (38.9%) 35 (31.0%)
No 20 (55.6%) 78 (69.0%)
Unknown 2 (5.5%) 0
Age at RR(S)O (median in years (range))  52 (30-71) 46 (32-80) 0.025***
Type of surgery
Bilateral oophorectomy 36 (100%) 113 (100%)
Bilateral salpingectomy 31 (86.1%) 113 (100%)
Unknown 2 (5.7%) 0
Hysterectomy (previous or simultaneous) 16 (44.4%) 1 (0.9%)
RR(S)O specimen entirely examined
Yes* 8 (22.2%) 113 (100%)
Atypia in fallopian tube 1 (12.5%) 9 (8.0%) NS^
STIC in fallopian tube 5 (62.5%) 0 <0.001^
No 22 (61.1%) 0
Unknown 5 (13.9%) 0
Time interval RR(S)O – PC (median in months (range)) 54.5 (11-292) N/A
Age at PC diagnosis (median in years (range)) 60 (37-75) N/A
Histology of PC N/A
Serous  21 (58.3%)
Clear cell 1 (2.8%)
Adenocarcinoma NOS  4 (11.1%)
Undifferentiated    2 (5.6%)
Unknown       8 (22.2%)
Stage N/A
III 18 (50.0%)
IV 8 (22.2%)
Unknown 10 (27.8%)
Grade N/A
High (grade 2/3)  24 (66.7%)
Low (grade 1)        1 (2.8%)
Unknown      11 (30.6%)
Deceased at last follow-up N/A
Yes 19 (52.8%)
Duration from PC diagnosis to death 
(median in months (range))
24 (2-80)
No 15 (41.7%)
Unknown 2 (5.5%)
Abbreviations: PC peritoneal carcinomatosis; RR(S)O risk-reducing (salpingo-)oophorectomy; NS not significant; STIC 
serous tubal intraepithelial carcinoma; N/A not applicable; NOS not otherwise specified; 
* Only the worst feature counted
** Chi square test
*** Mann-Whitney test
^ Fisher’s exact test
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DISCUSSION
Metachronous peritoneal carcinomatosis diagnosed in BRCA1/2 mutation carriers after risk-
reducing surgery is rare. However, every individual case is particularly dramatic because these 
patients did their utmost to prevent this lethal disease. In this study, we collected detailed clinical 
and pathological data on a relatively large series of such cases from centers in the Netherlands, 
Canada, and the United States. The majority of assembled cases were in BRCA1 mutation carriers 
with far fewer in BRCA2 mutation carriers. The median age at the time of risk-reducing surgery 
was younger for BRCA1 mutation carriers than for BRCA2 mutation carriers. The median age at the 
time of risk-reducing surgery was 52 years, the median age at peritoneal carcinomatosis was 60 
years, and the median interval between those two was 54.5 months. Most of the risk-reducing 
surgeries in assembled cases were performed before 2005, an era when pathology specimens 
were not necessarily fully examined nor was it particularly noted whether or not fallopian tubes 
were excised, which was not standard of care at that time. Five of eight entirely examined surgical 
specimens from RRSOs in assembled cases contained STIC and another showed atypia in the 
tubal epithelium. These findings from the assembled cases differed significantly from our single-
institution cohort, which consisted of BRCA1/2 mutation carriers with overall lower median age at 
the time of RRSO, a higher proportion of BRCA2 mutation carriers and no STIC or occult carcinomas 
detected in their surgical pathology specimens. 
Finch et al.7 reported on cancer incidence in an international registry from 43 hospitals in 7 countries 
including 3513 BRCA1/2 mutation carriers who underwent risk-reducing surgery. Twenty-eight of 
2649 BRCA1 (1.1%) and 4 of 864 BRCA2 mutation carriers (0.5%) developed peritoneal carcinomatosis. 
The mean age at the time of risk-reducing surgery was not reported by these authors. The mean 
age at the time of diagnosis was 51.6 years (range 36-69 years), and the average interval after risk-
reducing surgery was 6.1 years (range 1-20 years), which are consistent with the findings from our 
assembled cases. Finch et al. estimated cumulative risks of peritoneal carcinomatosis of 3.9% in 
BRCA1 and 1.9% in BRCA2 mutation carriers during the 20 years following risk-reducing surgery.7 
Metachronous peritoneal carcinomatosis occurred in 0.3% of the women in this cadre who 
underwent risk-reducing surgery before the age of 40 years and in 0.7% of those who underwent 
surgery between 40 and 50 years.7 The median age that peritoneal carcinomatosis was diagnosed 
was higher and the median interval between risk-reducing surgery and this diagnosis was shorter 
in our study of assembled cases than the mean age and interval reported by Finch et al.7 Although 
early RRSO seems beneficial in terms of lower incidence of STIC and metachronous peritoneal 
carcinomatosis,7,24,25 the latter still occurred after (complete) RRSO performed at 36 years in one 
case. Nevertheless, our data favor the current recommendation of risk-reducing surgery at 35-40 
years for BRCA1 mutation carriers and 40-45 years for BRCA2 mutation carriers.26 
Peritoneal carcinomas were high-grade serous in the vast majority of assembled cases (75% 
of cases with known histology). One clear cell carcinoma was detected. The remaining were 
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undifferentiated or unclassified carcinomas, consistent with histological findings of peritoneal 
carcinomatosis in other publications.27 However, the histological distribution may differ over time 
due to changes in histopathological classification guidelines over the years. Application of WHO 
2014 criteria for classification shows that most ovarian carcinomas are HGSC,28 which now we 
expect is the appropriate classification for most of the peritoneal carcinomatosis in our assembled 
cases.
Our findings support an important role for the fallopian tube in the pathogenesis of peritoneal 
carcinomatosis by the appearance of STICs and the time interval after risk-reducing surgery. First, 
5 STIC lesions were detected in 8 sufficiently pathologically examined RRSO specimens of women 
who subsequently developed peritoneal carcinomatosis (62.5%), compared with no STICs in 
our control cohort and up to 8.0% in literature.24,29 This difference is notable, although the event 
numbers are small, and we cannot discern whether these peritoneal carcinomas were related to the 
initial STIC or had a different site of origin. Patrono et al.30 reviewed the literature on the outcome of 
isolated STICs in RRSO specimens and found that 3 of 67 women (4.5%), mainly BRCA1/2 mutation 
carriers, subsequently developed peritoneal carcinomatosis. Follow-up time ranged from 2 to 
150 months.30 A more recent study from a single institution showed metachronous peritoneal 
carcinomatosis in 2 of 9 patients (22%) with isolated STICs in their RRSO specimen, in contrast to 
only 1.2% of women with benign histology (p=0.01).31 Interestingly, an identical TP53 mutation 
and a largely identical genomic imbalance were detected in a STIC from an RRSO specimen of a 
45-year-old BRCA1 mutation carrier and peritoneal carcinoma that occurred ten years later in the 
same patient, suggesting a clonal origin.32 It remains debatable to what extent STICs should be 
considered cancer and treated by full staging or chemotherapy.33
The second finding supporting a role for the fallopian tube in peritoneal carcinomatosis 
pathogenesis is the relatively short time interval between prophylactic surgery and peritoneal 
carcinomatosis, i.e., 5 years or less in 66.7% of collected cases. According to a model for time of 
progression from occult fallopian and ovarian in situ and invasive carcinomas to clinically advanced 
intra-abdominal carcinoma constructed from published data by Brown and Palmer,34 the entire 
occult period of serous carcinoma is 5.1 years (median; 95% confidence interval 3.2-8.1 years), 
so (pre)cancerous tubal epithelium cells that were shed into the abdominal cavity just before 
removal of fallopian tubes and ovaries could plausibly present as peritoneal carcinomatosis many 
years later. This may result in the latter being misdiagnosed as a “peritoneal” primary rather than 
being recognized as recurrent STIC or occult tubal carcinoma and this may mainly happen when 
(pre)malignancies were missed at incomplete histopathological examination of prophylactically 
removed fallopian tubes. Additionally, 98% of cases with metachronous peritoneal carcinomatosis 
after curatively treated colorectal carcinoma were diagnosed within 5 years (median 18 months; 
range 2.5-88 months).35 The same mechanism - tumor cells shedding intra-abdominally and 
implanting in the peritoneum - might be responsible for these colorectal cancer-related peritoneal 
metastases, a possibility supported by the observation that these are more common after colon 
carcinomas than after rectal carcinomas, the latter located outside the peritoneal cavity.35 
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Fourteen percent of the assembled cases were diagnosed more than 8 years after risk-reducing 
surgery. This interval exceeds the upper limit of 95% confidence for the calculated occult period of 
serous carcinoma.34 Attempting to explain this, it is important to note that although clinical notes 
may state “bilateral salpingo-oophorectomy”, the fallopian tube might not be entirely removed 
during risk-reducing surgery, as was so in at least three of our assembled cases, and in two cases 
remnants of fallopian tube fimbriae were recognized in subsequent peritoneal biopsies. Moreover, 
normal tubal epithelium might have ingrained into peritoneum prior to salpingectomy, remaining 
benign until later beginning malignant transformation several years after surgery.11,13 Alternatively, 
another site of peritoneal carcinoma origin remains plausible, especially in cases diagnosed after 
longer intervals following complete salpingo-oophorectomy with or without hysterectomy.
The strength of this study lies in the collection of 36 cases of peritoneal carcinomatosis in BRCA1/2 
mutation carriers after risk-reducing surgery with corroboration and expansion of data on these 
assembled cases through direct communication with the authors. In addition, we compared 
characteristics of the assembled cases with those of our single-institution cohort of BRCA1/2 
mutation carriers who had RRSO with benign histology. This comparison suggests that patients 
who are BRCA1 mutation carriers, who are older at risk-reducing surgery, and who harbor STICs are 
predisposed to develop peritoneal carcinomatosis. Although follow-up of this cohort is short and 
a few could develop peritoneal carcinomatosis in the future, that number would supposedly be 
very low and would not substantially alter the characteristics of this control cohort. Nevertheless, 
we have to take into account that this cohort has been counseled and treated according to the 
latest insights, while risk-reducing surgeries of 25/36 assembled cases were performed more than 
10 years ago. Therefore, the comparison should be interpreted with caution. Furthermore, the 
absence of any STICs in our single-institution cohort of 113 BRCA1/2 mutation carriers is remarkable 
although incidences of 1% or less have been reported elsewhere.24,36,37 A possible explanation for 
the absence of STICs in our single-institution cohort is our pathologists’ strict adherence to the 
algorithm published by Visvanathan et al.19 to classify precancerous lesions of the fallopian tube. In 
this algorithm, both a TP53 mutated immunohistochemical profile and Ki-67 positivity are required 
for the diagnosis of STIC. Application of these criteria to other studies reporting on STIC incidence 
would lower the incidence, e.g., only 1 of 8 isolated STICs detected in another study fulfilled these 
criteria, thereby decreasing the incidence from 10.4% to 1.3%.25 Other studies did not report the 
use of TP53 and Ki-67 immunohistochemistry.24,29,36 
This study has several limitations. In some cases, particularly those reported long ago, significant 
amounts of data were missing from the clinical records. With but few exceptions, the SEE-FIM 
protocol was not employed to examine pathology specimens from risk-reducing surgeries in many 
of our assembled cases of peritoneal carcinomatosis in BRCA1/2 mutation carriers, as the surgeries 
antedated widespread adoption of this now standard method for pathological processing.18 During 
that era, the role of the fallopian tube in “ovarian” carcinogenesis had not been recognized, and many 
risk-reducing oophorectomies did not specifically remove the fallopian tubes. Because complete 
diagnostic tissues were irretrievable in most of the assembled cases, centralized pathological review 
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was not done on either prophylactic surgery specimens or peritoneal carcinomatosis. Moreover, 
selection bias to a certain extent occurred because we asked professionals to send cases from their 
own practice. Remarkable cases are more likely to be remembered, e.g., peritoneal carcinomatosis 
after a previous STIC in the RRSO specimen, which might explain the high proportion of STICs 
among assembled cases. Additionally, metachronous peritoneal carcinomatosis might be a reason 
to meticulously revise histopathology of RRSO specimens thereby increasing the chance of finding 
STICs. Altogether, our findings cannot be fully generalized to patients coming through health 
services today. Lastly, we did not collect details on mutation location. It would be very interesting 
to see whether women with metachronous peritoneal carcinomatosis after RRSO harbor specific 
mutations in the ovarian cancer cluster regions, for instance.38,39
In conclusion, the majority of peritoneal carcinomatosis cases were diagnosed fewer than 5 
years after risk-reducing surgery in the 36 assembled cases, and these were mostly in women 
who underwent surgery later than the currently recommended ages of 35-40 years for BRCA1 
mutation carriers and 40-45 years for BRCA2 mutation carriers. These findings can be used to refine 
gynecologic counseling of BRCA1/2 mutation carriers who consider risk-reducing surgery and 
to stress the importance of complete RRSO at the recommended ages. Complete examination 
according to the SEE-FIM protocol should be followed in all pathological processing of surgical 
specimens from BRCA1/2 mutation carriers; albeit, as yet, there is no consensus as to how patients 
should be managed when preinvasive lesions are found. In the quest for better understanding 
of pathogenesis and to address outstanding questions for counseling and clinical management, 
further prospective research is needed using agreed standards for the delivery and processing 
of surgical specimens from BRCA1/2 mutation carriers and uniform formats and nomenclature 
for reporting demographic, medical, surgical and pathology data with long-term follow-up to 
specialized central cancer registries.  
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ABSTRACT
Objective
To identify influencing factors of BRCA1/2 mutation carriers and their professionals for risk-reducing 
salpingectomy (RRS) with delayed oophorectomy (RRO) as a substitute for risk-reducing salpingo-
oophorectomy (RRSO) and for study participation on this concept.
 
Methods
A qualitative study was performed by four focus group interviews with 39 BRCA1/2 mutation carriers 
and semi-structured in-depth interviews with 23 professionals in the field of hereditary cancer. We 
used a theoretical framework of determinants of innovation within healthcare organizations to 
classify influencing factors (barriers and facilitators).
Results
Among BRCA1/2 mutation carriers, main barriers for RRS with delayed RRO were seriousness of 
ovarian cancer, family history, and previous breast cancer. Among professionals, delay of risk-
reducing effect of oophorectomy on breast cancer risk and a second operation were recognized 
as main barriers. Both BRCA1/2 mutation carriers and professionals found uncertainty about the 
effect of RRS with delayed RRO and ease of the decision to undergo RRSO important barriers. The 
main facilitator mentioned by both was longer maintenance of ovarian function thereby delaying 
negative effects of early surgical menopause. For study participation, BRCA1/2 mutation carriers 
mentioned a randomized study design as the main barrier, whereas professionals identified two 
facilitators, namely willingness of BRCA1/2 mutation carriers for study participation and uniform 
counseling. Furthermore, most BRCA1/2 mutation carriers and professionals were willing to 
consider participation in a future non-randomized study.
Conclusions
We identified several barriers and facilitators for RRS with delayed RRO, and for study participation 
which can be addressed to optimize the design and implementation of a non-randomized study.
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INTRODUCTION
Epithelial ovarian cancer is the most lethal gynecological malignancy. More than 10% of all 
epithelial ovarian cancers are inherited, mostly caused by a mutation in the BRCA1 or BRCA2 
genes.1-3 The lifetime risk of developing ovarian cancer at age 70 in women harboring a BRCA1 or 
BRCA2 mutation varies between 31–40% and 6–18%, respectively,4,5 while the risk in the general 
population is 1.7%.
Therefore, risk-reducing salpingo-oophorectomy (RRSO) is recommended to BRCA1/2 mutation 
carriers around the age of 40 years. RRSO reduces the risk of ovarian cancer by 80–90%. The earlier 
assumption that performing RRSO at premenopausal age reduces breast cancer incidence by half6,7 
has recently became arguable.8,9 Besides the benefits of RRSO, concerns are growing regarding 
the adverse effects associated with early surgical menopause. Short-term effects of premature 
menopause are vasomotor and sexual symptoms, which may not be fully alleviated by the use of 
hormone therapy.10,11 Long-term effects include risk of osteoporosis, cardiovascular diseases, and 
cognitive impairment.12-14 Approximately 75% of all ovarian cancers diagnosed in BRCA1/2 mutation 
carriers are high-grade serous cancer of the ovaries, fallopian tubes or peritoneum.15 Based on 
recent scientific insights, a significant majority of high-grade serous ovarian cancer arise from the 
fallopian tube rather than the ovarian surface epithelium.16-23 Along with the side effects of early 
menopause, increasing attention is paid to a possible new strategy of risk-reducing salpingectomy 
(RRS) with delayed risk-reducing oophorectomy (RRO) in BRCA1/2 mutation carriers.24-26
To design an appropriate clinical trial to evaluate the safety of RRS with delayed RRO and its added 
value on not cancer-related morbidity and mortality is an interesting challenge. However, a broadly 
based support from both BRCA1/2 mutation carriers and professionals in this field is needed to give 
a potential study an optimal chance. Holman et al.27 recently performed an online survey in 204 
premenopausal BRCA1/2 mutation carriers to study the acceptability of, and interest in a clinical 
trial of RRS with delayed RRO. They reported that 34% were interested in a study on this subject, 
35% were unsure, and 31% were not interested.
To our knowledge, no qualitative data are yet available on the interest in RRS with delayed RRO 
and the willingness of both BRCA1/2 mutation carriers and their professionals to participate in a 
study on this subject. Therefore, our objective was to assess factors of influence, both at BRCA1/2 
mutation carrier and healthcare provider level, for the choice of RRSO or RRS with delayed RRO, and 
for willingness to participate in a study on this subject.
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MATERIALS AND METHODS
Study design and setting
A qualitative study was performed with BRCA1/2 mutation carriers and their treating professionals 
using explorative semi-structured interviews in group and individual setting, respectively. We opted 
for semi-structured interviews to let the participants talk freely with structured guidance from the 
interviewer using an interview guide. For BRCA1/2 mutation carriers, we chose a group setting as 
we expected that this is useful to obtain detailed information about personal and group feelings, 
perceptions and opinions related to RRS with delayed RRO. We opted for individual interviews with 
professionals to give everyone the opportunity to openly speak one’s mind on this subject without 
the risk of mutual influence or mainly politically correct answers.
In The Netherlands, BRCA1/2 mutation analysis is concentrated in eight university hospitals. After 
the diagnosis of a BRCA1/2 mutation, women are generally referred to a surgeon/oncologist and 
gynecologist in a university hospital for information on risk-reducing strategies for breast and 
ovarian cancer. Surveillance could take place in either university
or non-university hospitals.
Study population
BRCA1/2 mutation carriers
BRCA1/2 mutation carriers were recruited from the Radboud University Medical Center 
(Radboudumc) in Nijmegen, The Netherlands. Four focus group interviews were performed with 
partly different constitution. Three focus groups consisted of BRCA1/2 mutation carriers who 
had already undergone RRSO. Further selection in these three groups occurred on breast cancer 
history; one group of women without breast cancer, one group of women with prior breast cancer, 
and one mixed group of women with and without a history of breast cancer. The fourth group 
included younger women without a history of breast cancer who had not yet undergone RRSO.
Professionals
Six gynecological oncologists from eight university hospitals and one gynecological oncologist 
from a non-university hospital, all with special interest for hereditary cancer, were asked to 
participate in this study. None of the gynecological oncologists of our own institute were included, 
because they initiated this study. All seven gynecological oncologists were asked to propose 
collaborative professionals from their department of clinical genetics and breast surveillance for 
study participation. Seven clinical geneticists from seven university hospitals were interviewed; 
nine professionals taking care of breast surveillance participated, Of which five surgeons, one 
medical oncologist, two medical doctors, and one nurse practitioner.
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Data collection
BRCA1/2 mutation carriers
Invitations for the first three focus group interviews were sent by email to 45 BRCA1/2 mutation 
carriers who had given written consent to be contacted for focus group research in the past. For the 
fourth focus group, we approached 21 BRCA1/2 mutation carriers through a letter with information 
about the study. After one week, we contacted them by phone to answer any questions and to ask 
for consent to participate.
The interview guide was based on literature and on knowledge and experiences of all co-authors 
working in the fields of hereditary breast and/or ovarian cancer and qualitative research. This guide 
included questions about influencing factors on the acceptance of both the innovation itself and 
a study on this new concept. Prior to the interviews, confidentiality was assured and the process 
of the interview was explained. Written informed consent was gained from all participants. All 
focus group interviews were introduced by a 5–7 minute presentation about recent and relevant 
insights in strategies to reduce the risk of ovarian cancer. The focus group interviews were guided 
by a chairman (J.H.) and two researchers attended as observers (R.H. and M.A.). The focus group 
interviews took 90–105 min and were audiotaped after consent of the participants.
Professionals
Interviews with 23 professionals were performed in seven university hospitals and one non-
university hospital (about three professionals per hospital) irrespective of data saturation. In 
advance we expected different opinions between hospitals, therefore we allowed all professionals 
to speak about this topic. The interview guide was based on literature and on knowledge and 
experiences of all co-authors containing the following topics: pros and cons of the new concept 
(RRS with delayed RRO) for patients, professionals, and organization; bottlenecks of a study on this 
subject; and suggestions for study design. Prior to the interviews, confidentiality was assured and 
the process of the interview was explained. The interviews were performed by one researcher 
(M.A.), took 20–55 min, and were audiotaped after consent.
Analyses
Both focus group and individual interviews were fully transcribed. Transcripts were independently 
analyzed by two researchers (M.A. and M.H.). The analyses were conducted with the aid of 
qualitative analysis tool of ATLAS.ti GmbH Version 6 (Berlin, Germany). We used a process of 
constant comparison, originating from grounded theory.28 At first, we read the complete transcript 
to become familiar with the data. In a second step, we performed open coding independently 
of one another, and stayed semantically close to the participants’ wording. During this inductive 
coding process, the four determinants of innovation within health care organizations (at the level 
of innovation itself, patient, professional, and organization) defined by Fleuren29 and Grol30 served 
as ‘sensitizing concepts’. We analyzed the influencing factors for the choice of RRS with delayed 
RRO instead of RRSO, and subsequently we explored these factors for study participation on this 
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concept. Thirdly, we discussed our findings until we achieved mutual agreement. In this way, axial 
codes were defined. New insights were written down in memos. After constant iteration of these 
steps, ‘selective coding’ led to a deep understanding of the barriers and facilitators of RRS with 
delayed RRO, and of study participation on this subject from both BRCA1/2 mutation carriers’ and 
professionals’ perspectives.
As assessed by the institutional review board of the Radboud University Medical Center (CMO no. 
2013/050), the study was not subject to the Dutch ‘Medical Research Involving Human Subjects 
Act’ meaning that it was exempt from approval.
RESULTS
BRCA1/2 mutation carriers
Of 66 BRCA1/2 mutation carriers who were approached, 44 women (67%) agreed on study 
participation, of which five eventually were unable to attend. The total participation rate was 59% 
(39/66). Characteristics of focus groups are summarized in Table 1. In four focus groups with 39 
BRCA1/2 mutation carriers, we identified 18 barriers and facilitators influencing the choice for RRS 
with delayed RRO. We found two barriers and one facilitator for study participation on this concept. 
Factors (barriers and facilitators) mentioned in at least two focus groups are listed in Tables 2 and 
4. Factors cited in all four focus groups are described in the text and marked in the table with an 
asterisk (*). In both tables and text, barriers and facilitators are ranked by the amount of mentioning.
Table 1. Characteristics of focus groups
Focus Group 1 
(N=9)
Focus Group 2 
(N=10)
Focus Group 3 
(N=11)
Focus Group 4 
(N=9)
Duration; minutes 105 105 95 90
BRCA mutation; N (%)
BRCA1 8 (89) 9 (90) 10 (91) 5 (56)
BRCA2 1 (11) 1 (10) 1 (9) 3 (33)
BRCA1+2 1 (11)
Age; median (range) 46 (39-56) 47 (42-56) 46 (43-55) 37 (33-43)
Age at RRSO; median (range) 40 (37-46) 38.5 (35-46) 38 (32-41)
Years since RRSO; median (range) 5 (2-15) 8 (1-16) 11 (3-14)
History of breast cancer; N (%) 0 10 (100) 5 (45) 0
Age at breast cancer; median (range) 35 (31-48) 38 (36-42)
RRM; N (%) 6 (67) 3 (50) 5 (56)
Preference of strategy; N (%) 
RRSO 8 (80) 6 (55) 3 (33)
RRS with delayed RRO 7 (78) 2 (20) 3 (27) 5 (56)
Unsure 2 (22) 2 (18) 1 (11)
Abbreviations: RRSO risk-reducing salpingo-oophorectomy; RRM risk-reducing mastectomy; RRS risk-reducing 
salpingectomy; RRO risk-reducing oophorectomy
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Table 2. Influencing factors for RRS with delayed RRO according to BRCA1/2 mutation carriers
Determinants Barriers Facilitators
Domain 1: Seriousness of ovarian cancer* Delay of menopause*
Innovation Uncertainty of effect of innovation* Preserve fertility
Complexity of decision Earlier preventive option
Domain 2: Family history* Autonomy* 
Patients Ease of decision to RRSO* Reluctance to premature menopause
Personal history of breast cancera
Influence of family/having children
Difficulty of deciding based on numbers
Domain 3: Inadequate counselling about effects of RRSO*
Professionals Limited knowledge on this specialistic subject
Domain 4: Lack in continuity of professionals Sufficient information* 
Organization Approachable contact with 
professionals
Factors mentioned in at least two focus groups are listed and are ranked by the amount of mentioning; 
Abbreviations: RRS risk-reducing salpingectomy; RRO risk-reducing oophorectomy; RRSO risk-reducing 
salpingo-oophorectomy;
*mentioned in all four focus groups;
amentioned in focus groups with participants with a history of breast cancer (focus group 2 and 3)
Barriers and facilitators related to RRS with delayed RRO
Domain 1: determinants at innovation level 
Two main barriers and one facilitator were mentioned in this domain. Firstly, the seriousness of 
ovarian cancer was cited as the main barrier. The threat of ovarian cancer was brought up in all 
focus groups considering its inability of early discovery and its high lethality rate. Another main 
barrier of the innovation was the uncertainty about the effect of RRS with delayed RRO on the risk 
of ovarian cancer. According to this barrier, peace of mind after RRSO was cited as an important 
benefit of RRSO in all four focus groups.
The main facilitator of the innovation for BRCA1/2 mutation carriers was the delay of early 
menopause considering both physical and psychosocial aspects. From a physical point of view, this 
innovation could accomplish a delay in several negative effects of RRO, like vasomotor symptoms, 
sexual dysfunction, joint complaints, acceleration of aging, changes in appearance, and decrease 
of life expectancy. Positive psychosocial effects were the delay in mood alternations, influence 
of relationship with partner, sleeping complaints, and energy loss. Furthermore, the delay of 
menopause could also postpone the difficulties in deciding to use hormone replacement therapy 
mentioned in all focus groups.
Domain 2: determinants at patient level 
In all focus groups, participants emphasized that family history generally played an important role 
in decision making for preventive strategies. The main barrier for the innovation was having family 
members with ovarian cancer. The predominant type of cancer (breast or ovarian) in a family mainly 
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affected the anxiety for breast or ovarian cancer. Another main barrier among BRCA1/2 mutation 
carriers was the ease of decision to undergo RRSO. Different aspects seemed to be connected to 
this ease, including underestimation of short- and long-term impact of RRSO, limited impact of a 
laparoscopy, need for certainty/comforting feeling about reducing cancer risk, and furthermore 
predominant anxiety of cancer and choices based on anticipated regret. Nevertheless, most 
BRCA1/2 mutation carriers who underwent both RRSO and RRM cited a higher impact of RRSO 
compared to RRM. Having a personal history of breast cancer was identified as the main barrier in 
both focus groups with participants with prior breast cancer. The restraint in study participation 
on this innovation was mainly based on the need for certainty and to exclude all possible risks 
developing cancer again.
Need for maintenance of autonomy was identified as the main facilitator. BRCA1/2 mutation 
carriers in our focus groups attached an important value to freedom of choice, and the significance 
of individual considerations was underlined.
Domain 3: determinants at professional level 
BRCA1/2 mutation carriers reported insufficient counseling about effects of RRSO as the main 
barrier, and seemed to be in close connection with the ease of decision to undergo RRSO.
Domain 4: determinants at organization level 
In general, sufficient information was the main facilitator for making decisions in this group of 
BRCA1/2 mutation carriers. In all focus groups, different needs for information were mentioned 
consisting of new medical insights, contact with peers, group information, and/or contact 
with professionals. Specially, detailed explanation of the term ‘ovarian cancer’ and its origin was 
mentioned to be valuable, referring to the expected effect of RRS.
Barriers related to study participation
In all focus groups, acceptable designs to study the added value of RRS with delayed RRO instead 
of RRSO were discussed. The main discussion point was the concept of randomization and its 
preference as ideal study design. In all focus groups, a general consensus of opinion was that a 
randomized study design generates a main barrier for participation in a future study. The most 
important reasons for this aversion were the need for freedom of choice and maintenance of 
autonomy.
All focus group interviews finished with questions about the hypothetic choice between RRSO and 
RRS with delayed RRO (Table 1). In summary, 17 women were interested in the new strategy (44%), 
17 women preferred the current strategy (44%), and five were unsure (12%).
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Professionals
Of all 23 professionals, four were males (one gynecological oncologist, one clinical geneticist and 
two surgeons taking care of breast surveillance). Factors mentioned by at least two professionals 
are listed in Tables 3 and 4. In total, 20 barriers and facilitators influencing the choice for RRS with 
delayed RRO were identified (Table 3). For study participation, 10 barriers and facilitators were 
denominated at the level of patients, professionals and organization (Table 4). Factors mentioned by 
more than 50% of the professionals are described in the text and marked in the table with asterisks 
(**). In both tables and text, barriers and facilitators are ranked by the amount of mentioning. 
Table 3. Influencing factors for RRS with delayed RRO according to professionals 
Determinants
Barriers Facilitators
Domain 1: Undergoing two operations* Delay of menopause*
Innovation Delay of risk reduction of breast cancer* Preserve fertility
Risks attended by two operations* Delay of HRT use
Uncertainty of effect of innovation* Earlier examination of tubes
Seriousness of ovarian cancer 
Domain 2: Ease of decision to RRSO* Reluctance to premature menopause
Patients Family history Well-informed and involved patients
Domain 3: Insufficient evidence* General scientific attitude
Professionals Insufficient knowledge of professionals
Domain 4: 
Organization
Increase in health care consumption
Cooperation between hospitals
Lack of capacity
Cooperation in multidisciplinary teams on  
   hereditary cancer 
Factors mentioned by at least two professionals are listed in this table and are ranked by the amount of 
mentioning; RRS risk-reducing salpingectomy; RRO risk-reducing oophorectomy; RRSO risk-reducing salpingo-
oophorectomy;
*mentioned by more than 50% of the professionals
Barriers and facilitators related to RRS with delayed RRO 
Domain 1: determinants at innovation level 
Four main barriers were identified in this domain. Undergoing two operations were mentioned as 
a barrier by almost all professionals. Furthermore, inherent risks of two operations were named as 
a barrier, including the entailed doubled peri-operative risk, the possibly increased complication 
risk of RRO after earlier RRS, and the risk of coexisting co-morbidity. The majority of professionals 
nominated the delay of risk reduction of breast cancer owing to the delay of RRO as a barrier 
with the comment that an RRM would nullify this barrier. For professionals in breast surveillance 
this barrier seemed less important. The last important barrier was the uncertainty of the effect of 
RRS with delayed RRO. To overcome this barrier, some professionals suggested to perform more 
research on the origin of ovarian cancer, while the majority of professionals thought that a clinical 
study on this new strategy is most appropriate. 
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The main facilitator of this new strategy was the delay of menopause. The majority of professionals 
mentioned that delay of vasomotor and sexual complaints, osteoporosis, and cardiovascular disease 
together with maintenance of quality of life are main advantages of the delay of menopause.
Table 4. Influencing factors for study participation according to BRCA1/2 mutation carriers and professionals
Barriers Facilitators
BRCA1/2 mutation carriersa
Domain 2: Value of participation for next generation
Patients
Domain 4: Randomized study design*
Organization Cost of study / insufficient cover by insurance
Professionalsb
Domain 2: Amount of other undoing studies Willingness to participate in study**
Patients Value of participation for next generation
Domain 3: Time investment Willingness to participate in studies
Professionals Diversity of viewpoints of professionals
Domain 4: Insufficient cover by insurance Uniform counseling**
Organization Differences in pathology examination of tubes
Assessment by institutional review board
a Factors mentioned in at least two focus groups are listed; 
b Factors mentioned by at least two professionals are listed; 
*mentioned in all focus groups; 
**mentioned by more than 50% of the professionals
Domain 2: determinants at BRCA1/2 mutation carrier level
The ease of the decision of BRCA1/2 mutation carriers to undergo RRSO was mentioned as the 
main barrier. According to professionals, BRCA1/2 mutation carriers generally underestimate the 
impact of early menopause, receive limited information concerning side effects of RRSO, and are 
less emotionally attached to their ovaries compared to breasts and uterus.
Domain 3: determinants at professional level
In this domain, the main barrier for professionals was insufficient scientific foundations of this new 
strategy. The major drawback was the unproven effect of RRS as a preventive strategy, and the 
unknown effect of delaying RRO on the risk of ovarian cancer.
Domain 4: determinants at organization level
No barriers or facilitators were mentioned by more than 50% of the professionals; therefore, no 
main factors of influence at the level of organization were expected.
Barriers and facilitators related to study participation
The main facilitator at patient level mentioned by almost all professionals was the expected 
willingness of a substantial part of BRCA1/2 mutation carriers to participate in a study on RRS with 
delayed RRO.
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At organization level, the main facilitator for study participation was uniform counseling according 
to a widely supported study protocol. Important remarks about study design were the need for 
an observational study with long-term follow-up concentrating on ovarian cancer risk and quality 
of life. Furthermore, professionals mentioned the need for a reliable power calculation, and clear, 
extensive, and scientifically based patient information considering all pros and cons of this new 
strategy.
DISCUSSION
Our study identified a wide variety of barriers and facilitators influencing the choice for RRS with 
delayed RRO instead of RRSO in BRCA1/2 mutation carriers and their treating professionals. Barriers 
identified on the level of the innovation itself and on the level of BRCA1/2 mutation carriers 
appeared to provide the most important impact. Both BRCA1/2 mutation carriers and professionals 
experienced the uncertainty of the effect of the innovation, and the ease of the decision to 
undergo RRSO as main barriers. Among BRCA1/2 mutation carriers, the other main barriers were 
1) seriousness of ovarian cancer; 2) family history; 3) personal history of breast cancer; and 4) 
inadequate information about all side effects of RRSO. Among professionals, undergoing two 
operations with its inherent additional risks, delay of risk reduction of breast cancer, and insufficient 
supportive evidence were recognized as main barriers. Delay of menopause was suggested as the 
main facilitator for both BRCA1/2 mutation carriers and professionals. BRCA1/2 mutation carriers 
mentioned autonomy in the choice between RRSO and RRS with delayed RRO, and sufficient 
information as main facilitators.
For study participation, additional barriers and facilitators were identified. A randomized study 
design was mentioned to be the main barrier for BRCA1/2 mutation carriers. Among professionals, 
main facilitators were expected willingness of BRCA1/2 mutation carriers to participate and uniform 
counseling. Overall, a general interest in a non-randomized observational study of RRS with 
delayed RRO was observed taking into account all mentioned barriers and facilitators. Apparently, 
a substantial part of the BRCA1/2 mutation carriers (43.6%) indicated interest in RRS with delayed 
RRO, which is slightly higher than the 34.3% reported by Holman et al.27 Possible explanations 
for this difference could be the size of the study groups (n= 39 versus n = 204), type of research 
(qualitative versus quantitative), and included BRCA1/2 mutation carriers (before and/or after risk 
reducing strategies). Almost all professionals in our study were also interested to participate in a 
study on this innovation.
Elaborating on this innovation as possible addition to the current strategy,  suggestions are made 
by Anderson et al. to perform a clinical trial to test the equivalence of RRS to RRSO in reducing pelvic 
serous cancer risk in BRCA mutation carriers, needing up to 4000 women in each arm.25 A recent 
decision-analytic model of Kwon24 compared costs, risks, and benefits of three strategies (RRS alone, 
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RRS with delayed RRO, and RRSO) confirming the greatest risk reduction for breast and pelvic serous 
cancer of the current standard RRSO. However, when considering quality-adjusted life expectancy, 
RRS with delayed RRO is a cost-effective strategy.24 The evidence regarding RRS with delayed RRO 
is still limited, and only two clinical trials on this subject are currently recruiting BRCA1/2 mutation 
carriers. A French study by Leblanc and colleagues is currently offering salpingectomy to BRCA1/2 
mutation carriers who are reluctant to undergo RRSO (NCT01608074). In addition, an American 
research group recently started a study on patient compliance with the strategy consisting of RRS 
with delayed RRO (NCT01907789). Altogether, there is an increasing interest in the role of RRS with 
delayed RRO for BRCA1/2 mutation carriers. Findings of our study will undoubtedly help to foresee 
difficulties in designing and implementing new studies on this subject. Based on our study, we 
designed a multicenter prospective non-randomized controlled study with menopause-related 
quality of life as primary outcome measure. BRCA1/2 mutation carriers will choose between the 
current standard (RRSO) and RRS with delayed RRO (NCT02321228).
Appreciable differences in main barriers were found between BRCA1/2 mutation carriers and 
professionals at the level of innovation. The first difference was the interest in influence of the 
delay of breast cancer reduction as a result of the new strategy. Professionals reported this as the 
main barrier, whereas this delay was not a relevant issue for BRCA1/2 mutation carriers considering 
better available strategies for breast cancer reduction, irrespectively of previous RRM. Only some 
BRCA1/2 mutation carriers mentioned the breast cancer risk reduction of RRSO as an additional 
advantage; however, the delay of risk reduction due to the new strategy is a matter of minor 
significance. From patients’ perspective, the suggestion of Anderson et al.25 to perform a clinical 
trial in BRCA1/2 mutation carriers who previously underwent RRM is therefore questionable. 
Unfortunately, Holman et al.27 did not ask their participants of their thoughts about the delay of 
reduction of breast cancer. The altering insight of the scarcely reduction of breast cancer risk by 
RRSO at premenopausal age8,9 might give an even more important role for RRM in young BRCA1/2 
mutation carriers. The second difference between BRCA1/2 mutation carriers and professionals 
was the judgment on the inevitability of two operations and its additional risks involved with the 
new strategy. This was considered as the main barrier by professionals, whereas BRCA1/2 mutation 
carriers explicitly attached little importance to this aspect.
Another consideration for participation in a study of RRS with delayed RRO was the possible 
influence of a personal history of breast cancer. Only two of the 15 women with a history of breast 
cancer (13%) were interested in the option of RRS with delayed RRO. It may be assumable that a 
personal history of cancer makes women more willing to minimize their future cancer risk and to 
accept the negative effects of RRO. However, earlier studies on uptake of RRSO showed conflicting 
results on the predictive value of a personal history of breast cancer.31-33
Potential ovarian damage was suggested by Holman et al.27 as a reason for not participating in a 
study on RRS with delayed RRO. Recently, no negative effects on the ovarian function were found 
in premenopausal low-risk women for ovarian cancer who underwent bilateral salpingectomy in 
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addition to laparoscopic hysterectomy for benign uterine pathologies.34 In our study, the potential 
effects of RRS on ovarian function were not mentioned as a barrier by BRCA1/2 mutation carriers 
or professionals.
Our study is the first reported performance of an in-depth qualitative analysis of the new concept 
of RRS with delayed RRO from both patients’ and professionals’ perspectives. Another strength is 
the considerable number of participating BRCA1/2 mutation carriers, and the different constitutions 
of focus groups regarding medical background. Furthermore, professionals from almost all Dutch 
university hospitals participated in our study representing three different disciplines. 
A possible limitation of our study is that all focus groups with only Caucasian BRCA1/2 mutation 
carriers were performed in one hospital. Performing only one focus group with BRCA1/2 mutation 
carriers prior to RRSO might have caused a biased view. Although, we thought that BRCA1/2 
mutation carriers after RRSO could have provided an important contribution to amplify the 
impact of RRSO and to explain the value of a history of breast cancer on the subject of our study. 
Furthermore, BRCA1 mutation carriers were overrepresented in our study. This might be partly 
explained by a higher invitation rate (46 BRCA1 and 20 BRCA2 mutation carriers, 70% vs. 30%), 
although there was also an unforeseen higher participation rate (33 BRCA1 and 6 BRCA2 mutation 
carriers; 72% vs. 30%). This might be due to coincidence; however, it is also possible that the subject 
concerned BRCA1 mutation carriers more because of the higher risk and the earlier age of onset 
of ovarian cancer. The feasibility of internationalization of our results may be difficult to appraise, 
because of unknown or unforeseen international difference, for example insurance systems. 
Although, the interest in study participation on this innovation is in accordance with the results of 
Holman,27 both studies elucidate various aspects of RRS with delayed RRO.
In summary, our study provides new and additional data on influencing factors of BRCA1/2 
mutation carriers and their treating professionals for RRS with delayed RRO as a substitute for RRSO 
and for study participation on this concept. Knowledge of these factors may help to improve the 
design and implementation of a non-randomized study on this subject in which special attention 
should be paid to scientific basis, importance of autonomy, and providing sufficient information.
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ABSTRACT
Objective 
To estimate BRCA1/2 mutation carriers’ cumulative ovarian cancer risks after risk-reducing 
salpingectomy at various ages with delayed oophorectomy several years later compared with risk-
reducing salpingo-oophorectomy.
Methods 
A literature search was performed on cumulative ovarian cancer risks and effects of risk-reducing 
salpingo-oophorectomy and salpingectomy. Results were used in a modeling study to estimate 
cumulative ovarian cancer risks for various scenarios of salpingectomy with delayed oophorectomy 
and risk-reducing salpingo-oophorectomy using Cox proportional hazard models.  
Results 
Estimated cumulative ovarian cancer risks at age 70 years for risk-reducing salpingectomy with 
delayed oophorectomy are highest for BRCA1 mutation carriers undergoing surgeries at higher age. 
Maximum increase in point estimates (from 1.8% to 4.1%) occurs in 40-year-old BRCA1 mutation 
carriers undergoing oophorectomy at age 45 years after nonprotective salpingectomy instead of 
salpingo-oophorectomy at age 40 years. In the best-case scenario, assuming 65% risk reduction 
by salpingectomy and 96% by salpingo-oophorectomy, point estimates increase (from 1.8% to 
2.6%) or decrease (from 3.4% to 3.3%) depending on age. In the worst-case scenario for BRCA2, 
point estimates maximally increase from 0.6% to 1.8% in 45-year-old carriers when oophorectomy 
is performed at age 50 years instead of risk-reducing salpingo-oophorectomy at age 45 years. In 
the best-case scenario, point estimates increase (from 1.3% to 1.5%) or decrease (from 1.5 to 1.3%).
Conclusion 
Differences in estimated ovarian cancer risks between risk-reducing salpingo-oophorectomy 
and salpingectomy with delayed oophorectomy are small, even if salpingectomy is ineffective. 
Presented estimated ovarian cancer risks can be used in counseling BRCA1/2 mutation carriers, 
thereby facilitating a personalized and well-informed choice for either strategy. 
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INTRODUCTION
Germline mutations in the BRCA1/2 genes are associated with high susceptibility for breast and 
ovarian cancer and these mutations are highly penetrant.1 Risk-reducing salpingo-oophorectomy 
is the only proven surgical strategy in reducing ovarian cancer risk.2,3 Until recently, risk-reducing 
salpingo-oophorectomy was also thought to reduce breast cancer risk by half when performed 
before natural menopause;2 however, this is contradicted by several recent publications.4-6 
The most important disadvantage of salpingo-oophorectomy at premenopausal age is onset 
of premature menopause, which is known to have several short- and long-term adverse effects 
like vasomotor symptoms, sexual dysfunction, osteoporosis, cardiovascular disease, cognitive 
impairment, and increased risk of premature death.7-10 Hormone therapy alleviates most 
menopausal effects to greater or lesser extent but not all.7 Therefore, a risk-reducing strategy 
enabling preservation of the ovaries and thereby increasing quality of life may be of great 
advantage. Together with the growing evidence for the fallopian tube as the place of origin of 
ovarian carcinoma,11-14 an alternative risk-reducing strategy has been suggested.15-20 This consists 
of early risk-reducing salpingectomy upon completion of childbearing followed by delayed risk-
reducing oophorectomy several years later than currently recommended. However, data on its 
effects on ovarian cancer risk are lacking. We need optimal insight into ovarian cancer risks before 
offering this alternative risk-reducing strategy to BRCA mutation carriers. Therefore, the aim of this 
study is to estimate cumulative ovarian cancer risks for this alternative strategy and to compare 
them with risks under standard risk-reducing salpingo-oophorectomy with the ultimate goal to 
personalize and optimize risk communication.
MATERIALS AND METHODS 
Literature search
We determined three important variables in estimating cumulative ovarian cancer risks, which were 
included in this modeling study: 1) cumulative ovarian cancer risks for BRCA1/2 mutation carriers, 2) 
the ovarian cancer risk reduction attributable to risk-reducing salpingo-oophorectomy, and 3) the 
assumed effect of risk-reducing salpingectomy based on the distribution of the histotypes of BRCA-
related ovarian carcinomas. An extensive review of the literature was performed on these variables 
to obtain hazard ratios as input for our risk model (Table 1). The MEDLINE database was searched 
for publications between 1964 and September 1, 2014 (date of our last search) using the following 
terms: 1) MeSH: Penetrance; Genes, BRCA1; Genes, BRCA2. Title&abstract: Meta-analysis; 2) title and 
abstract: Salpingo-oophorectomy; Salpingectomy; Oophorectomy; BRCA1; BRCA2; BRCA; Meta-
analysis; 3) MeSH: Humans; Title&Abstract: BRCA1; BRCA2; BRCA; Ovarian Cancer; Ovarian Carcinoma; 
Mutation Carrier(s); Germline; Pathology; Histology; Morphology; Epithelial. Titles and abstracts of 
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the identified 3, 10, and 171 reports, respectively, were read by one of the authors (M.G.H.) to select 
articles that were likely to report the requested effect sizes. Full texts of the remaining articles were 
scrutinized by one of the authors (M.G.H.) to further determine relevance and applicable hazard 
ratios were extracted from the relevant articles describing the largest patient groups as input for 
our model: one, two, and three articles, respectively. When available, most recent meta-analyses 
were considered best evidence (level I). The entire selection procedure was separately checked by 
one of the authors (J.A.d.H.). Whenever broad ranges in published data existed, we ran the model 
for the “best-case” and “worst-case” scenarios.
Table 1. Overview of the literature search
Parameter MEDLINE Search Hits Screening title 
and abstract on 
relevance
Selected after 
reading full 
text
Cumulative ovarian 
cancer risks 
MeSH Terms: Penetrance; Genes, BRCA1; 
Genes, BRCA2  
Title&Abstract: Meta-analysis
3 2 Chen 20071 
Efficacy of RRSO in 
reduction of ovarian 
carcinoma
MeSH Terms: - 
Title&Abstract: Salpingo-oophorectomy; 
Salpingectomy; Oophorectomy; BRCA1; 
BRCA2; BRCA; Meta-analysis
10 2 Marchetti 20143
Rebbeck 20092
Assumptions on 
efficacy of RRS 
(percentage of serous 
carcinomas among 
BRCA-related ovarian 
carcinomas)
MeSH Term: Humans  
Title&Abstract: BRCA1; BRCA2; BRCA; 
Ovarian Cancer; Ovarian Carcinoma; 
Mutation Carrier(s); Germline; Pathology; 
Histology; Morphology; Epithelial
171 7 Russo 20098
Bolton 201224 
Mavaddat 201225 
Abbreviations: RRSO, risk-reducing salpingo-oophorectomy; RRS, risk-reducing salpingectomy.
Data and assumptions
Chen et al.1 performed a meta-analysis of 10 studies to calculate mean cumulative ovarian cancer 
risks for BRCA1/2 mutation carriers until the age of 70 years taking into account competing deaths 
(Table 2). In our opinion, this most recent meta-analysis reflects the best available evidence (i.e., 
level I) and is worldwide frequently referred to when cumulative risks in BRCA1/2 mutation carriers 
are described.
Table 2. Mean cumulative risks for ovarian cancer at a certain age for a 20-year-old mutation carrier in absence 
of any risk-reducing surgery
Age (y)
Gene 30 40 50 60 70
BRCA1 1 (0.68-1.8) 3.2 (2.3-5.1) 9.5 (7.3-13) 23 (18-28) 39 (34-44)
BRCA2 0.19 (0.09-.47) 0.7 (0.37-1.5) 2.6 (1.5-4.5) 7.5 (5.1-11) 16 (12-20)
Data are % (95% confidence interval).
Data from Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
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Risk-reducing salpingo-oophorectomy is well established in reducing ovarian cancer risk in BRCA1/2 
mutation carriers. Although various hazard ratios (HRs) were found in previous studies (HR 0.04–
0.29), two meta-analyses were quite consistent and showed HRs of 0.21 and 0.19 corresponding to 
a risk reduction of approximately 80%.2,3
Rebbeck et al.2 performed a fixed-effects meta-analysis of pooled results from three nonoverlapping 
publications. Among 2,840 BRCA1/2 mutation carriers, an HR of 0.21 (95% confidence interval (CI) 
0.12–0.39) for ovarian cancer was found for risk-reducing salpingo-oophorectomy. A second fixed-
effects meta-analysis by Marchetti et al.3 included three studies, one overlapping Rebbeck et al.2 and 
two more recent prospective cohort studies. A total number of 9,192 BRCA1/2 mutation carriers 
were included; 46% had undergone risk-reducing salpingo-oophorectomy. They found an HR of 
0.19 (95% CI 0.13-0.27) for ovarian cancer after risk-reducing salpingo-oophorectomy.3 Sufficient 
data are lacking to discriminate between BRCA1 and BRCA2 mutation carriers with respect to the 
effect of risk-reducing salpingo-oophorectomy. In conclusion, the reported HRs for the whole 
group of BRCA1/2 mutation carriers are close to 0.20, so we assumed an HR of 0.20 for risk-reducing 
salpingo-oophorectomy (i.e., 80% risk reduction). 
However, the HR of 0.20 might be an underestimation of the effect of risk-reducing salpingo-
oophorectomy. First, the mean age at salpingo-oophorectomy was roughly 45 years in the 
previously mentioned studies, whereas current guidelines recommend risk-reducing salpingo-
oophorectomy at age 35-40 (BRCA1) or 40-45 (BRCA2). Second, it was not always clear whether 
complete salpingo-oophorectomy or oophorectomy alone was performed, the latter performed 
at times until the role of the fallopian tube became illuminated. Furthermore, histologic assessment 
of earlier salpingo-oophorectomy specimens might have missed occult carcinomas, because 
the protocol for sectioning and extensively examining the fimbriated end of the fallopian tube 
was introduced in 2006.21,22 Follow-up of patients was continued until after the introduction of 
sectioning and extensively examining the fimbriated end of the fallopian tube in only two of 
eight studies in the meta-analyses. When metastasized disease was subsequently misdiagnosed 
as primary peritoneal cancer, risk reduction of salpingo-oophorectomy could be underestimated. 
In conclusion, inclusion of older patients who might have undergone oophorectomy only or 
whose fallopian tubes were not fully examined in aforementioned studies could have led to 
underestimation of the effect. Therefore, we decided to also run the model with the best effect of 
risk-reducing salpingo-oophorectomy ever reported: HR of 0.04 (95% CI 0.01-0.16), corresponding 
to 96% risk reduction.23
No published data on the risk-reducing effect of salpingectomy in BRCA1/2 mutation carriers are 
available. The theory of ovarian carcinoma arising from the fallopian tube is related to the serous 
histotype. Therefore, we extracted data on the proportion of the serous histotype within BRCA-
related ovarian carcinoma to estimate the possible risk-reducing effect of salpingectomy. Two 
reviews8,24 and one original study using a large international database25 report on this. Altogether, 
approximately 65% of BRCA-related ovarian carcinomas are of the serous histotype (Table 3), 
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which equals the distribution within sporadic ovarian carcinoma.24 Assuming that most serous 
cancers originate from the fallopian tube, we expect that the best possible HR for risk-reducing 
salpingectomy lies around 0.35, that is, 65% risk reduction. 
However, the effect of risk-reducing salpingectomy can turn out to be greater because specimens 
in these large studies were not necessarily assessed or revised by a specialized gynecologic 
pathologist. Revision has been shown to partially reclassify former endometrioid and clear cell 
carcinomas as serous carcinomas, thereby slightly increasing the amount of serous carcinomas 
and indirectly the potential risk-reducing effect of salpingectomy.26 Furthermore, links between 
the fallopian tube and endometrioid and mucinous ovarian carcinomas have been described as 
well: through retrograde menstruation and endometriosis for the first and through Walthard cell 
nests, paratubal cysts and Brenner tumors for the latter.14 The effect of risk-reducing salpingectomy 
thus could be greater than we now assume if it is not limited to the serous histotype. 
In contrast, there is still a possibility that salpingectomy does not reduce ovarian cancer risk at all 
and it is uncertain at what age it should be performed. Therefore, we ran scenarios with HRs of 
either 0.35 or 1.0 for risk-reducing salpingectomy.
Table 3. Distribution of the serous histotype within BRCA-related ovarian carcinoma
 BRCA1 BRCA2
Study n Serous n (%) n Serous n (%)
Russo et al, 20098 543 296 (55%) 81 43 (53%)
Bolton et al, 201224 909 617 (68%) 304 213 (70%)
Mavaddat et al, 201225 813 534 (66%) 272 191 (70%)
Total 2265 1447 (64%) 657 447 (68%)
Model design and analyses
Chen et al.1 presented ovarian cancer risk estimates per 10-year intervals (e.g., cumulative risk for 
ovarian cancer at age 50 assuming no cancer at age 20). To transform these 10-year risks into yearly 
cumulative risk estimates, we used nonparametric interpolating splines. The resulting risks were 
used to calculate cumulative hazards for each age (t) as H(t)=-log(S(t)), where log is the natural 
logarithm and S(t) is the probability that cancer has not occurred at age t. Hazards h(t) for age t 
were calculated as the increment between H(t-1) and H(t). The hazards were multiplied with the 
hypothesized HRs (Table 4): if risk-reducing salpingectomy took place at age t
RRS
 and delayed risk-
reducing oophorectomy took place at age t
RRO
, the hazards between ages t
RRS
 and t
RRO
 (>t
RRS
 and 
≤t
RRO
) were multiplied with the assumed HR for risk-reducing salpingectomy (e.g., 0.35 in case of 
65% risk reduction or 1.0 in case of no risk reduction), and the hazards corresponding to ages >t
RRO
 
were multiplied with the assumed HR for risk-reducing salpingo-oophorectomy (i.e., 0.04 in case 
of 96% risk reduction or 0.20 in case of 80% risk reduction). New cumulative risks were calculated 
as 1 minus the exponentiated negative sum of the appropriate hazards, that is, 1- exp(-Sh
i
), where 
i denotes the relevant ages. For example, if a 35-year-old woman presents without ovarian cancer, 
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and risk-reducing salpingo-oophorectomy will take place at age 45 years with 80% risk reduction 
(HR 0.20), her estimated cumulative risk for ovarian cancer at age 70 is based on the hazards from 
age 36 years up to and including age 70 years, where the hazards from age 46 years onwards are 
multiplied with 0.20. The model design is illustrated in Figure 1.
Table 4. Overview of hazard ratios used in the Cox proportional hazard model
Model input
Parameter Best case Worst case
Risk reduction of ovarian cancer by RRSO or RRO HR 0.0423 HR 0.202,3
Assumed risk reduction of ovarian cancer by RRS HR 0.358,24,25 HR 1.0
Abbreviations: RRSO, risk-reducing salpingo-oophorectomy; RRO, risk-reducing oophorectomy; RRS, risk-
reducing salpingectomy; 
Twenty scenarios were run for BRCA1 with five explicitly chosen combinations of risk-reducing 
salpingectomy (risk reduction 65% or 0%) between age 33 and 40 years and second-stage risk-
reducing oophorectomy (risk reduction 96% or 80%) between age 40 and 45 years. For BRCA2, 
28 scenarios were run with seven different combinations of risk-reducing salpingectomy (risk 
reduction 65% or 0%) between age 33 and 43 years and second-stage risk-reducing oophorectomy 
(risk reduction 96% or 80%) between age 45 and 50 years. More scenarios for BRCA2 were run 
because the interval between completion of childbearing and recommended age for risk-reducing 
salpingo-oophorectomy is longer in BRCA2 mutation carriers.
Figure 1. Overview of model for each risk-reducing strategy with assumed hazard ratios per branch. The 
darker the field, the higher the mean cumulative ovarian cancer risk. Similar colors represent comparable risks 
at each age. The range of point estimates of the mean cumulative risk at age 70 is given for a mutation carrier 
who is currently 25 years old, and includes point estimates for different ages at risk-reducing surgeries and 
various intervals between them (if applicable).
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Because no human subjects were involved in this study, no informed consent was needed and the 
study was exempt from application to and approval of the institutional review board according to 
Dutch law.
RESULTS
BRCA1
BRCA1 mutation carriers’ cumulative risks of ovarian cancer at age 70 for several scenarios are 
provided in Table 5, conditional on the current age. Estimated cumulative risks assuming both 96% 
and 80% risk reduction by either risk-reducing salpingo-oophorectomy or delayed risk-reducing 
oophorectomy are displayed with corresponding 95% CIs. 
Postponing oophorectomy from age 38 to 43, for example, will increase the point estimate of a 
30-year-old BRCA1 mutation carrier’s cumulative risk from 3.4% to 5.2% (assuming 96% risk reduction 
of risk-reducing salpingo-oophorectomy) or from 10.4% to 11.8% (assuming 80% risk reduction of 
salpingo-oophorectomy) in case there is no effect of previous salpingectomy. In case risk-reducing 
salpingectomy at age 33 years already reduces her risk by 65%, point estimates will decrease from 
3.4% to 3.3% (96% risk reduction of salpingo-oophorectomy) or from 10.4% to 10.0% (80% risk 
reduction of salpingo-oophorectomy). Differences in risk estimates for this example assuming 96% 
risk reduction are displayed in Figure 2A.  
In a second example, a 35-year-old BRCA1 mutation carrier considers standard risk-reducing 
salpingo-oophorectomy at short term or risk-reducing salpingectomy at short term with delayed 
oophorectomy at age 40 years. Risk estimates for this example are illustrated in Figure 2B for an 
assumed 96% risk reduction of salpingo-oophorectomy. 
The maximum increase in point estimates (from 1.8% to 4.1%) occurs in a 40-year-old BRCA1 
mutation carrier undergoing oophorectomy at age 45 years after nonprotective salpingectomy 
instead of salpingo-oophorectomy (96% risk reduction) at age 40 years. Assuming 65% risk 
reduction by salpingectomy and 96% of salpingo-oophorectomy, point estimates either increase 
(maximum increase from 1.8% to 2.6%) or decrease (maximum decrease from 3.4% to 3.3%) 
depending on current age and intervals between surgeries.
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Figure 2. Estimated cumulative ovarian cancer risk (point estimates and 95% confidence intervals) for 
currently unaffected BRCA1 (A en B) and BRCA2 (C and D) mutation carriers. Abbreviations: RRS, risk-reducing 
salpingectomy; RRSO, risk-reducing salpingo-oophorectomy; RRO, risk-reducing oophorectomy.
BRCA2
Table 6 provides cumulative risks of ovarian cancer at age 70 years for several scenarios for BRCA2 
mutation carriers conditional on the current age. Estimated cumulative risks assuming both 96% 
and 80% risk reduction by either risk-reducing salpingo-oophorectomy or delayed risk-reducing 
oophorectomy are displayed with 95% CIs.
For example, postponing oophorectomy from age 40 to 45 years will increase the point estimate 
of a 35-year-old BRCA2 mutation carrier’s cumulative risk from 1.0% to 1.7% (assuming 96% risk 
reduction of salpingo-oophorectomy) or from 3.6% to 4.2% (assuming 80% risk reduction of 
salpingo-oophorectomy) in case there is no effect of previous salpingectomy. In case risk-reducing 
salpingectomy at age 35 years already reduces her risk by 65%, point estimates will be equal 
assuming 96% risk reduction of salpingo-oophorectomy and increase from 3.5% to 3.6% assuming 
80% risk reduction of salpingo-oophorectomy. Differences in risk estimates for this example 
assuming 96% risk reduction of salpingo-oophorectomy are displayed in Figure 2C. 
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In a second example, a 40-year-old BRCA2 mutation carrier considers standard risk-reducing 
salpingo-oophorectomy at age 43 years or risk-reducing salpingectomy at short term with delayed 
risk-reducing oophorectomy at age 48 years. Risk estimates for this example are illustrated in Figure 
2D for an assumed 96% risk reduction of salpingo-oophorectomy. 
In the worst-case scenario for BRCA2, point estimates maximally increase from 0.6% to 1.8% in 
45-year-old carriers when oophorectomy is performed at age 50 years instead of risk-reducing 
salpingo-oophorectomy at age 45 years. Assuming 65% risk reduction of salpingectomy, and 96% 
of salpingo-oophorectomy, point estimates either increase (maximum increase from 1.3% to 1.5%) 
or decrease (maximum decrease from 1.5% to 1.3%) depending on current age and age at surgery.
DISCUSSION
In this study, cumulative risks of ovarian cancer for several risk-reducing strategies in BRCA1/2 
mutation carriers are estimated by modeling data from the literature. Because risk-reducing 
salpingectomy with delayed oophorectomy has not been clinically studied yet, risk reduction 
rates for salpingectomy were estimated by combining existing data: 65% (best-case) or 0% 
(worst-case). In the best-case scenario, risk estimates were very similar for risk-reducing salpingo-
oophorectomy at the currently recommended age and for risk-reducing salpingectomy with 
delayed oophorectomy 5 years beyond the currently recommended age. In the worst-case 
scenario (assuming no risk-reducing effect of salpingectomy), delaying oophorectomy by 5 years 
is estimated to maximally increase cumulative risk point estimates by 2.3 (BRCA1) and 1.2 (BRCA2) 
percentage points compared with risk-reducing salpingo-oophorectomy. Oophorectomy remains 
part of every scenario and none of the presented risk estimates are for salpingectomy alone. 
Two research groups have published simulation models for risk-reducing surgery in BRCA1/2 
mutation carriers since 2010.16,27 Kurian et al.27 published a Monte Carlo simulation model as an 
online tool for cancer incidences and survival under risk-reducing mastectomy and risk-reducing 
salpingo-oophorectomy at different ages. For scenarios matching ours, results lie within the same 
range. They conclude that early mastectomy and salpingo-oophorectomy most effectively prevent 
cancer. However, alternative strategies resulted in similar survival rates, albeit reducing cancer 
incidence less substantially. 
Kwon et al.16 published the only model that included risk-reducing salpingectomy (at age 40 years, HR 
0.40) with delayed oophorectomy (at age 50 years) besides risk-reducing salpingo-oophorectomy 
(at age 40 years, HR 0.20 for ovarian and HR 0.30–0.60 for breast cancer). They calculated gain in life 
expectancy and quality-adjusted life-years using a Markov model with Monte Carlo simulations. 
Risk-reducing salpingo-oophorectomy at age 40 years offered the greatest risk reduction for 
ovarian and breast cancer, but risk-reducing salpingectomy with delayed oophorectomy was cost-
effective considering quality-adjusted life expectancy and therefore a reasonable alternative for 
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BRCA1/2 mutation carriers who are reluctant to undergo risk-reducing salpingo-oophorectomy.
BRCA1/2 mutation carriers’ choice for risk-reducing strategies is highly personal. To make an 
informed choice between risk-reducing salpingo-oophorectomy and risk-reducing salpingectomy 
with delayed oophorectomy, knowledge of estimated ovarian cancer risks under several scenarios 
is essential. BRCA mutation carriers should decide themselves which consequence outweighs 
the other: the possibility of slightly higher estimated ovarian cancer risks or the acute onset of 
surgical menopause and its consequences. The main strength of our model is that we provide 
such risk estimates for a number of potential scenarios: surgery at several ages and with various 
time intervals between risk-reducing salpingectomy and oophorectomy. Consequently, the risk 
estimates generated by our model can contribute to the decision for or against the alternative 
strategy. Another strength is that we have taken into account two different risk reduction rates for 
risk-reducing salpingo-oophorectomy: 80% (two meta-analyses) and 96% (best ever reported).2,3,23
Although halving of breast cancer risk by premenopausal risk-reducing salpingo-oophorectomy 
was widely communicated until recently,2 we did not include the effect of salpingo-oophorectomy 
on breast cancer in our model. Heemskerk-Gerritsen et al.6 found no beneficial effect of risk-
reducing salpingo-oophorectomy on breast cancer after applying alternative analyses to earlier 
large cohort studies, thereby minimizing amounts of bias. Furthermore, the effect of salpingo-
oophorectomy is irrelevant for the substantial part (up to 32%) of BRCA1/2 mutation carriers having 
already undergone mastectomy by age 40-45 years.28
The most important limitation of our study is the uncertainty about assumptions the model 
was built on. First, reported penetrance of ovarian cancer at different ages in BRCA1/2 mutation 
carriers widely differs.1,5,29 This might be the result of methodologic differences and differences 
in patient populations. If penetrance appears to be higher in reality than reported by Chen et al.,1 
our model might underestimate absolute differences in cumulative risks. Second, given the lack of 
previous studies on its efficacy, risk reduction estimates for salpingectomy were totally based on 
the hypothesis that all serous ovarian carcinomas in BRCA1/2 mutation carriers could be prevented 
by salpingectomy. The 58% risk reduction of ovarian cancer after tubal ligation in BRCA1 mutation 
carriers could be considered indirect evidence.30 
Based on the presented risk estimates, we conclude that risk-reducing salpingectomy necessarily 
followed by delayed oophorectomy may be offered to BRCA1/2 mutation carriers as an alternative 
strategy to risk-reducing salpingo-oophorectomy, preferably within a clinical trial. With current age 
as well as timing and type of surgeries taken into account, these ovarian cancer risk estimates are 
highly personalized. Providing these personal risk estimates, our model may support both patients 
and physicians in shared decision-making, and this may contribute to individualized health care. A 
decision aid might be helpful to comprehensibly present these risk estimates to patients.
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ABSTRACT
Background
Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to 
BRCA1/2 mutation carriers. This procedure decreases the elevated ovarian cancer risk by 80–96% 
but it initiates premature menopause as well. The latter is associated with short-term and long-
term morbidity, potentially affecting quality of life (QoL). Based on recent insights into the fallopian 
tube as possible site of origin of serous ovarian carcinomas, an alternative preventive strategy has 
been put forward: early risk-reducing salpingectomy (RRS) and delayed oophorectomy (RRO). 
However, efficacy and safety of this alternative strategy have to be investigated.
Methods
A multicenter non-randomized trial in 11 Dutch centers for hereditary cancer will be conducted. 
Eligible patients are premenopausal BRCA1/2 mutation carriers after completing childbearing 
without (a history of ) ovarian carcinoma. Participants choose between standard RRSO at age 35–
40 (BRCA1) or 40–45 (BRCA2) and the alternative strategy (RRS upon completion of childbearing 
and RRO at age 40–45 (BRCA1) or 45–50 (BRCA2)). Women who opt for RRS but do not want to 
postpone RRO beyond the currently recommended age are included as well. Primary outcome 
measure is menopause-related QoL. Secondary outcome measures are ovarian/breast cancer 
incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and diseases, and 
cost-effectiveness. Mixed model data analysis will be performed.
Discussion 
The exact role of the fallopian tube in ovarian carcinogenesis is still unclear. It is not expected that 
further fundamental research will elucidate this role in the near future. Therefore, this clinical trial 
is essential to investigate RRS with delayed RRO as alternative risk-reducing strategy in order to 
improve QoL. 
Trial registration
ClinicalTrials.gov (NCT02321228)
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BACKGROUND
BRCA germline mutations and ovarian cancer
Epithelial ovarian cancer is the most lethal malignancy of the female genital tract. With respect 
to treatment and prognosis, primary carcinomas of the ovaries, fallopian tubes and peritoneum 
are considered one disease entity often referred to as ‘ovarian carcinoma’. Women with germline 
mutations in one of the two BRCA genes are at increased risk of developing breast and ovarian 
cancer. Cumulative breast cancer risks are estimated 57–65% (95% CI: 44–78%) for BRCA1 and 45–
49% (95% CI: 31–57%) for BRCA2 mutation carriers by age 70, whereas cumulative ovarian cancer 
risks lie around 39–40% (95% CI: 18–54%) and 11–18% (95% CI: 2.4–23%) by the age of 70 for 
BRCA1 and BRCA2, respectively.1,2 Ovarian carcinoma occurs at younger age in BRCA1 mutation 
carriers than in BRCA2 mutation carriers or the general population (both mean and median 51 
versus 56 versus 60 years respectively).3 In BRCA1/2 germline mutation carriers, approximately 65% 
of all ovarian carcinomas are of the serous subtype.4-6
Risk-reducing salpingo-oophorectomy (RRSO) 
In contrast to breast cancer surveillance, screening for ovarian cancer has been highly ineffective.7-9 
Therefore, the only intervention to reduce ovarian cancer risk is risk-reducing salpingo-
oophorectomy (RRSO), which decreases ovarian cancer incidence by about 80–96%.4,10-12 However, 
this effect might be underestimated due to studies that included women who underwent 
oophorectomy alone and/or underwent surgery above the currently recommended age: 35–40 
for BRCA1 and 40–45 for BRCA2 mutation carriers.4,11,13 The residual risk of primary peritoneal cancer 
after RRSO is approximately 1%; however, it was also reported to be more than 4%.10,14-16 RRSO is 
often laparoscopically performed at an outpatients’ department. Serious surgical complications 
rates are low.4,17,18 Main adverse effects of RRSO are related to premature surgical menopause, 
including short-term effects like vasomotor symptoms (i.e. hot flushes), sleep disturbances, 
vaginal dryness and sexual symptoms.4 Long-term effects include osteoporosis, increased risk of 
cardiovascular disease, cognitive impairment and increased depressive and anxiety symptoms, 
although prospective studies on these long-term effects in BRCA mutation carriers in particular 
are not available.4,19-22 Postsurgical hormone replacement therapy (HRT) does not fully alleviate 
climacteric and sexual symptoms.20,23 The reduction of breast cancer incidence by half achieved 
by performing RRSO at premenopausal age11,12 has recently become arguable24-26 and therefore 
questionable as motivation to undergo RRSO.
Role of fallopian tube in “ovarian” carcinogenesis
Based on recent scientific insights, the fallopian tube is considered the most important site of origin 
of pelvic high grade serous carcinoma nowadays.27-31 It is suggested that benign tubal epithelium 
can transform into serous tubal intraepithelial carcinoma (STIC) or invasive tubal carcinoma.32 The 
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(pre)malignant cells can exfoliate from the tubal epithelial lining and migrate to the ovary and 
abdominal cavity. This theory is based on several findings. First, no clear precursor of ovarian cancer 
has been found in the ovary itself. Second, earlier studies showed the presence of STIC in 36–60% 
of sporadic pelvic serous carcinomas33-35 which harbored identical mutation in the TP53 gene to the 
cells of concurrent pelvic serous carcinomas in 92%.36 Third, pelvic serous carcinoma cells resemble 
tubal lining epithelium more than ovarian surface epithelium.37 Several investigators focused on 
prophylactically removed fallopian tubes of germline BRCA1/2 mutation carriers, showing the 
presence of STIC in about 4% (range 0–12%);14,38-47 nearly all STICs were localised in the tubal distal 
fimbrial ends.34
Innovative preventive strategy: risk-reducing salpingectomy (RRS) with delayed 
oophorectomy (RRO) 
The growing evidence of the role of the fallopian tube in the origin of serous ovarian carcinoma 
together with the disadvantages of premature surgical menopause caused by RRSO underlie the 
need for an alternative risk-reducing strategy. RRS upon completion of childbearing offers an early, 
potentially risk-reducing intervention; however, it is still uncertain whether and to what extent 
the risk of ovarian cancer will be reduced. Furthermore, around 68% of occult carcinomas are 
found in tubes48 and could now be detected at an early stage. The main advantage of delaying 
subsequent RRO beyond the currently recommended age will be postponement of premature 
menopause and its effect on noncancer-related morbidity and (menopause-related) quality of 
life (QoL). Several authors previously suggested this innovative strategy48-50 and a feasibility study 
among both professionals and germline BRCA1/2 mutation carriers from our group showed a 
broad national support to evaluate this new strategy in a prospective study.51
Objective
The aim of this study is to determine whether an innovative risk-reducing strategy, consisting of 
RRS upon completion of childbearing with delayed RRO, results in better menopause-related QoL 
without increase of ovarian and breast cancer risk in germline BRCA1/2 mutation carriers compared 
to standard treatment, consisting of RRSO at currently recommended age.
METHODS/DESIGN
Study design
We will perform a nationwide prospective non-randomized multicenter trial in 11 hospitals 
with a department for hereditary cancer. Eligible patients will have the opportunity to choose 
for standard or innovative strategy. Women who opt for RRS but do not want to postpone RRO 
beyond the currently recommended age or are unsure about this at enrollment are included 
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as well; however, they will not contribute to the number of inclusions needed according to the 
sample size calculation. See Figure 1 for an overview of the study design.
Figure 1. TUBA study design
Although a randomized controlled trial would be the preferred study design, an earlier published 
feasibility study among healthcare professionals and germline BRCA1/2 mutation carriers showed 
that randomization would be an insurmountable barrier for participation in a clinical study.51 These 
women want to decide themselves on their risk-reducing strategy and it is therefore unlikely that 
they will participate in a randomized controlled trial. Taken this into account, a prospective non-
randomized design seems the most appropriate, letting women the opportunity to decide for 
themselves.
In addition, a control group will be formed by women who underwent RRSO between 1 and 5 
years ago, in order to compare QoL between study participants and women who did not have the 
opportunity to choose for an alternative treatment.
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Study population
a. Hospitals
Eleven hospitals with a hereditary cancer department will participate in this study, of 
which seven are university tertiary hospitals.
b. Patients
Women carrying a documented germline BRCA1/2 mutation from the department of 
Clinical Genetics or Hereditary Cancer of each hospital, who are between 25 and 40 
(BRCA1) or 45 (BRCA2) years old without previous RRSO.
Inclusion criteria
- Premenopausal women with a documented BRCA1 and/or BRCA2 gene germ- 
   line mutation
- Age 25–40 years for BRCA1 mutation carriers and 25–45 years for BRCA2
- Childbearing completed
- Presence of at least one fallopian tube
- Participants may have a personal history of non-ovarian malignancy
- Informed consent
Exclusion criteria
- Postmenopausal status (natural menopause or due to (cancer) treatment)
- Wish for second stage RRO within two years after RRS (if clear at enrollment)
- Legally incapable
- Prior bilateral salpingectomy
- A personal history of ovarian, fallopian tube or peritoneal cancer
- Evidence of malignant disease at enrollment
- Current treatment for malignant disease
- Inability to read or speak Dutch
c. Patient recruitment
Eligible women will be sent a letter to inform them on this study. BRCA1/2 mutation 
carriers will be asked to respond whether or not they would be interested to participate. If 
they are interested, the patient information form will be sent and an appointment will be 
made to explain the rationale, design and aims of the study in person. The patient will have 
sufficient time (at least one week) to consider the study before deciding to participate. 
Written informed consent from the patient is required before participation. Furthermore, 
every newly diagnosed germline BRCA1/2 mutation carrier at the department of Clinical 
Genetics that fulfills the inclusion criteria will be informed on the study.
Outcome measures
a. Primary outcome measure
Menopause-specific QoL, measured by the Greene Climacteric Scale (GCS) questionnaire 
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in Dutch.52 This questionnaire consists of 21 items divided into various domains: 
psychological (11 items, divided into anxiety and depression subscales), somatic (7 items), 
vasomotor symptoms (2 items) and sexual (1 item). Each symptom is rated according to 
its severity using a four-point Likert scale. The Greene Climacteric score is the sum of all 
21 items ranging from 0 to 63. A higher total score corresponds with more menopausal 
symptoms.
b. Secondary outcome measures
- General QoL and QoL-related items, measured by several questionnaires (see section 
Pre-treatment evaluation)
- Incidence of ovarian and breast cancer
- Surgical complications, e.g. infection, conversion, hemorrhage and complications at the 
second laparoscopic procedure (RRO) due to previous RRS.
- Histopathological findings of removed fallopian tubes and ovaries, i.e. (pre)malignancies
- Cardiovascular risk factors and incidence of cardiovascular disease
- Cost-effectiveness of the innovative treatment
Interventions
a. Standard treatment (control arm):
RRSO between age 35–40 in BRCA1 mutation carriers and between 40–45 in BRCA2 
mutation carriers (exact ages vary across different hospitals) and when childbearing is 
completed.
b. Innovative treatment (experimental arm):
RRS when childbearing is completed with second stage RRO delayed for five years 
compared to the currently recommended age for RRSO, i.e. at the age of 40–45 in BRCA1 
and 45–50 in BRCA2 mutation carriers. Regarding the definitive contraception which is a 
result of RRS and the age at which RRS is performed, women will be counseled in a similar 
manner as women consulting the gynecologist for sterilization. RRS will be performed 
according to Leblanc et al.53 Whenever a (pre)malignancy is found in the RRS specimen, 
RRO will be performed as soon as possible, as well as additional surgery or treatment if 
necessary, e.g. staging procedure.
Data collection
a. Pre-treatment evaluation
All patients will be asked to fill out web-based baseline questionnaires. Questionnaires on 
demographic data and medical history with a special focus on cancer and cardiovascular 
risk factors are included. Furthermore, QoL(−related) questionnaires include Dutch 
versions of the Greene Climacteric Scale (GCS),52 SF-36,54 EQ-5D-5 L,55 Cancer Worry Scale 
(CWS),56,57 Female Sexual Function Index (FSFI),58,59 Female Sexual Distress Scale (FSDS),59,60 
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and Decisional Conflict Scale (DCS).61 Questions based on the Institute of Medical 
Technology Assessment Productivity Cost Questionnaire (iPCQ)62 and the Medical 
Consumption Questionnaire (iMCQ)63 will be used to collect data on productivity loss 
and health consumption. Moreover, blood pressure, body mass index and waist-hip ratio 
will be documented. Fasting blood samples will be taken to measure cardiovascular risk 
factors.
b. Follow-up
Six weeks after surgery, data on surgical complications and histopathological findings 
are collected. The Sectioning and Extensively Examining the FIMbriated End (SEE-
FIM) of the fallopian tube (SEE-FIM) protocol will be used for the latter.64 Follow-up by 
web-based questionnaires as described at baseline except for the Decisional Conflict 
Scale is scheduled at 3 and 12 months after surgery. At 1, 5 and 15 years follow-up, the 
Decision Regret Scale (DRS) is added.65 From one year after surgery, questionnaires will 
be sent biennially until the end of follow-up (in case of only one surgery in the standard 
treatment arm) or until undergoing RRO (in the innovative arm). After RRO, data will be 
collected at six weeks and 3 and 12 months after surgery, comparable to follow-up after 
the first operation, and then biennial questionnaires will be sent until the end of follow-
up, 15 years after the last (or only) surgery. Additionally, blood pressure, body mass index, 
waist-hip ratio and cardiovascular risk factors in fasting blood samples will be collected 
five years after each surgery. Follow-up by questionnaires will continue biennially until 
15 years after the last surgery to detect occurrence of ovarian cancer. Since the wide 
possible range of age at inclusion, timing of surgeries and interval between surgeries, it 
is hard to specify and generalize the exact amount and timing of follow-up. A flowchart 
visualizing the follow-up schedule can be found in Figure 2.
c. Cost-effectiveness
This economic evaluation will compare costs and quality adjusted life years (QALY) of 
the innovative treatment with standard treatment. The perspective of this economic 
evaluation will be a societal perspective. Both healthcare and societal costs which can be 
related to this study will be assessed until 15 years after last surgery. Costs are collected 
on a per patient level. The incremental costs of innovative care compared to standard 
care will be based on the difference in costs between groups. The healthcare costs, 
measured by the Medical Consumption Questionnaire (iMCQ) tailored to this context, 
will be calculated. Societal costs will be calculated from a selection of the Productivity 
Cost Questionnaire (iPCQ). The output or consequences of both innovative and standard 
care will be determined by measuring QoL before and during the study. The SF-36 and 
EQ-5D-5 L will be used for this analysis. The outcomes will be translated to a long-time 
difference in QALY. Key variables will be varied in a sensitivity analysis to evaluate their 
impact on the incremental costs per QALY gained ratio. Including the innovative strategy 
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in future guideline recommendations depends on the incremental cost per QALY. 
As mentioned before, data will be collected until 15 years after last surgery. However, 
an interim cost-effectiveness analysis will be performed after eight years to provide 
information for proceeding implementation. Recommendation for implementation will 
be based on the empirical cost data completed with modeled costs over the remaining 
period. Accuracy of this model will be evaluated at the end of 15 years follow-up, when 
data collection on the actual costs during the remaining seven years will have been 
completed.
d. Potential adverse events
In the innovative treatment, BRCA1/2 mutation carriers will undergo an additional 
laparoscopy. Known complication rates for RRSO in a comparable population vary from 
0.6–5% for major complications (conversion, bladder or bowel injury, additional surgery 
required) and 3.7–10% for minor complications (infection, bleeding, hematoma).17,18,42,66 
Risks might be lower for RRS alone. As mentioned before, data on surgery-related 
complications will be collected six weeks after each surgery. Furthermore, the worst-case 
scenario is that RRS does not reduce ovarian cancer risk at all. Then, the postponement of 
RRO for five years might result in a higher ovarian cancer incidence in the experimental 
arm. We used a model to calculate the risk for interval ovarian carcinoma when RRO is 
performed five years later than the current guideline age. The risk to develop ovarian 
carcinoma within these five years is estimated to be up to 1–2% for BRCA1 mutation 
carriers and up to 0.5–1% for BRCA2 mutation carriers. Cancer incidence will be monitored 
by questionnaires.
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Statistical analysis
a. Sample size calculation
The primary outcome measure is menopause-specific QoL. Menopausal symptoms will 
be assessed by the Greene Climacteric Scale (GCS). The main comparison is the difference 
in GCS between women getting the innovative treatment and women getting standard 
RRSO without postsurgical hormone replacement therapy (HRT), which is about one 
third of women after RRSO. This difference is estimated at five points on the GCS, with 
standard deviation 7.36, based on figures of Barentsen et al.67 Each hospital will provide 
both innovative and standard treatment, based on patient choice (no randomization). We 
assume an intra-cluster correlation coefficient ≤0.10. When we have about 10 hospitals, 
with 51 patients per hospital (total n = 510), we expect that the majority of hospitals 
(7 hospitals or more) will provide at least 3 patients with the innovative treatment. The 
remaining hospitals (3 or less) provide 51 patients with standard treatment of whom 16 
will be on RRSO without HRT. This scenario gives an 80% power (alpha = 0.05). 
b. Data analysis
To test differences between two subgroups on the course of QoL since baseline, we 
will carry out a mixed model analysis to accommodate for hospital effects and repeated 
measurements. All secondary outcome measures will be analyzed using mixed models 
in a similar manner. Cost-effectiveness, as far as it concerns the empirical data, is analyzed 
in a stochastic fashion using bootstrapped regression based techniques (i.e. linear mixed 
model) adhering to the net benefit framework.
c. Safety
An independent Data Safety Monitoring Board (DSMB) is established, existing of three 
independent experts who have no conflict of interest. This committee will meet once a 
year to perform interim analysis specifically with respect to safety. The DSMB will report to 
the study coordinator and may recommend changes in the conduct of the study or even 
premature study termination.
Ethics
The study is conducted according to the principles of the Declaration of Helsinki (2008) and to the 
Medical Research Involving Human Subjects Act (Dutch: WMO). The protocol has been medical-
ethically approved to be conducted in all 11 centers by the Medical-Ethical Committee of Arnhem-
Nijmegen (NL 50048.091.14). The participating centers are the Radboud university medical center 
Nijmegen, Maastricht University Medical Centre, Erasmus MC Cancer Clinic Rotterdam, Center 
for Gynecological Oncology Amsterdam (CGOA): location Netherlands Cancer Institute/Antoni 
van Leeuwenhoek Hospital and location Amsterdam Medical Center, University Medical Center 
Groningen, UMC Utrecht Cancer Centre, Leiden University Medical Centre, Gynecologic Oncologic 
Center South: two locations of Elisabeth-TweeSteden Hospital Tilburg and location Catharina 
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Hospital Eindhoven. Furthermore, the protocol is registered in Clinicaltrials.gov (NCT02321228). 
Written informed consent is obtained from all patients before enrollment.
DISCUSSION
In this study protocol, we describe a prospective non-randomized multicenter trial in premenopausal 
BRCA mutation carriers. We compare the standard strategy to reduce ovarian cancer risk, i.e. RRSO 
at recommended age of 35–40 in BRCA1 and at recommended age of 40–45 in BRCA2 mutation 
carriers, with an innovative risk-reducing strategy. In this innovative strategy, early RRS is performed 
upon completion of childbearing and subsequent RRO is delayed for five years compared to 
the currently recommended age for the standard strategy. The primary outcome measure is 
menopause-related QoL. Secondary outcome measures include safety (cancer incidence and 
surgical complications), histopathological findings of surgery specimens, cardiovascular risk factors 
and cost-effectiveness. 
Currently, there are two other ongoing studies investigating different aspects of salpingectomy in 
germline BRCA mutation carriers. A research group from Texas investigates patient compliance with 
delayed oophorectomy after having undergone prophylactic salpingectomy (NCT01907789). They 
compare three regimens: ovarian cancer screening (3 years follow-up), prophylactic salpingectomy 
with delayed oophorectomy (4 years of follow-up including 1 year after oophorectomy) and risk-
reducing salpingo-oophorectomy (1 year follow-up). QoL is measured as well. Like our study, 
they do not randomize. This study focuses on another endpoint, i.e. whether BRCA mutation 
carriers return for oophorectomy after earlier salpingectomy. Duration of follow-up is adjusted to 
this endpoint en is relatively short to assess the safety of RRS with delayed RRO as it comes to 
cancer incidence and noncancer-related morbidity. In our study, we focus on QoL, and several 
subdomains of QoL are measured as well. Nevertheless, our follow-up will not be ceased after QoL 
data completion, but will be prolonged to guarantee a close monitoring of cancer incidence and 
noncancer-related morbidity.
In a French study, BRCA mutation carriers who are reluctant to RRSO because of onset of premature 
menopause are offered a radical fimbriectomy as alternative (NCT01608074). Primary outcome 
is the number of pelvic serous carcinomas occurring between fimbriectomy and menopause. 
Secondary outcomes are perioperative morbidity, histopathologic findings of fimbriectomy 
specimens, incidence of breast cancer and the rate of secondary oophorectomy and associated 
morbidity. In this study, fimbriectomy is only offered to women who refuse RRSO and RRS will in 
principle not be followed by RRO, while all women in our study eventually undergo RRO (current 
uptake of RRSO among BRCA mutation carriers is 95% in the Netherlands). Furthermore, in this 
French study BRCA mutation carriers have to be older than 35 years to be included. We include 
women from 25 years old, to optimize possible risk reduction by removing the fallopian tubes as 
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early as possible upon completion of childbearing. At last, the possible advantages of preservation 
of the ovaries for QoL are not evaluated in this fimbriectomy study, while this is the primary 
outcome in our study.
In conclusion, the current standard RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2) is highly effective 
in reducing ovarian cancer incidence. However, consequent premature surgical menopause comes 
with short- and long-term noncancer-related morbidity and probably affects QoL. New insights in 
the origin of serous pelvic cancer put the fallopian tube forward as target for alternative preventive 
surgery. The extent of the role of the fallopian tubes in ovarian carcinogenesis remains uncertain. 
We expect that early salpingectomy with delayed oophorectomy is a reasonable alternative to 
preserve ovarian function towards the age of natural menopause without a significant increase in 
ovarian cancer incidence.
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ABSTRACT
Objective 
Risk-reducing salpingo-oophorectomy around 40 years of age is currently recommended to 
BRCA1/2 mutation carriers to reduce their increased ovarian cancer risk. Premature menopause 
is the main adverse effect of this procedure. Therefore, an alternative strategy consisting of 
salpingectomy with delayed oophorectomy is currently being investigated in a preference trial. A 
patient decision aid that combines evidence with patient preferences is needed to facilitate this 
complex decision-making process.
Methods 
A patient decision aid was systematically developed in an iterative process of prototype 
development, pilot testing by patients and clinicians, and revisions. Information was based on 
available literature and current guidelines. Development was in accordance with the International 
Patient Decision Aid Standards (IPDAS) quality criteria. A multidisciplinary steering group supervised 
the process.
Results 
The patient decision aid underwent four rounds of pilot testing and revisions. Finally, two paper 
decision aids were developed: one for BRCA1, one for BRCA2. They both contained a general 
introduction, three chapters, and a step-by-step plan containing a personal value clarification 
worksheet. During pilot testing, risk communication and information about premature menopause 
and hormone replacement therapy were the most revised items. The patient decision aids fulfill 37 
of 43 IPDAS criteria for content and development process. Effectiveness has not been evaluated 
yet.
Conclusion 
Both BRCA1/2 mutation carriers and professionals are willing to use or offer the developed patient 
decision aids for the choice between risk-reducing salpingo-oophorectomy and salpingectomy 
with delayed oophorectomy. The patient decision aids have been found clear, balanced and 
comprehensible. Future testing among patients facing the decision should point out its 
effectiveness in improving decision-making.
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INTRODUCTION 
Women harboring a germline mutation in the BRCA1 and/or BRCA2 genes have an increased risk of 
breast and ovarian cancer.1 The most effective way to diminish this ovarian cancer risk is removing 
fallopian tubes and ovaries during risk-reducing salpingo-oophorectomy, preferably around the 
age of 40 years.2,3 However, salpingo-oophorectomy at that age results in acute onset of premature 
menopause with several short- and long-term health consequences.4-6
Therefore, salpingectomy upon completion of childbearing with delayed oophorectomy has 
been proposed as alternative strategy to reduce ovarian cancer risk.7-9 This strategy is based on the 
growing evidence that (serous) ovarian cancer mainly originates from the fallopian tube,10-12 and is 
currently being investigated in a Dutch preference trial (NCT02321228).13 However, safety in terms 
of ovarian cancer risk has not been proven yet, which is the main disadvantage of this alternative 
strategy.
Because of different pros and cons of both strategies, the choice of trial participants between 
risk-reducing salpingo-oophorectomy and salpingectomy with delayed oophorectomy is complex 
and highly personal. It is important to educate and empower these women in the decision-making 
process. Previously, patient decision aids have been shown to increase knowledge, improve risk 
perception, lower decisional conflict, reduce proportions of people remaining undecided, and can 
improve patient satisfaction.14 Interestingly, they also increase the number of patients who prefer 
conservative treatment options rather than invasive surgery.14
Our aim was to systematically develop and pilot-test a patient decision aid for ovarian cancer risk 
reduction in BRCA1/2 mutation carriers that combines evidence with patient preferences.
METHODS
Development
Recommendations published by Coulter et al.15 guided the development process of the patient 
decision aid (Figure 1). The prototype was developed by a project group consisting of a medical 
doctor, a gynecologic oncologist, and an expert in shared decision-making and guideline 
implementation, assisted by a patient and professional expert panel, and in accordance with the 
international quality criteria of the International Patient Decision Aid Standards (IPDAS).16 The 
development process was supervised by a steering group, consisting of a professor of gynecologic 
oncology, professor of hereditary cancer, and biostatistician. None of the steering group members 
had any conflicts of interest.
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Figure 1. Systematic development process of the patient decision aid
Scope and purpose
Given the complex decision that has to be made within our preference trial on risk-reducing 
salpingo-oophorectomy and salpingectomy with delayed oophorectomy in BRCA1/2 mutation 
carriers (NCT02321228),13 the project and steering group agreed on the need for a decision support 
tool for trial participants. Options to be discussed in the decision aid resulted from the two possible 
options in the preference trial. Besides, watchful waiting (i.e., no risk-reducing surgery) completed 
the overview of options.
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Exploring patients’ decisional needs
Points of consideration in the choice between risk-reducing salpingo-oophorectomy and 
salpingectomy with delayed oophorectomy were extracted from literature, searching the Medline 
database for “BRCA” or equivalents and “salpingectomy” or “delayed oophorectomy”. Furthermore, 
we interviewed BRCA1/2 mutation carriers and their healthcare professionals in the process of 
designing the aforementioned preference trial.8 The purpose of these interviews was to explore 
barriers and facilitators for the introduction of salpingectomy with delayed oophorectomy as 
alternative risk-reducing strategy. One year later, a random selection of these women attended 
another session to discuss the content of the trial patient information booklet and decision aid. 
Content and format
Based on the identified decisional needs, guidelines, and expert opinions, the project group 
together with the steering group determined five domains that are important for decision-
making in this setting: 1) risks and 2) benefits of watchful waiting, salpingo-oophorectomy, and 
salpingectomy with delayed oophorectomy; 3) premature menopause and hormone replacement 
therapy (HRT); 4) strength and availability of evidence; 5) women’s preferences. For the first three 
domains, we collected available literature to compose the content of the decision aid; the fourth 
domain was based on appraisal of the evidence found. The literature search for domains 1) and 
2) is described in detail elsewhere.17 The Medline database was searched for the third domain 
using the terms “BRCA” or equivalents and “menopause” or equivalents in September 2014. For the 
fifth domain, the best way to clarify individual preferences was also extracted from literature and 
combined with expert opinions within our project group. To be able to hand out and discuss the 
patient decision aid at the outpatient department, the patient decision aid was developed as print 
booklet that can be used complimentary to face-to-face counseling. The booklet is also a good 
format to be mailed.
Pilot testing and revision
An iterative process of reviewing and revising was followed to develop the version of the patient 
decision aid that is ready for field testing. The first draft was evaluated by a patient communication 
expert to ameliorate comprehensibility. 
The second draft was sent to a patient expert panel consisting of six BRCA1/2 mutation carriers who 
had one or more consultations at our tertiary hospital and had already undergone risk-reducing 
salpingo-oophorectomy. Although they do not belong to the ultimate target population, we 
invited these women to assess the decision aid for two reasons: first, they know the consequences 
of salpingo-oophorectomy from their own experience and second, we considered it unethical 
to offer a preliminary version of the decision aid to women who still had to make a choice for 
either strategy. They were asked to fill out a questionnaire on structure, content, layout, length, 
comprehensibility, relevance, credibility and usability of the patient decision aid that was (e)mailed 
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to them. The questionnaire contained 21 questions, of which 13 were open-ended, and was 
previously used in the development of another patient decision aid.18 Additionally, the decision aid 
was discussed during an individual audio-recorded telephone interview to let them ‘think aloud’. 
Based on the received feedback, a third draft was developed and pilot-tested. Forty-four BRCA1/2 
mutation carriers who had undergone premenopausal risk-reducing salpingo-oophorectomy in 
our hospital between 2010 and 2015 were sent an invitation letter and informed consent form. A 
reminder was sent after one month in case of no response. Women who consented to participate 
were sent the decision aid and a short questionnaire with 12 Likert scale questions, 12 multiple-
choice items and two opportunities for suggestions. Questions were about basic demographics, 
content, structure, length, balance, comprehensibility, completeness, and usefulness. The main 
difference with the questionnaire in the previous test round was a lower number of open-ended 
questions. Again, the questionnaire was based on a questionnaire previously used.18 Participants 
who did not return their questionnaires were repeatedly reminded. Furthermore, feedback on the 
decision aid was also requested from patient advocates. Based on feedback on the third draft, a 
revised version together with an adjusted questionnaire was emailed to an expert panel of 14 
healthcare professionals from ten hospitals throughout the country who counsel participants 
about ovarian cancer risk-reducing options in the national preference trial. They were not involved 
in the initial development of the decision aid. Their suggestions were incorporated in the final 
version that is ready for field testing.
Based on the study design and confirmed by the Medical Ethical Committee ‘CMO Regio Arnhem-
Nijmegen’, the Medical Research Involving Human Subjects Act (Dutch: WMO) is not applicable 
to this study. Therefore, the study was exempted from being appraised by a medical ethical 
committee.
RESULTS
Development
Scope and purpose
The purpose of the patient decision aid is to provide decision support for BRCA1/2 mutation carriers 
who participate in the preference trial that compares risk-reducing salpingo-oophorectomy with 
salpingectomy and delayed oophorectomy. Therefore, the target audience consists of all trial 
participants: premenopausal BRCA1/2 mutation carriers who completed childbearing, who are 25-
40 (BRCA1) or 25-45 (BRCA2) years old, and who are currently not being treated for any malignancy. 
Three options are discussed in the decision aid. The first option is watchful waiting: no risk-reducing 
surgery. The second option is risk-reducing salpingo-oophorectomy between 35-40 years old 
(BRCA1) or 40-45 years old (BRCA2), as currently recommended in national and international 
guidelines. The third option is risk-reducing salpingectomy upon completion of childbearing with 
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delayed oophorectomy between 40-45 (BRCA1) or 45-50 years old (BRCA2), which has not been 
proven effective yet in terms of improved quality of life or safe in terms of ovarian cancer risk. To 
stick closely to the objective of the preference trial and to limit the length of the decision aid, the 
project group decided to focus on ovarian cancer risk management. Hence, information on breast 
surveillance and risk-reducing mastectomy was not included. However, we did discuss the effect 
of the three aforementioned options on breast cancer risk.
Patients’ decisional needs
From our qualitative study, we identified the following factors important in the decision for 
salpingo-oophorectomy or salpingectomy with delayed oophorectomy: ovarian and breast cancer 
risks; onset of premature menopause; level of evidence for the efficacy and safety of either strategy; 
medical history; family history; number of operations.8 The additional literature search yielded two 
publications on BRCA1/2 mutation carriers9 and professionals19 surveyed about salpingectomy with 
delayed oophorectomy. Factors reported to influence the decision are consequences of premature 
menopause, HRT, surgical morbidity, potential ovarian damage, and lack of data on level of benefit 
and cancer risks.9,19
Content and format
Search results for domains 1) risks and 2) benefits of watchful waiting, salpingo-oophorectomy, and 
salpingectomy with delayed oophorectomy are described elsewhere.17 Risk estimates based on 
literature were incorporated into the decision aid. Literature search for the third domain concerning 
premature menopause and HRT yielded 79 publications. Two relevant articles outlining all aspects 
of premature menopause and HRT in BRCA1/2 mutation carriers were identified and used in the 
decision aid.20,21 Critical appraisal of the level of evidence of selected publications (fourth domain) 
resulted in how conclusively information was presented. The format of the value clarification 
worksheet (fifth domain) was based on a systematic review22 and the experience within our project 
group.18,23
Analogous to another decision aid,23 ours was subdivided into a general introduction, three 
chapters, and a step-by-step plan containing a personal value clarification worksheet. Chapter 1 
outlined the three options in ovarian cancer risk management with the main risks and benefits. 
Chapter 2 contained more specific information on (estimated) ovarian and breast cancer risks. 
Chapter 3 goes into menopause and HRT. The step-by-step plan contained 9 steps to guide the 
user which information should be read, which individual values matter most, and whether one 
is well-prepared and confident enough to decide. To elicit one’s preferences, eight statements 
were selected based on patients’ decisional needs and had to be scored for (dis)agreement on 
a 6-point Likert scale (3-point Likert scale in the initial version). Subsequently, the user is asked to 
rank the three most important statements to clarify which values matter most; however, first drafts 
contained a rating instead of a ranking exercise. Finally, implications of their stated values for their 
decision are explicitly shown. 
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Pilot testing and revision
Pilot 1
After the text of the first draft was adapted according to the patient communication expert’s 
comments, 5 of 6 invited BRCA1/2 mutation carriers consented to participate in pilot test 1. They 
filled out a questionnaire and audio-recorded telephone interviews were subsequently transcribed 
by one of the authors (M.H.). Their comments led to several major changes. An image of the 
anatomy of the female internal genitals was added, as was an overview of options with their main 
(dis)advantages. Participants preferred icon arrays and pie charts for risk communication so risk 
tables, that were found confusing, were deleted. Limited alterations were made in wording, text 
order, and color use which resulted in the third draft.
Pilot 2
Twenty-five of 44 eligible women (57%) signed and returned the informed consent form for 
participation in the next pilot, two declined and 17 responded neither to our letter nor to a reminder. 
Nineteen of 25 women (76%) who consented filled out the semi-quantitative questionnaire. Four 
did not return their questionnaires in spite of several reminders, one withdrew her consent, and 
one was physically not able to complete the questionnaire. Baseline characteristics of the 19 
participants are presented in Table 1. Mean age at risk-reducing salpingo-oophorectomy was 42.3 
years and 14 (73.7%) carried a BRCA1 mutation. Twenty percent were breast cancer survivors and 
42% were higher educated.
Table 1. Baseline characteristics of BRCA1/2 mutation carriers who had already undergone risk-reducing 
salpingo-oophorectomy and participated in Pilot 2
N=19
Current age (years, mean ± SD) 45.6 ±3.878 range 37-51
Age at RRSO (years, mean ± SD) 42.3 ±3.603 range 34-48
Mutation (n, %)
BRCA1 14 73.7
BRCA2 5 26.3
Previous breast cancer (n, %)
Yes 4 21.1
No 15 78.9
Level of education (n, %)  
Primary/pre-vocational school 2 10.5
Vocational education 7 36.9
Pre-college education 2 10.5 
College/university 8 42.1
Abbreviations: RRSO Risk-reducing salpingo-oophorectomy; 
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For chapters 1 and 2 about the three options and (estimated) ovarian and breast cancer risks, the 
content was judged ‘good’ or ‘excellent’ on a 4-point Likert scale by at least 95% and presentation 
of information was judged ‘good’ or ‘excellent’ by at least 89%. Both content and presentation 
of information in chapter 3 were scored ‘good’ or ‘excellent’ in 84% (menopause part) and 74% 
(HRT part). Results of other items surveyed are presented in Table 2. Length and the amount of 
information were assessed ‘just right’ by the majority of participants. Including more information 
about menopause and about risks and prognosis of ovarian cancer was suggested. Furthermore, 
the information was mainly judged as balanced, realistic and comprehensible, and 79% would 
find it useful in decision-making if they would have to choose between salpingo-oophorectomy 
and salpingectomy with delayed oophorectomy. The preference elicitation tool of the personal 
worksheet was the most criticized: 32% either wanted to add, remove or change some of the 
statements. No differences were observed between women with and without breast cancer history. 
In general, patient reviewers were very positive about the clear language and images. The decision 
aid provided readers with easy-to-read information to get an overview of all relevant matters. In 
contrast, suggestions for improvement were mainly related to information on menopause and 
HRT, and statements in the preference elicitation tool. A revised version of the decision aid was 
based on all comments of these 19 patients and four patient advocates. In addition to some 
textual changes, major changes included revision of chapter 3 (menopause and HRT), adjustment 
of statement order in the personal worksheet, rephrasing five statements, and replacing one 
statement. Furthermore, the initial rating exercise was replaced by the ranking exercise at this 
stage. Moreover, we added more detailed information about ovarian cancer prognosis and about 
the (estimated) risk reduction by the two strategies to chapter 1.
Pilot 3: professionals
Ten of 14 (71%) professionals from eight hospitals then reviewed the decision aid and filled out the 
questionnaire: eight gynecologic oncologists, one gynecologist, and one medical doctor involved 
in counseling and supportive care of BRCA1/2 mutation carriers. For chapters 1 and 2 about the 
three options and (estimated) cancer risks, both content and presentations were judged ‘good’ or 
‘excellent’ on a 4-point Likert scale by at least 70% of professionals, except for the presentation of 
HRT that was scored ‘good’ or ‘excellent’ by 60% and ‘moderate’ by the remaining 40%. The majority 
(70%) found the decision aid too long. Five suggested to develop two separate booklets for BRCA1 
and BRCA2. Another concern for half of the responders was the lack of comprehensibility of the 
presented risks. However, the vast majority classified the information as balanced and realistic, 
estimated that it would be a useful tool for BRCA1/2 mutation carriers, and confirmed to be willing 
to offer this decision aid to their patients additionally to in-person counseling (Table 2).
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Table 2. Pilot testing among BRCA1/2 mutation carriers and their healthcare providers
Draft 3 Draft 4 
BRCA mutation carriers Healthcare providers 
(n=19) (n=10)
Length of PtDA (n (%))
Too long 1 (5%) 7 (70%)
Too short 2 (11%) 0
Just right 16 (84% 2 (20%)
Missing 0 1 (10%)
Amount of information (n (%))
Too much 1 (5%) 1 (10%)
Too little 6 (32%) 1 (10%)
Just right 12 (63%) 3 (30%)
Missing 0 5 (50%)
Information balanced? (n (%))
Yes 15 (79%) 8 (80%)
Slanted towards RRSO 3 (16%) 0
Slanted towards RRS/RRO 1 (5%) 2 (20%)
PtDA is comprehensible (n (%))
In general 17 (89%) N/A
Risk communication
Yes 17 (89%) 4 (40%)
No 2 (11%) 4 (40%)
Missing 0 2 (20%)
Consequences of RRSO (n (%))
Realistic 16 (84%) 9 (90%)
Underestimated 3 (16%) 1 (10%)
Consequences of RRS/RRO (n (%))
Realistic 13 (68%) 10 (100%)
Underestimated 5 (27%) 0
Overestimated 1 (5%) 0
Useful in decision-making (n (%))
Yes 15 (79%) 8 (80%)
No 3 (16%) 0
Missing 1 (5%) 2 (20%)
Sufficient information to decide (n (%))
Yes 16 (84%) 8 (80%)
No 3 (16%) 1 (10%)
Missing 0 1 (10%)
Personal worksheet statements (n (%)) 
Are well chosen 12 (63%) 6 (60%)
At least one needs to be removed 5 (27%) 1 (10%)
At least one needs to be added 1 (5%) 0
Missing 1 (5%) 3 (30%)
Willing to offer PtDA to patients (n (%))  
Yes N/A 8 (80%)
No, not this PtDA N/A 1 (10%)
No, no PtDA at all N/A 0
Missing N/A 1 (10%)
Abbreviations: PtDA Patient decision aid; RRSO Risk-reducing salpingo-oophorectomy; RRS/RRO Risk-reducing 
salpingectomy with delayed risk-reducing oophorectomy; N/A Not applicable
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Besides some textual revisions, three significant changes were incorporated into the ultimate 
version of the decision aid. First, we developed separate decision aids for BRCA1 and BRCA2. Second, 
examples to estimate ovarian cancer risk were more explicitly described. Third, non-hormonal 
options to alleviate effects of premature menopause were added to chapter 3. Figure 2 shows the 
personal value clarification worksheet (translated from Dutch into English). 
Figure 2. Personal value clarification worksheet of final draft (translated from Dutch into English)
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IPDAS criteria
Quality of the patient decision aid was tested against the 64 IPDAS criteria. Since none of the 
additional criteria were applicable, we checked it against the 50 ‘regular’ items and 37 were satisfied. 
Among the 23 criteria for ‘Content’, only criterion 3.9 was not entirely met: whether the decision 
aid allows the user to view probabilities based on their own situation (e.g., age). The decision aid 
provides one example applicable to a certain age. We developed tables with risks for various ages17 
but those were found to be too complicated for this decision aid. However, they are available for 
healthcare providers and can be discussed during face-to-face contact. Fifteen of 20 criteria in the 
‘Development Process’ were met. We did not use a readability score to verify readability (criterion 
10.4). In addition, we have not field-tested the decision aid yet (criteria 1.4-1.5), although we did 
pilot-test it. Therefore, criteria regarding the results of field testing were not satisfied: whether it is 
acceptable (criteria 1.6-1.7), balanced (criterion 9.3), and can be understood by those with limited 
reading skills (criterion 10.6). Nevertheless, it scored high on the first two criteria during pilot 
testing. The decision aid was not evaluated by patients with low health literacy, although it was by 
one dyslectic patient. Lastly, the seven criteria for ‘Effectiveness’ could not be assessed because we 
have not field-tested the final version yet. 
DISCUSSION
This paper describes the systematic development process of a paper patient decision aid for ovarian 
cancer risk management in premenopausal BRCA1/2 mutation carriers, in close collaboration with 
BRCA1/2 mutation carriers and their healthcare professionals. The decision aid elaborates on the 
risks and benefits of watchful waiting, risk-reducing salpingo-oophorectomy, or salpingectomy 
with delayed oophorectomy. It can be used additionally to face-to-face consultation. The last 
version is found to be clear, complete, balanced and usable by the vast majority of reviewers. It 
fulfills 37 of 43 quality requirements for content and development process as formulated in the 
IPDAS checklist. Patient reviewers who underwent risk-reducing surgery before, would have liked 
to use the decision aid if they would have to decide now.
The systematic development in a multidisciplinary team and the input of patient and professional 
experts are the main strengths of this study. Furthermore, four patient advocates of a national 
patients’ association also reviewed the decision aid. The last strength is that we present the user 
with the implications of their expressed values in the personal worksheet, supposedly leading to 
better outcomes when using value clarification methods.22
The most important limitation in the development of this patient decision aid is the lack of (univocal) 
evidence for some items. First, salpingectomy with delayed oophorectomy has not been clinically 
investigated yet, so its effect on ovarian cancer risk is unknown. Second, health consequences of 
premature menopause in this particular population has not been entirely unraveled and the same 
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applies to the effect of HRT. However, there are no convincing arguments to expect differences 
between BRCA1/2 mutation carriers and the general population regarding effects of premature 
menopause. Furthermore, existing evidence only provides relative risks, which are very hard to be 
interpreted. For instance, a two- to four-fold increase in the risk of cardiovascular disease is very hard 
to translate into absolute risks without knowing the background risk, which depends on lifestyle, 
personal and family medical history etcetera. Furthermore, we did not pilot-test the decision aid in 
the actual target population because lack of experience with premature menopause and because 
of ethical reasons. Finally, women with low literacy skills were underrepresented in both pilot tests: 
a common problem in this kind of research that we were not able to resolve.14
Two randomized controlled trials evaluating patient decision aids for women at increased risk 
of ovarian cancer only included risk-reducing salpingo-oophorectomy and ovarian screening as 
options.24,25 One also contained information on breast cancer risk management options besides 
those for ovarian cancer.24 All together, they found that women who used the decision aid felt 
better informed and were more satisfied with the amount and quality of received information 
compared with women who received usual care. Furthermore, users’ risk estimates for ovarian 
cancer were more accurate and they chose risk-reducing surgery more often. However, no 
statistically significant differences were found for well-being and decision-related outcomes, 
possibly because of lack of power. Tiller et al.25 developed their decision aid for women with a 
family history of breast and/or ovarian cancer or Lynch syndrome. Besides ovarian screening and 
risk-reducing salpingo-oophorectomy, information about watchful waiting and chemoprevention 
was included. Women who used the decision aid reported higher acceptability and the received 
information as more sufficient and helpful in decision-making compared with women receiving 
a general educational pamphlet. Greater knowledge and lower decisional conflict were found 
two weeks after the intervention but did not last after 6 months. Use of the decision aid did not 
affect psychological outcomes.25 Besides, several decision aids on management options of breast 
cancer risk in BRCA1/2 mutation carriers have been developed and tested.26-29 Women who used 
these decision aids also reported less decisional conflict, reduced uncertainty and cancer-specific 
distress, increased knowledge, and more satisfaction with their decision.26-29
In conclusion, our systematically developed patient decision aid for premenopausal BRCA1/2 
mutation carriers participating in a Dutch clinical preference trial (NCT02321228) appears to be 
acceptable and usable according to both patients and professionals. However, whether its use 
really lowers decisional conflict, increases patient satisfaction, and results in informed decisions 
that are congruent with personal values has to be studied yet. Moreover, the rapidly growing body 
of evidence for this particular population will require regular updates of the content of the patient 
decision aid.
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The focus of this thesis is on risk management of ovarian carcinoma in germline BRCA1/2 mutation 
carriers. Women who are aware of their elevated cancer risk because of such a mutation are 
considered “cancer previvors”. Besides the purpose of preventing them from developing ovarian 
carcinoma by several risk-reducing strategies, increasing importance is attached to previvors’ 
quality of life. This is in parallel with cancer survivors for whom quality of life has increasingly been 
brought into focus since survival rates have improved for many types of cancer, e.g. breast cancer. 
In this chapter, the main findings of this thesis are presented and discussed in the light of knowledge 
acquired composing this thesis and existing literature. Furthermore, the methods that were used 
are discussed and future perspectives are provided.
MAIN RESULTS 
•	 Quality of life of BRCA1/2 mutation carriers is mostly impaired by premature menopause 
resulting from risk-reducing salpingo-oophorectomy (RRSO). Hormone replacement 
therapy does not fully alleviate climacteric symptoms, especially sexual symptoms. 
Furthermore, not all BRCA1/2 mutation carriers are eligible for hormone replacement 
therapy mainly due to a personal breast cancer history.
•	 Deciding not to undergo RRSO is highly exceptional in BRCA1/2 mutation carriers 
counseled at the Family Cancer Clinic of our institution and almost all of them have RRSO 
at the currently recommended age, if applicable.
•	 Metachronous peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation 
carriers occurred mostly in BRCA1 mutation carriers, within 5 years after risk-reducing 
surgery, and when risk-reducing surgery was performed at older age. A role for the 
fallopian tube in the pathogenesis of primary peritoneal carcinoma was supported by 
the interval between risk-reducing surgery and diagnosis of peritoneal carcinomatosis, 
and the frequent detection of STICs.
•	 The differences in estimated ovarian carcinoma risks between standard RRSO and the 
proposed alternative strategy consisting of salpingectomy with delayed oophorectomy 
are small when oophorectomy is delayed by 5 years, even when salpingectomy would be 
completely ineffective in reducing the risk of ovarian carcinoma.
•	 The uncertainty about the effect of risk-reducing salpingectomy with delayed 
oophorectomy and the ease of the decision to undergo RRSO were indicated as important 
barriers for the alternative strategy among BRCA1/2 mutation carriers and professionals. 
The main facilitator mentioned by both was postponement of surgical menopause.
•	 The majority of BRCA1/2 mutation carriers and their professionals were willing to 
participate in a clinical trial on risk-reducing salpingectomy with delayed oophorectomy 
under the consideration that it would not be a randomized study. Therefore, we designed 
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the TUBA study: a currently ongoing non-randomized clinical preference trial comparing 
salpingectomy with delayed oophorectomy with standard RRSO in terms of menopause-
related quality of life and several secondary outcome measures. As part of this TUBA study, 
we developed a patient decision aid to support BRCA1/2 mutation carriers who face 
the choice between salpingectomy with delayed oophorectomy and RRSO in this trial. 
The final version met 37 of 43 IPDAS criteria for content and development process and 
was found clear, balanced and comprehensible in pilot tests among BRCA1/2 mutation 
carriers and professionals.  
DISCUSSION OF THE MAIN RESULTS
As shown in chapter 2, premenopausal RRSO is an important factor that can affect quality of life 
of BRCA1/2 mutation carriers.1 Nearly all previvors at our institution undergo RRSO before the age 
of 45, as evaluated in chapter 3, and may thus face several quality of life issues.2 The alternative 
strategy to reduce the risk of ovarian carcinoma among BRCA1/2 mutation carriers proposed in this 
thesis, consisting of salpingectomy with delayed oophorectomy, aims to improve menopause-
related quality of life in ovarian carcinoma previvors by delaying premature menopause.3 However, 
the effect on ovarian carcinoma risk is still unclear and can only be estimated (chapter 6).4 In other 
words, the challenge is to weigh pros and cons of RRSO in terms of implications for quality of life 
and carcinoma risk. Accurate estimation of this risk is crucial in this consideration.
Estimated ovarian and breast carcinoma risks in BRCA1/2 mutation carriers
Estimated carcinoma risks for two different risk-reducing strategies play a central role in this thesis: 
on the one hand, for standard RRSO and on the other hand, for salpingectomy with delayed 
oophorectomy. Despite our utmost effort to estimate risks as accurately as possible, several 
considerations have to be made when interpreting these risk estimates. 
Cumulative risk of ovarian carcinoma
In this thesis, cumulative carcinoma risks published by Chen and Parmigiani in a meta-analysis 
formed the basis for most hypotheses we elaborated on.5 Although this is a frequently cited meta-
analysis, large heterogeneity existed between included studies that could not be well explained by 
its authors. Studies were performed in different populations with their own prevalence of specific 
(founder) mutations.6 Furthermore, included studies that were published earlier reported higher 
penetrance of BRCA1/2 genes than more recent studies which might be explained by the criteria 
for genetic testing.6 Genetic testing was primarily offered to women with a strong family history, 
which is known to increase carcinoma risk.7,8 Furthermore, the use of different risk estimation 
methods and bias corrections across studies may be responsible for the diversity of reported 
cumulative risks of ovarian carcinoma, as has been shown for breast cancer.9 
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In addition, we assumed that the same mean cumulative risk for BRCA1/2 mutation carriers applies 
to every single BRCA1/2 mutation carrier throughout this thesis. However, a lot of risk modifiers 
have already been identified telling us that heterogeneity exists even within a group of women 
carrying a germline mutation in the same gene. First, the risk of ovarian carcinoma is influenced 
by the type and position of the mutation: mutations in the ovarian carcinoma cluster region 
are associated with an increased risk.7,10,11 As far as we know, however, this has not changed risk 
counseling until now. Second, the risk can be further modified by other risk-modifying genes or by 
certain single nucleotide polymorphisms (SNPs).12-15 Third, several reproductive factors have been 
associated with reduced ovarian carcinoma risk in mutation carriers: tubal ligation, breastfeeding 
and increasing parity in BRCA1 mutation carriers, and use of oral contraceptives in both BRCA1 and 
BRCA2 mutation carriers.16 Taking all these factors into account may result in individualized risk 
estimates contributing to more tailored counseling in cancer risk management: a relatively low or 
high personal residual risk may be a reason for women to choose for one risk-reducing strategy or 
the other.
Residual risk of ovarian carcinoma after risk-reducing salpingo-oophorectomy
Besides the wide divergence in reported cumulative risk of ovarian carcinoma in BRCA1/2 mutation 
carriers, a variety also exists in reported effect sizes of RRSO and residual risk of primary peritoneal 
carcinoma occurring after RRSO. Understandably, this is another important issue in decision-
making regarding interventions to lower the risk of ovarian carcinoma. 
There are several ways to present the residual risk of primary peritoneal carcinoma. Some authors 
reported the percentage of BRCA1/2 mutation carriers who were diagnosed with primary 
peritoneal carcinoma after RRSO in their cohort studies: 0.3-1.1%.17-23 Those cohorts varied in terms 
of mean or median age at RRSO (42 to 49 years) and duration of follow-up (22-109 months). Finch 
et al.21 differentiated for age at RRSO: 0.3% developed primary peritoneal carcinoma after RRSO 
undergone before the age of 40 years and 0.7% after RRSO undergone between 40 and 50 years 
old during a mean follow-up of approximately 6 years. Based on these findings, they calculated 
the cumulative risk of primary peritoneal carcinoma in the first 20 years after RRSO: 3.9% for BRCA1 
mutation carriers and 1.9% for BRCA2 mutation carriers.21 Earlier, Casey et al.24 estimated this risk 
also at 3.9% for BRCA1 mutation carriers. Another way to report the effect of risk-reducing surgery is 
by hazard ratios. Several of the aforementioned studies report hazard ratios for ovarian carcinoma 
after RRSO between 0.04 and 0.28, corresponding to 96% and 72% risk reduction, respectively. 
Two meta-analyses by Rebbeck et al.25 and Marchetti et al.26 calculated hazard ratios of 0.21 (95% 
Confidence Interval (CI) 0.12 to 0.39) and 0.19 (95% CI 0.13 to 0.27).17,19,21,25-27 Although it seems 
reasonable that RRSO at younger age results in lower hazard ratios, sufficient data lack to calculate 
separate hazard ratios for certain ages at RRSO. Therefore, we assumed the hazard ratios to be stable 
regardless of age at RRSO throughout this thesis, i.e. hazard ratios of 0.20 and 0.04 corresponding 
to 80% and 96% risk reduction after RRSO, respectively. Follow-up of women undergoing RRSO 
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at the recommended age may reveal a more accurate estimate of the residual risk for a more 
homogeneous group in terms of mutation (BRCA1 or BRCA2) and age.
Residual risk of ovarian carcinoma after risk-reducing salpingectomy
As repeatedly mentioned in this thesis, no clinical data on the effect of salpingectomy on the risk 
of ovarian carcinoma are available to date. We assumed a potential maximum effect based on 
available indirect evidence (chapter 6).4 The effectiveness in terms of menopause-related quality of 
life of delaying oophorectomy after salpingectomy is the primary outcome of the ongoing TUBA 
study (chapter 7).3 However, we will not be able to draw conclusions whether salpingectomy with 
delayed oophorectomy is non-inferior (or even superior) to standard RRSO in terms of the residual 
risk of ovarian carcinoma, mainly because of two reasons. At first, Anderson et al.28 calculated the 
sample size that would be needed in a randomized controlled trial of equivalence between RRSO 
and risk-reducing salpingectomy. Assuming 95% risk reduction for RRSO, 3980 BRCA1 mutation 
carriers are needed in each arm. Including BRCA2 mutation carriers would require even more 
patients per arm, given the lower incidence of ovarian carcinoma in that group. Enrolling these 
numbers of study participants in a reasonable time interval is not feasible in the Dutch population. 
At second, although a randomized controlled trial would be the right study design, BRCA1/2 
mutation carriers nor healthcare professionals find randomization acceptable in such a clinical 
trial (chapter 5).29 Therefore, the TUBA study is the first step towards clinical data on the efficacy 
and safety of salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers and it will 
prevent healthcare providers to perform salpingectomies outside a clinical trial (without close 
and structural follow-up). Nevertheless, more initiatives and international collaborations on this 
topic will be necessary to be able to study the real effect of salpingectomy on ovarian carcinoma 
incidence in a sufficient number of BRCA1/2 mutation carriers.
Effect of RRSO on breast cancer risk
Until recently, it was widely accepted that RRSO before menopause reduced BRCA1/2 mutation 
carriers’ risk of developing breast cancer approximately by half.19,27,30,31 However, the four studies 
in which this risk-reducing effect was found used various study designs and eligibility criteria and 
some of the study characteristics could have caused bias in several ways, which was addressed by 
Heemskerk-Gerritsen et al. in 2015.32 They applied all four methods of these studies to their own 
Dutch cohort of BRCA1/2 mutation carriers and found effect sizes similar to the original studies. 
Thereupon, they proposed an alternative analytical method thereby minimizing the potential 
sources of selection bias. Applying this alternative method to the same Dutch cohort resulted in 
no statistically significant risk reduction of breast cancer after RRSO.32 Judging by the strength of 
this evidence, we assumed no effect of RRSO on breast cancer risk in this thesis. Nevertheless, the 
authors commented that the total number of BRCA2 mutation carriers and the number of events 
in this study were too small to draw conclusions for the group of BRCA2 mutation carriers alone. 
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Kotsopoulos et al.33 did find a statistically significant risk reduction in breast cancer diagnosed prior 
to age 50 years among BRCA2 mutation carriers who underwent RRSO (HR 0.18, 95% CI 0.05 to 
0.63). However, there were only three cases of breast cancer in the RRSO group.33 
BRCA2 mutation carriers are known to have more estrogen receptor (ER) positive breast cancer 
compared to BRCA1 mutation carriers.34 Therefore, a difference in the effect of RRSO on breast 
cancer incidence between BRCA1 and BRCA2 is quite conceivable. Further studies with a larger 
number of BRCA2 mutation carriers and extended duration of follow-up are needed to find out 
whether a risk-reducing effect of RRSO does exist in the subgroup of BRCA2 mutation carriers. 
If such an effect does exist, it should be taken into account when counseling women from this 
group on RRSO versus salpingectomy with delayed oophorectomy and it should be included in an 
updated version of the patient decision aid that we developed (chapter 8).
Carcinoma risks other than breast and ovarian
Risk of endometrial carcinoma in BRCA1/2 mutation carriers
Up to now, it is uncertain whether BRCA1/2 mutation carriers also have an increased risk of 
endometrial carcinoma, especially BRCA1 mutation carriers.22,35-40 Internationally, RRSO is often 
accompanied by hysterectomy so that hormone replacement therapy with estrogens alone is 
sufficient and the potential increase of breast cancer risk by progestins is eliminated. However, 
evidence for a beneficial effect has been found insufficient to make hysterectomy part of standard 
risk-reducing surgery in the Netherlands until now: data on an elevated risk of endometrial 
carcinoma are not convincing and the intrauterine part of the fallopian tube has not been proven 
a preference site for the development of carcinoma of any type after RRSO.
In 2016, the publication by Shu et al.41 brought this discussion back to life. In a large prospective 
study, they found that BRCA1 mutation carriers had an increased risk of serous or serous-like 
endometrial carcinoma after RRSO without hysterectomy compared to the general population: 
observed versus expected ratio 22.2 (95% CI 6.1 to 56.9). They calculated that the cumulative risk 
of developing serous or serous-like endometrial carcinoma is 2.6% to 4.7% between RRSO at age 
45 years and age 70 years.41 In comparison, the lifetime risk of developing any type of endometrial 
carcinoma is 2.8% in the general population.42 The role of tamoxifen exposure as potential risk 
modifier is still unclear but might (partially) explain the higher incidence in BRCA1 mutation 
carriers, although tamoxifen use has been associated with endometrioid rather than with serous 
endometrial carcinoma. Confirmation of these findings in other populations including the Dutch 
population is needed by the collection and analysis of detailed clinical and pathological data. 
Until then, there is not enough evidence to routinely incorporate hysterectomy into risk-reducing 
surgery for BRCA1/2 mutation carriers.
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Alternatives to risk-reducing surgery  
In this thesis, we proposed an alternative surgical strategy to reduce the ovarian carcinoma 
risk of BRCA1/2 mutation carriers. However, any risk-reducing surgery would be less needed if 
premalignant or early invasive lesions could be detected. Screening methods with transvaginal 
ultrasound and measurement of serum CA125 have not resulted in improved survival rates in 
BRCA1/2 mutation carriers until now.43-45 
In a recent report, however, a significant risk reduction of ovarian carcinoma mortality by annual 
measurement of serum CA125 was found in a large cohort of postmenopausal women from the 
United Kingdom general population after a median follow-up of 11 years.46 The pattern of CA125 
levels over time was interpreted according to a risk of ovarian cancer algorithm rather than a fixed 
cut-off value. Mortality due to ovarian carcinoma was significantly reduced by 20% (95% CI -2 to 
40) when prevalent cases at the start of the screening program were excluded. However, mortality 
rates were very low: about 0.29% in the CA125 screened group and 0.34% in the unscreened 
group. The authors note that further follow-up is needed to draw firm conclusions on efficacy and 
cost-effectiveness of this screening program.46 Furthermore, results from the general population 
cannot simply be extrapolated to the high-risk population of BRCA1/2 mutation carriers.
To detect (pre)malignant lesions, a test easily performed at the outpatient department or even 
by the patient herself would be preferred. One could think of the use of Papanicolaou (Pap) tests 
or tampons to collect cells of vaginal, cervical, endometrial, and hopefully even tubal or ovarian 
origin. These samples may subsequently be analyzed for TP53 mutations: a detected mutation 
can be the clue for precursor lesions or early invasive carcinoma of the upper genital tract. This 
principle has already been described for patients with ovarian carcinoma not necessarily carrying 
a BRCA mutation.47,48 In 9 of 22 (41%) ovarian carcinomas (FIGO stage IA to IV), identical mutations 
were detected in both the tumor itself and the Pap smear.47 In another study by the same group, 
3 of 5 (60%) stage IIIC ovarian carcinoma patients without previous tubal ligation identical TP53 
mutations were detected in tumor DNA and DNA extracted from a tampon that had been placed 
in the vagina 8-12 hours before surgery.48 On these small numbers, conclusion cannot be drawn. 
Sensitivity is not convincing and might be far worse for premalignant lesions compared to full-
blown ovarian carcinomas. In an ongoing study from our center (NTR4299), samples from patients 
with endometrial or ovarian carcinoma are collected by Pap smear, endometrial biopsy (Pipelle) 
and a brush-based cervicovaginal self-sample. DNA from these samples will be extracted and 
compared to tissue DNA from the primary tumor. Still, more studies and further development of 
advanced techniques are needed.
Another test to detect serous tubal intraepithelial carcinomas (STICs) in women at high risk of high-
grade serous ovarian carcinoma is currently under investigation in an international multicenter 
trial: the LUSTIC study (NCT02039388). Aim of the study is to detect TP53 mutations from STICs 
in fluid retrieved after lavage of the uterine cavity. Lavage is performed right before RRSO with or 
without hysterectomy. Yet, no (preliminary) results are available.
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FUTURE PERSPECTIVES
Implications for future research
Minimizing the number of BRCA1/2 mutation carriers with impaired quality of life due to the 
consequences of RRSO is an important goal for future research in this field, next to effective 
methods to reduce carcinoma risk. 
One way of diminishing the number of women who face premature menopause is finding 
reasonable alternatives to risk-reducing surgery. To obtain better survival rates, further attempts 
are needed to improve early detection of ovarian carcinoma. Several options have been already 
discussed in the paragraph on alternatives to risk-reducing surgery. Additionally, improvement and 
individualization of hormone replacement therapy may also alleviate adverse effects of RRSO. Ideally, 
randomized controlled trials should be carried out to investigate safety of hormone replacement 
therapy and to evaluate the optimal type and duration of hormone replacement therapy for 
subgroups within the BRCA1/2 population. Non-medical interventions to cope with psychosocial 
and sexual consequences of RRSO are also promising and currently under investigation in the Dutch 
PURSUE study: Psychosexual Consequences of RRSO in BRCA1/2 Mutation Carriers (NCT02372864).
The effect of salpingectomy and its future role in reducing the risk of ovarian carcinoma among 
BRCA1/2 mutation carriers needs further investigation. Our ongoing TUBA study will answer the 
question on its efficacy in improving quality of life. Besides, it will give us clues on safety regarding 
ovarian carcinoma risk. Results from some other ongoing studies will contribute to our knowledge 
on salpingectomy as risk-reducing option. In the United States, compliance with salpingectomy 
and oophorectomy delayed for three years is being investigated (NCT01907789). Eligible are 
premenopausal BRCA1/2 mutation carriers aged 47 years or younger. The same study group is 
evaluating sexual functioning and quality of life after salpingectomy with delayed oophorectomy 
and compares it to women undergoing standard RRSO (NCT02760849). Women are eligible 
between 30 and 50 years old and when they carry a germline mutation in an ovarian carcinoma 
gene including BRCA1/2. A French study group looks at the rate of pelvic carcinoma occurring 
between radical fimbriectomy and menopause in women at high risk for ovarian carcinoma who are 
reluctant to undergo oophorectomy. As previously mentioned, more initiatives and international 
collaborations on salpingectomy are necessary to determine its entire effect in a sufficient number 
of BRCA1/2 mutation carriers. An international consortium needs to be established to coordinate 
studies as mentioned in this paragraph and to match outcome measures and methods of these 
studies. Only then we might be able to find out the full effect and safety of salpingectomy with 
delayed oophorectomy in BRCA1/2 mutation carriers.
Additionally, more data on risk modifiers of ovarian carcinoma risk in BRCA1/2 mutation carriers 
are needed to facilitate risk tailoring. We expect that individualized estimations of the (residual) 
cumulative lifetime risk of ovarian carcinoma or either the cumulative risk over the next 10 years, 
for example, will be crucial in decision-making on ovarian carcinoma risk management.
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Furthermore, the exact effects of premature menopause have to be further elucidated. 
Cardiovascular effects after RRSO, for example, are currently under investigation in a study initiated 
by our research group: CArdiovascular Risk after risk-reducing Salpingo-Oophorectomy in BrCA 
mutation carriers (CARSOBRA study, NL51609.091.15). Traditional cardiovascular risk factors are 
investigated and non-invasive measurements of atherosclerosis (carotid intima media thickness 
and pulse wave velocity) are performed in BRCA1/2 mutation carriers who underwent RRSO at age 
45 or younger and at least 5 years ago.  
It is still under debate whether BRCA1/2 mutation carriers have an earlier age of onset of natural 
menopause.49 This might be more relevant for reproductive issues (e.g. ovarian reserve) than for 
risk-reducing issues since RRSO is currently recommended several years before the average age of 
natural menopause onset. However, it might become important again when oophorectomy after 
previous salpingectomy can be delayed until natural menopause commences or ovaries can be 
indefinitely retained. 
Writing about reproductive issues, women might also benefit when delaying risk-reducing surgery, 
especially oophorectomy, would be proven safe. In our center, we experience an increasing 
demand for fertility preservation options among BRCA1/2 mutation carriers who reached the 
currently recommended age for RRSO but still have the desire to become pregnant. The place of 
several methods of fertility preservation (e.g. cryopreservation of oocytes or ovarian tissue) for this 
indication and issues like the upper age of cryopreservation should be further explored. 
Finally, if we consider one step ahead of reducing cancer risks in BRCA1/2 mutation carriers, we 
can think of preventing offspring from inheriting the mutated gene. Two approaches are available 
now: prenatal diagnosis with the possibility to terminate pregnancy when the mutation is found 
in fetal DNA, and pre-implantation genetic diagnosis (PGD) testing embryos obtained by in vitro 
fertilization (IVF/ICSI) for the presence of the BRCA mutation and only transferring the unaffected 
embryos into the uterus.50 However, both approaches involve several ethical issues and safety 
regarding breast cancer risk due to hormonal stimulation has to be further confirmed for PGD.50,51 
Larger studies and studies on new techniques with are future challenges.
Implications for clinical practice
As long as the efficacy and safety of the alternative strategy of salpingectomy with delayed 
oophorectomy in BRCA1/2 mutation carriers has not been proven, it should exclusively be 
performed within the context of a clinical trial (e.g. the TUBA study) with close and structured 
follow-up. Our patient decision aid may be offered to BRCA1/2 mutation carriers who face the 
choice between standard RRSO and salpingectomy with delayed oophorectomy to fully inform 
them on the two strategies and in attempt to facilitate their decision-making process.
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SUMMARY
This thesis discusses an alternative strategy to reduce the risk of ovarian carcinoma in BRCA1/2 
mutation carriers. As we described in chapter 1, these women have an increased risk to develop 
ovarian carcinoma and the currently recommended intervention to reduce that risk is undergoing 
risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 years. However, RRSO results 
in acute onset of surgical menopause with several adverse health consequences in short and long 
term. To improve quality of life and reduce side-effects of early surgical menopause, we explored 
the possibility of risk-reducing salpingectomy with delayed oophorectomy as alternative to RRSO 
allowing preservation of the ovaries and thereby postponement of premature menopause.
In chapter 2, we reviewed the literature to evaluate quality of life in unaffected BRCA mutation 
carriers and the influence of several choices they make with respect to cancer risk management. 
Overall, we found that general quality of life is not permanently affected in BRCA1/2 mutation carriers 
or by their choices for surveillance and/or risk-reducing surgery. However, premature menopause 
caused by RRSO affects (menopause-specific) quality of life most. Hormone replacement therapy 
does not fully alleviate climacteric symptoms and therefore, we concluded that there is a 
strong need for alternative strategies to reduce ovarian carcinoma risk and for improvements in 
postoperative care after RRSO, e.g., hormone replacement therapy and supportive care. 
We studied the uptake and timing of RRSO among BRCA1/2 mutation carriers in chapter 3 in 
order to evaluate how many women potentially face long-term health consequences after RRSO. 
We performed a single-center retrospective cohort study of BRCA1/2 mutation carriers diagnosed 
and counseled at the multidisciplinary Family Cancer Clinic of our institution between 1999 and 
2014. Data of 580 BRCA1/2 mutation carriers were available for descriptive analyses and we found 
the uptake of RRSO to be 98.5% and 97.5% among BRCA1 and BRCA2 mutation carriers who are 
past the recommended age for RRSO, respectively. The vast majority undergoes RRSO ≤40 years 
(90.8% of BRCA1 mutation carriers) or ≤45 years (97.3% of BRCA2 mutation carriers), provided that 
mutation status is known by that age. We concluded that the uptake of RRSO among BRCA1/2 
mutation carriers who were counseled at our Family Cancer Clinic is extremely high, which might 
be largely attributed to the directive and uniform way of counseling by our professionals. The 
fact that RRSO in our population is often undergone at premenopausal age reinforced the need 
for minimization of long-term health consequences of premature surgical menopause, either by 
optimization of hormone replacement therapy or by inventing alternative strategies to RRSO.
Despite RRSO, metachronous intra-abdominal carcinomatosis is occasionally diagnosed in 
BRCA1/2 mutation carriers. We assembled cases to increase knowledge regarding occurrence 
and pathogenesis of intra-abdominal carcinomatosis after RRSO in chapter 4. The literature was 
searched for publications describing BRCA1/2 mutation carriers with peritoneal carcinomatosis 
after risk-reducing surgery and authors were requested to provide additional data. Cases were 
compared with an unselected single-institution control cohort of BRCA1/2 mutation carriers who 
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underwent risk-reducing salpingo-oophorectomy between 2014 and 2016. We found that 31 of 
36 collected cases (86.1%) concerned BRCA1 mutation carriers. Median age was 52 years (range 
30-71) at risk-reducing surgery and 60 years (range 37-75) at peritoneal carcinomatosis diagnosis, 
and median interval between those two was 54.5 months (range 11-292). The vast majority of 
peritoneal carcinomatosis was of the high-grade serous subtype. Histopathological details of 
RRSO specimens including the complete fallopian tubes were retrieved in 8 cases: 5 (62.5%) with 
serous tubal intraepithelial carcinoma (STIC), one with epithelial atypia. Cases were statistically 
significantly older (p=0.029) at risk-reducing surgery and harbored more STICs (p<0.001) than 
women from the control cohort. We concluded that metachronous peritoneal carcinomatosis 
after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, within 5 years. Data 
suggest that surgery at younger age might lower rates of peritoneal carcinomatosis. These data can 
be used in gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete 
salpingectomy and detailed histopathological examination of specimens removed at the time of 
RRSO is essential.
Alternatively to RRSO, a strategy consisting of risk-reducing salpingectomy with delayed 
oophorectomy had been put forward in several publications. Before introducing this strategy, we 
asked 39 Dutch BRCA1/2 mutation carriers and 23 healthcare professionals in the field of hereditary 
cancer how to move on with the growing body of evidence for the fallopian tube as site of origin of 
ovarian cancer and its role in risk-reducing surgery. In this qualitative study reported in chapter 5, 
we identified barriers and facilitators for salpingectomy with delayed oophorectomy and for 
participation in a clinical trial on this topic during focus groups and in-depth semi-structured 
interviews. Among BRCA1/2 mutation carriers, main barriers for risk-reducing salpingectomy with 
delayed oophorectomy were seriousness of ovarian cancer, family history, and previous breast 
cancer. Among professionals, delay of the risk-reducing effect of oophorectomy on breast cancer 
risk and a second operation were recognized as main barriers. Both BRCA1/2 mutation carriers 
and professionals found uncertainty about the effect of the alternative strategy and the fact that 
women often easily decide to undergo RRSO important barriers. The main facilitator mentioned by 
both was postponement of surgical menopause. For trial participation, BRCA1/2 mutation carriers 
would experience a randomized study design as a insurmountable barrier. Professionals identified 
two facilitators: uniform counseling and willingness of BRCA1/2 mutation carriers to participate in 
trials. Most BRCA1/2 mutation carriers and professionals were willing to consider participation in a 
future non-randomized study.
In attempt to answer the question on ovarian carcinoma risks under the alternative risk-reducing 
strategy, we modeled the cumulative ovarian carcinoma risks after risk-reducing salpingectomy 
at various ages with delayed oophorectomy several years later and compared these estimates 
to those after RRSO in chapter 6. We extracted the input parameters for this Cox proportional 
hazard model from the (indirect) evidence available. The estimated cumulative ovarian cancer 
risks at age 70 years for risk-reducing salpingectomy with delayed oophorectomy are highest for 
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BRCA1 mutation carriers undergoing surgeries at higher age. Maximum increase in point estimates 
(from 1.8% to 4.1%) occurs in a 40-year-old BRCA1 mutation carriers undergoing oophorectomy 
at age 45 years after non-protective salpingectomy instead of RRSO at age 40 years. In the best-
case scenario, assuming 65% risk reduction by salpingectomy and 96% by RRSO, point estimates 
increase (from 1.8% to 2.6%) or decrease (from 3.4% to 3.3%) depending on age. In the worst-case 
scenario for BRCA2, point estimates maximally increase from 0.6% to 1.8% in 45-year-old carriers 
when oophorectomy is performed at age 50 years instead of RRSO at age 45 years. In the best-case 
scenario, point estimates increase (from 1.3% to 1.5%) or decrease (from 1.5 to 1.3%). We concluded 
that differences in estimated ovarian cancer risks between RRSO and salpingectomy with delayed 
oophorectomy are small, even if salpingectomy is ineffective. 
The findings in aforementioned chapters resulted in the design of a clinical preference trial, the 
TUBA study. The outline of the study protocol is described in chapter 7 and participants have 
been recruited since January 2015. It concerns a multicenter non-randomized trial conducted in 
11 Dutch centers for hereditary cancer. Eligible patients are premenopausal BRCA1/2 mutation 
carriers who completed childbearing without (a history of ) ovarian carcinoma. Participants choose 
between standard RRSO at age 35–40 (BRCA1) or 40–45 (BRCA2) and the alternative strategy 
(salpingectomy upon completion of childbearing and delayed oophorectomy at age 40–45 
(BRCA1) or 45–50 (BRCA2)). Women who opt for early salpingectomy but do not want to postpone 
oophorectomy beyond the currently recommended age are included as well. Primary outcome 
measure is menopause-related quality of life. Secondary outcome measures are ovarian and breast 
carcinoma incidence, surgery-related morbidity, histopathology, cardiovascular risk factors and 
diseases, and cost-effectiveness. Data will be analyzed using mixed model data analysis.
Making the choice between standard RRSO and salpingectomy with delayed oophorectomy can 
be complex. Therefore, we developed a paper patient decision aid that combines evidence-based 
information with patient preferences to facilitate this complex decision-making process (chapter 8). 
The patient decision aid was systematically developed in an iterative process of prototype 
development, pilot testing by both patients and clinicians, and revisions. Information  included in 
the patient decision aid was based on available literature and current guidelines. The development 
process was in accordance with the International Patient Decision Aid Standards (IPDAS) quality 
criteria and supervised by a multidisciplinary steering group. Finally, two paper patient decision 
aids were developed: one for BRCA1, one for BRCA2. They both contained a general introduction, 
three chapters, and a step-by-step plan containing a personal value clarification worksheet and 
underwent four rounds of pilot testing and revisions. Risk communication and information about 
premature menopause and hormone replacement therapy were the most revised items. The patient 
decision aid fulfills 37 of 43 IPDAS criteria for content and development process. Effectiveness 
has not been evaluated yet. Both BRCA1/2 mutation carriers and professionals are willing to use 
or offer the patient decision aid for the choice between RRSO and salpingectomy with delayed 
oophorectomy. It has been found clear, balanced and comprehensible. Future testing among 
patients facing the decision should point out its effectiveness in improving decision-making.
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At last, the content of this thesis is discussed in broader sense in chapter 9. The main focus of 
this chapter is on the difficulty of estimating, interpreting, and personalizing cancer risks among 
BRCA1/2 mutation carriers. Besides, possibilities for early detection of ovarian carcinoma are passed 
in revue as well as other implications and suggestions for the future. 
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SAMENVATTING
Dit proefschrift gaat over een alternatieve methode om het risico op eierstokkanker van BRCA1/2 
mutatiedraagsters te verlagen. Zoals in hoofdstuk 1 beschreven, hebben deze vrouwen 
een verhoogd risico op eierstokkanker. Zij krijgen momenteel het advies om een eileider- en 
eierstokverwijdering (risicoreducerende salpingo-oöphorectomie (RRSO)) te ondergaan rond 
de leeftijd van 40 jaar. Een RRSO resulteert echter in het plotselinge begin van de (chirurgische) 
menopauze, hetgeen gevolgen heeft voor de gezondheid op korte en lange termijn. Om de kwaliteit 
van leven te verbeteren en de effecten van de vervroegde menopauze te verminderen, hebben 
we de mogelijkheid verkend van een eileiderverwijdering met uitgestelde eierstokverwijdering 
als alternatief voor RRSO. Hierbij wordt de eierstokfunctie langer behouden en daarmee wordt de 
overgang uitgesteld.
In hoofdstuk 2 hebben we de literatuur bestudeerd over de kwaliteit van leven van BRCA1/2 
mutatiedraagsters die (nog) geen kanker hebben gehad. We hebben gekeken hoe de kwaliteit 
van leven beïnvloed wordt door verschillende medische keuzes. In algemene zin vonden we dat 
de kwaliteit van leven niet verschilde van die van vrouwen uit de algemene populatie. Bovendien 
vonden we geen permanente verandering in kwaliteit van leven door hun keuze voor screening 
of risicoverlagende operaties. De vervroegde menopauze, veroorzaakt door RRSO, bleek echter de 
(menopauzegerelateerde) kwaliteit van leven het meest te beïnvloeden. Hormoontherapie kan 
de overgangsklachten niet altijd volledig wegnemen. Op basis daarvan concludeerden wij dat er 
een sterke behoefte is aan alternatieven voor RRSO om het risico op eierstokkanker te verlagen 
enerzijds en aan verbeteringen in begeleiding van patiënten na RRSO anderzijds, bijvoorbeeld op 
het gebied van hormoontherapie.
We hebben onderzocht hoeveel BRCA1/2 mutatiedraagsters uit het Radboudumc hebben gekozen 
voor RRSO in hoofdstuk 3, waarbij we ook hebben gekeken naar het moment waarop deze 
vrouwen de operatie ondergingen. Hiermee wilden we een beeld krijgen van het aantal vrouwen dat 
mogelijk te maken krijgt met de langetermijneffecten van de vervroegde menopauze. De huidige 
adviesleeftijd voor RRSO is tussen 35 en 40 jaar voor BRCA1 mutatiedraagsters en tussen 40 en 45 
jaar voor BRCA2 mutatiedraagsters. We hebben een retrospectief dossieronderzoek uitgevoerd in 
het Radboudumc naar BRCA1/2 mutatiedraagsters die gediagnosticeerd en gecounseld waren op 
onze multidisciplinaire polikliniek Familiaire Tumoren tussen 1999 en 2014. De gegevens van 580 
BRCA1/2 mutatiedraagsters konden worden geanalyseerd. We vonden dat 98,5% van de BRCA1 
mutatiedraagsters en 97,5% van de BRCA2 mutatiedraagsters, die ouder waren dan respectievelijk 
40 en 45, een RRSO hadden ondergaan. Het overgrote deel van de vrouwen, die hun mutatie 
wisten op de bovengenoemde adviesleeftijd, onderging de RRSO ook op de adviesleeftijd: 90,8% 
van de BRCA1 mutatiedraagsters vóór 41-jarige leeftijd en 97,3% van de BRCA2 mutatiedraagsters 
vóór 46-jarige leeftijd. Het merendeel van de BRCA1/2 mutatiedraagsters ondergaat de RRSO dus 
vóór de natuurlijke menopauze. Dit benadrukte nogmaals hoe belangrijk het is om manieren 
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te zoeken om de hormonale gevolgen van de vervroegde menopauze te minimaliseren door 
enerzijds hormoontherapie te optimaliseren en anderzijds een alternatief te vinden voor RRSO.
Ondanks RRSO krijgen sommige BRCA1/2 mutatiedraagsters alsnog buikvlieskanker. Buikvlieskanker 
valt ook onder de verzamelnaam ‘eierstokkanker’ en kan ook na een RRSO nog optreden aangezien 
het buikvlies bij een preventieve operatie niet kan worden verwijderd. In hoofdstuk 4 hebben we 
casus verzameld van BRCA1/2 mutatiedraagsters die inderdaad buikvlieskanker kregen, nadat zij al 
een risicoverlagende operatie hadden ondergaan (meestal RRSO). Voor dit hoofdstuk hebben we 
in de literatuur gezocht naar publicaties waarin één of meer van deze casus werden beschreven en 
we hebben desbetreffende auteurs gevraagd om aanvullende gegevens. Deze casus hebben we 
vergeleken met een controlegroep van BRCA1/2 mutatiedraagsters die tussen 2014 en 2016 een 
RRSO ondergingen in het Radboudumc. In totaal hebben we 36 casus vanuit de literatuur verzameld 
waarbij het in 31 gevallen ging om BRCA1 mutatiedraagsters (86,1%). De mediane leeftijd tijdens 
de risicoverlagende operatie was 52 jaar (spreiding 30-71 jaar) en de mediane leeftijd waarop 
buikvlieskanker werd vastgesteld was 60 jaar (spreiding 37-75 jaar). De mediane tijd die verstreek 
tussen de risicoverlagende operatie en de diagnose buikvlieskanker was 54,5 maand (spreiding 11-
292 maanden). Buikvlieskanker was meestal van het hooggradig sereuze type. Voor 8 casus waren 
de details over de volledig onderzochte eileiders beschikbaar: 5 hiervan (62,5%) toonden een 
sereus tubair intra-epitheliaal carcinoom (STIC), dat beschouwd wordt als een voorstadium van 
eierstokkanker. De eileiders van één casus hadden atypisch epitheel. De BRCA1/2 mutatiedraagsters 
die na een risicoverlagende operatie nog buikvlieskanker ontwikkelden waren significant ouder 
ten tijde van de ingreep en hadden meer STICs dan de vrouwen uit de controlegroep. We 
concludeerden dat buikvlieskanker na een risicoverlagende operatie vooral voorkomt bij BRCA1 
mutatiedraagsters, binnen 5 jaar. De gegevens suggereren dat RRSO op de adviesleeftijd leidt tot 
een lagere kans op buikvlieskanker nadien dan een RRSO op oudere leeftijd. De bevindingen van 
dit onderzoek kunnen ons helpen bij het voorlichten van BRCA1/2 mutatiedraagsters. Verder wordt 
het belang onderstreept van een volledige eileiderverwijdering tijdens de eierstokverwijdering en 
van het nauwkeurig microscopisch onderzoek van de verwijderde eileiders en eierstokken.
In verschillende publicaties wordt een alternatief voor RRSO gesuggereerd, bestaande uit 
een eileiderverwijdering met uitgestelde eierstokverwijdering. Over de beste manier om die 
alternatieve methode te onderzoeken bestond echter geen duidelijkheid. Wij hebben 39 BRCA1/2 
mutatiedraagsters en 23 zorgprofessionals van de poliklinieken Familiaire tumoren in Nederland 
om advies gevraagd hoe verder te gaan met het steeds duidelijkere bewijs dat eierstokkanker 
in de eileider ontstaat. Een belangrijke vraag was wat de gevolgen hiervan zouden kunnen zijn 
voor risicoverlagende operaties. In deze kwalitatieve studie, die wordt beschreven in hoofdstuk 5, 
hebben we barrières en faciliterende factoren voor de alternatieve methode en voor deelname 
aan een klinisch onderzoek geïnventariseerd. Dit werd gedaan tijdens focusgroepen en individuele 
semigestructureerde interviews. Voor de BRCA1/2 mutatiedraagsters waren de belangrijkste barrières 
voor eileiderverwijdering met uitgestelde eierstokverwijdering: de ernst van eierstokkanker, een 
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belaste familieanamnese en het gehad hebben van borstkanker. Voor professionals waren het 
uitstellen van het (vermeende) gunstige effect van RRSO op borstkanker en het ondergaan van 
twee operaties de belangrijkste barrières. Zowel BRCA1/2 mutatiedraagsters als de professionals 
vonden de onzekerheid over het risicoverlagende effect van de eileiderverwijdering en het feit 
dat vrouwen over het algemeen relatief makkelijk besluiten tot het ondergaan van een RRSO 
belangrijke barrières. De belangrijkste faciliterende factor die door beide groepen werd benoemd 
was de mogelijkheid tot het uitstellen van de menopauze. Ten aanzien van deelname aan een 
klinisch onderzoek naar de alternatieve methode, gaven BRCA1/2 mutatiedraagsters aan dat een 
gerandomiseerde onderzoeksopzet, waarin het type behandeling wordt bepaald door loting, een 
reden zou zijn om zeker niet deel te nemen. Volgens de zorgprofessionals waren er twee factoren 
die faciliterend zouden kunnen werken: landelijk een uniforme manier van voorlichten en de 
bereidheid van BRCA1/2 mutatiedraagsters om deel te nemen aan wetenschappelijke onderzoeken. 
De meeste BRCA1/2 mutatiedraagsters en zorgprofessionals waren bereid om deelname aan zo’n 
niet-gerandomiseerd onderzoek te overwegen.
Om het risico op eierstokkanker zo goed mogelijk in te schatten, hebben we een model gemaakt 
voor het risico na de eileiderverwijdering en latere eierstokverwijdering op verschillende leeftijden 
en dat vergeleken met het risico na RRSO. Deze schattingen worden beschreven in hoofdstuk 6. 
Het Cox proportional hazard model hebben we gebaseerd op gegevens uit de literatuur. Het 
geschatte eierstokkankerrisico tot de leeftijd van 70 jaar voor de alternatieve methode was 
het hoogst voor BRCA1 mutatiedraagsters die beide operaties (eileiderverwijdering en latere 
eierstokverwijdering) op hogere leeftijd ondergaan. De grootste toename van het geschatte risico 
(puntschatting van 1,8% naar 4,1%) werd gevonden voor een 40-jarige BRCA1 mutatiedraagster 
die zou kiezen voor eierstokverwijdering op 45-jarige leeftijd na een eerdere eileiderverwijdering 
die geen beschermend effect had, in plaats van een RRSO op 40-jarige leeftijd. In het beste geval, 
uitgaande van 65% risicoverlaging door de eileiderverwijdering en 96% risicoverlaging door de 
RRSO, zouden de puntschattingen van het cumulatief risico iets stijgen (van 1,8% naar 2,6%) of 
dalen (van 3,4% naar 3,3%), afhankelijk van de leeftijd. Voor een 45-jarige BRCA2 mutatiedraagster 
stijgt de puntschatting van het cumulatief risico in het slechtste geval van 0,6% naar 1,8% 
indien zij op 50-jarige leeftijd de uitgestelde eierstokverwijdering ondergaat na een ineffectieve 
eileiderverwijdering in plaats van een RRSO op 45-jarige leeftijd. In het beste geval stijgen (van 
1,3 naar 1,5%) of dalen (van 1,5% naar 1,3%) de puntschattingen gering, afhankelijk van de leeftijd. 
We concludeerden dat de verschillen in het geschatte risico op eierstokkanker tussen RRSO en 
eileiderverwijdering met uitgestelde eierstokverwijdering klein zijn, zelfs als de eileiderverwijdering 
het risico op eierstokkanker niet verlaagt.
De bevindingen uit de voorgaande hoofdstukken hebben geresulteerd in de opzet van een klinisch 
onderzoek, de TUBA studie: “Early salpingectomy (TUbectomy) with delayed oophorectomy 
to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 
mutation carriers”. De samenvatting van het onderzoeksprotocol vormt hoofdstuk 7. Sinds januari 
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2015 kunnen BRCA1/2 mutatiedraagsters meedoen aan dit multicenter, niet-gerandomiseerde 
onderzoek in 11 Nederlandse ziekenhuizen met een polikliniek Familiaire tumoren. BRCA1/2 
mutatiedraagsters kunnen meedoen aan de TUBA studie als zij premenopauzaal zijn, hun 
kinderwens voltooid hebben en geen eierstokkanker hebben (gehad). Deelneemsters maken zelf de 
keuze voor hetzij de standaard RRSO op de adviesleeftijd (35-40 jaar voor BRCA1 mutatiedraagsters 
en 40-45 jaar voor BRCA2 mutatiedraagsters), hetzij de alternatieve methode (eileiderverwijdering 
na het voltooien van de kinderwens met uitgestelde eierstokverwijdering tussen 40-45 jaar 
(BRCA1) of tussen 45-50 jaar (BRCA2)). Vrouwen die kiezen voor een eileiderverwijdering, maar de 
eierstokverwijdering niet willen uitstellen tot voorbij de adviesleeftijd, kunnen ook deelnemen 
aan het onderzoek. Menopauzegerelateerde kwaliteit van leven is de primaire uitkomstmaat. De 
incidentie van borst- en eierstokkanker, complicaties rondom de operaties, histopathologisch 
onderzoek van de verwijderde weefsels, risicofactoren op en incidentie van hart- en vaatziekten, 
en kosteneffectiviteit zijn secundaire uitkomstmaten. 
Het maken van de keuze tussen de standaard RRSO en eileiderverwijdering met uitgestelde 
eierstokverwijdering kan zeer complex zijn. Om dit keuzeproces te ondersteunen hebben we een 
papieren keuzehulp ontwikkeld waarin wetenschappelijk bewijs gecombineerd wordt met de 
voorkeuren van de patiënt (hoofdstuk 8). De keuzehulp is op systematische wijze ontwikkeld 
door middel van een herhaaldelijk proces van ontwikkelen, testen door patiënten en artsen, en 
reviseren. De informatie in de keuzehulp is gebaseerd op de literatuur en bestaande richtlijnen. 
Bij de ontwikkeling zijn de IPDAS criteria (International Patient Decision Aid Standards) leidend 
geweest en dit ontwikkelingsproces werd gesuperviseerd door een multidisciplinaire stuurgroep. 
Uiteindelijk zijn er twee keuzehulpen tot stand gekomen: één voor BRCA1 en één voor BRCA2. Beide 
bestaan uit een algemene inleiding, drie hoofdstukken en een stappenplan met een werkblad om 
de persoonlijke voorkeuren van de gebruiker te verhelderen. In totaal zijn er vier rondes van testen 
en reviseren doorlopen. Risicocommunicatie en de informatie over de vroegtijdige overgang en 
hormoontherapie waren de onderwerpen die het meest gereviseerd werden. De uiteindelijke 
keuzehulpen voldoen aan 37 van de 43 IPDAS criteria voor de inhoud en het ontwikkelingsproces. 
De effectiviteit is nog niet onderzocht. Zowel BRCA1/2 mutatiedraagsters als de artsen die 
meededen in de testrondes waren bereid om de keuzehulpen te gaan gebruiken. Ze werden als 
duidelijk, gebalanceerd en begrijpelijk bestempeld. De volgende stap zal zijn om de keuzehulpen 
aan te bieden aan BRCA1/2 mutatiedraagsters, die inderdaad voor de keuze staan tussen RRSO en 
eileiderverwijdering met uitgestelde eierstokverwijdering, en te evalueren in hoeverre het gebruik 
van deze keuzehulpen inderdaad de besluitvorming verbetert.
Tot slot wordt in hoofdstuk 9 de inhoud van dit proefschrift in bredere zin bediscussieerd. Dit 
hoofdstuk richt zich vooral op de complexiteit van het schatten, interpreteren en individualiseren 
van de kankerrisico’s van BRCA1/2 mutatiedraagsters. Verder worden mogelijkheden van vroege 
opsporing van eierstokkanker kort besproken, evenals andere suggesties voor toekomstig 
onderzoek. 
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Mijn proefschrift is af! Uiteraard heb ik dit niet alleen gedaan en ik wil een ieder die een bijdrage 
heeft geleverd heel hartelijk danken. 
Allereerst wil ik graag de BRCA1/2 mutatiedraagsters bedanken die geheel belangeloos bereid 
waren om vanuit huis of in het Radboudumc mee te denken over de rol van de tubectomie, de 
opzet van de TUBA studie, de patiënteninformatie en/of de keuzehulp. Ook de input van de patient 
advocates van Borstkankervereniging Nederland was zeer waardevol, waarvoor dank. Alle vrouwen 
die meedoen aan de TUBA studie: hartelijk dank voor jullie interesse en deelname!
Zonder goede begeleiding komt er geen proefschrift: wat heb ik het getroffen met mijn vierkoppige 
promotieteam! Prof.dr. L.F.A.G. Massuger, beste Leon, ik denk dat er weinig mensen zijn, die een 
vergelijkbaar drukke baan hebben en het toch presteren om de hele dag fluitend en neuriënd 
rond te lopen! Overigens weet je daardoor wel altijd wanneer je in de buurt bent en dus wanneer 
er even snel een handtekening gescoord kan worden of wanneer je kunt proberen illegaal in te 
breken in je overvolle agenda. Ik heb bewondering voor je kennis, rust, daadkracht en creativiteit. 
Met je kritische blik wist je de vinger vaak op de zere plek te leggen en projecten tijdig bij te sturen. 
Ik wil je enorm bedanken voor je vertrouwen.
Prof.dr. N. Hoogerbrugge, beste Nicoline, ik bewonder je bevlogenheid waarmee je probeert zo 
veel mogelijk mensen met erfelijke aanleg voor kanker op te sporen en de zorg voor deze populatie 
te verbeteren. Als een artikel focus miste, wist jij mij met enkele opmerkingen de boodschap 
weer helder te laten krijgen door terug te gaan naar de basis. Dit leidde altijd tot een veel betere 
volgende versie, waarvoor ik je wil bedanken. Daarnaast hebben we ook meermaals hard gelachen. 
De treinrit naar Schiphol op weg naar het BRCA symposium in Montreal is me daarvan het meest 
bijgebleven: een Katja Apenkop zal nooit meer hetzelfde zijn! 
Dr. J.A. de Hullu, beste Joanne, een ding is duidelijk: zonder jou was dit proefschrift er nooit 
geweest. Wat ben jij een voorbeeld voor mij! Alles lijkt bij jou op de eerste plaats te komen: familie, 
patiëntenzorg, onderzoek, sport, maar zeker ook het wel en wee van je promovendi. Hoe je dit 
alles weet te combineren is mij een raadsel, maar ik kan er alleen maar oneindig veel respect voor 
hebben en hopen dat ik dat ook kan “als ik later groot ben”, al is het maar half zo goed. Verder kunnen 
niet veel promovendi zeggen dat ze met “de baas” vijf dagen in een Airbnb hebben doorgebracht 
met maar één huissleutel, maar wat was het ontspannen (op het half uurtje loopband op de eerste 
dag na…). Bedankt dat je me deze kans hebt geboden en nog veel meer dank voor het grenzeloze 
vertrouwen en de persoonlijke interesse die je vanaf de eerste dag in mij hebt gehad, je bent goud 
waard!
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Dr. R.P.M.G. Hermens, beste Rosella, jouw expertise vanuit een hele andere hoek was een zeer 
welkome aanvulling op het team. Pogingen om ergens niet over uit te weiden of “overheen te 
schrijven” sneuvelden steevast als jij het stuk onder ogen kreeg en daarnaast bracht jij altijd de 
structuur terug in een artikel. Onze afspraken (als ze in je agenda stonden tenminste ;-)) waren 
constructief en efficiënt, waardoor er ook genoeg tijd overbleef voor een lolletje. Door de 
vakantiefoto’s en kleine of grotere overwinningen die gedeeld werden in de TUBA groepsapp 
bleven we goed van elkaar op de hoogte. Hartstikke bedankt voor alles!
Beste Marieke, doordat jij een tweede persoon zocht voor het coderen en analyseren van de 
interviews en focusgroepen uit hoofdstuk 5, ben ik in dit onderzoek gerold. Mede door al jouw 
voorwerk, heb ik een zeer voorspoedig promotietraject gehad. Hiervoor ben ik je eeuwig dankbaar!
Lieve Christel, wat een ongekende luxe om als arts-onderzoeker samen te mogen werken met 
een research verpleegkundige, want wat heb jij mij ongelooflijk veel werk uit handen genomen! 
Zonder al jouw werk voor de TUBA studie, zou nog niet de helft van dit proefschrift nu klaar zijn. 
Daarnaast was het gewoon ook altijd leuk om bij te kletsen in de auto, samen te zeuren over alle 
regelgeving, oplossingen te bedenken voor allerlei grote en kleine problemen en het land door te 
crossen naar al onze tijdelijke werkgevers. Dankjewel!
Uiteraard wil ik alle medeauteurs bedanken die hun bijdrage hebben geleverd aan een of meerdere 
hoofdstukken van dit proefschrift. Dr. J.M.J. Piek, beste Jurgen, het is een eer om zo nauw samen 
te werken met degene die ruim 15 jaar geleden de tuba voor het eerst aanwees als mogelijke 
boosdoener in het ontstaan van eierstokkanker bij BRCA1/2 mutatiedraagsters. Ik ben benieuwd of 
ik hier net zo’n “tubafetisj” aan overhoud als jij! Dr. J. in ’t Hout, beste Joanna, zonder jouw statistische 
expertise was hoofdstuk 6 er niet geweest, dankjewel!
Ook al zullen de resultaten van de TUBA studie nog even op zich laten wachten, ik wil toch graag 
alle lokale onderzoekers van de deelnemende centra bedanken voor alle tijd die jullie er tot nu 
toe al in hebben gestopt. Hierbij gaat mijn dank natuurlijk minstens zo veel uit naar alle betrokken 
research verpleegkundigen en verpleegkundig specialisten die veel werk verzetten voor de TUBA 
studie, evenals naar de pathologen die de preparaten nauwkeurig bekijken en naar de klinisch 
genetici die het bestaan van de studie noemen tijdens hun counseling. Ik kan niet wachten tot de 
resultaten er zijn!  
Beste gynaecologisch oncologen van het Radboudumc, heel hartelijk dank voor het counselen 
en includeren van patiënten voor de TUBA studie, alsmede voor het uitvoeren van de extra 
handelingen die van jullie worden gevraagd tijdens de laparoscopieën. Beste Bertho, dankjewel 
voor je inzet voor het project waarmee ik bijkluste bij de benigne gyn, hopelijk komen daar ook 
mooie resultaten uit (en natuurlijk minstens zoveel dank voor de recordpogingen op de skipiste). 
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Lieve dames van het secretariaat: dank voor jullie ondersteuning. Yvonne, Els, Wilma en Ans, jullie 
maken het leven van een onderzoeker net een beetje makkelijker!
Beste gynaecologen, assistenten, verloskundigen en verpleegkundigen uit het Rijnstate ziekenhuis, 
mede door jullie is mijn enthousiasme voor het vak na mijn studie verder aangewakkerd. Ik heb dan 
ook heel veel zin om dit najaar weer terug te komen en hopelijk beland ik dan weer in datzelfde 
warme bad (met Zwitsal) als waar ik in juni 2014 letterlijk uitklom. 
Lieve “Rijnstatematties”, wat heb ik genoten van onze 3-gangendiners de afgelopen jaren! Door 
alle verhalen (en veel oude koeien) had ik tijdens die etentjes toch nog het gevoel een beetje in 
de kliniek te zitten.
Lieve (ex-)tuinbewoners, niets is zo belangrijk als leuke collega’s! Jullie waren de belangrijkste reden 
dat ik niet deed aan “thuiswerken” en zonder jullie had mijn onderzoekstijd er heel anders uitgezien. 
Bedankt voor alle theemomentjes, lunches, vrijmibo’s, weekendjes, (water)skitripjes, pubquizzen, 
sushidiners, (vierdaagse)feestjes, (extended) congressen etcetera. Jullie zijn top! Lieve Michelle, de 
Radboudumc server zal het moeilijk gehad hebben met de hoeveelheid e-mails die wij elkaar per 
dag stuurden terwijl we zo’n acht meter van elkaar af zaten. Daarbuiten ging de communicatie 
meestal in hetzelfde tempo door via WhatsApp. Kortom, wat hebben wij de afgelopen 2,5 jaar veel 
gedeeld en dan laat ik alle gedeelde bedden nog buiten beschouwing: Nederlandse, Oostenrijkse, 
Franse, Portugese, Colombiaanse… Gelukkig gaan we elkaar nog veel zien! 
Lieve Gang, ongelooflijk dat we alweer 13 jaar geleden van school gingen. Gaaf dat er inmiddels 
een volledige minigang is en dat we elkaar af en toe nog zien. We zijn een bijzonder clubje! Lieve 
Gies, ik ken weinig mensen die zo kunnen stralen als jij! Knap hoe je weet te kiezen vanuit jezelf en 
voor dingen waar je blij van wordt. Ik koester onze memorabele stapavondjes die meestal eindigen 
in een zeer dubieuze kroeg, maar ook onze saunatraditie met Roos. Laten we er nog vele jaren aan 
vastplakken, je bent een schat! Lieve Roos, wat verschillen wij van elkaar! Wellicht is dat de kracht 
van onze vriendschap die op de basisschool nog wat wisselvallig was, maar vanaf de brugklas 
alleen maar beter werd. Van jou heb ik geleerd dat niets onmogelijk is en met jou is het nooit saai. 
Van samen GoGo bellen tot onszelf uitnodigen op de after party van de Boliviaanse equivalent van 
the Stones: het gebeurt alleen als jij erbij bent. Dankjewel voor wie je bent!
Lieve Ranger ladies, wat zijn jullie toch leuk! Ik ben blij dat jullie mij al twee jaar in jullie 
studententeam gedogen en dat we een paar keer per week met z’n allen de mooiste sport ter 
wereld kunnen beoefenen, maar ook dat we veel leuke teamuitjes en Rangerborrels hebben. Lieve 
Mien en Rens, jammer dat ik te ver weg woon om nog samen met jullie te softballen, maar ik 
koester onze vriendschap waarvoor we circa drie keer per week gedurende bijna 10 jaar een goede 
basis hebben gelegd!
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Lieve Bruutjes, dat we als club na bijna 13 jaar af en toe nog compleet zijn, vind ik echt heel 
bijzonder! Op naar de volgende life events en wanneer mogen we weer op lustrumreis? Lieve Val, 
wat kom ik graag bij jullie over de vloer en wat ben jij een held! Lieve Lou, ook al is Zwitserland niet 
naast de deur, als wij elkaar na maanden/jaren weer zien, is het gelijk goed! Lieve Celine, fijn dat we 
allebei in Nijmegen wonen!
Lieve paranimfen, waar het organiseren van een assistentenweekend allemaal niet toe kan leiden! 
Na alle etentjes en borrels met z’n drieën was de keuze voor mijn paranimfen snel gemaakt. 
Lieve Yalckie, wat keek ik tegen jou op toen ik een maand na jou in het Rijnstate begon, want “jij 
kon al zo veel”! Sindsdien zijn we ruim vijf jaar naaste collega’s geweest, maar wisten we elkaar 
gelukkig ook buiten het ziekenhuis vaak te vinden (doorgaans bij Samson of Anneke…). Lieve 
Thijs, wat is het toch fijn dat jij zo eerlijk en direct ben, geen onderwerp onbesproken laat (ook 
alvorens de Karmeliet Tripels inslaan) en ook zo houdt van een terrasje in de zon. Lieverds, laten we 
Assistentenweekend Volendam 2014 nog lang blijven evalueren!
Lieve opa en oma Harmsen, ik vind het ongelooflijk bijzonder dat jullie het gereedkomen van mijn 
proefschrift nog mogen meemaken. Ik heb veel bewondering voor jullie en geniet nog altijd van 
jullie prachtige verhalen over vroeger.
En tot slot, wie of wat zou ik zijn zonder het fantastische gezin waar ik uit kom? Lieve Joep, super 
mooi om te zien hoe snel jij carrière aan het maken bent in de Amsterdamse ziekenhuizen! Wij 
begrijpen elkaars humor als geen ander en ik waardeer je creativiteit, handigheid en gastvrijheid 
met bijbehorende kookkunsten (als ik weer eens een slaapplaats zoek in Amsterdam bijvoorbeeld). 
Ik zeg altijd vol trots dat ik een grote broer heb! Lieve Jud, ik zou me geen leuker, slimmer, gezelliger 
en grappiger schoonzusje kunnen wensen. Het is altijd leuker als jij erbij bent! Liefste pap en 
mam, jullie zijn de belangrijkste personen in mijn leven en ik zou mij geen betere ouders kunnen 
bedenken. Jullie onvoorwaardelijke emotionele steun ervaar ik in alles, maar ook de praktische 
ondersteuning die jullie me nog vaak bieden is goud waard. Ik zou niet weten wat ik zonder jullie 
moest en mijn dankbaarheid voor alles wat jullie voor me doen en gedaan hebben is eigenlijk niet 
in woorden uit te drukken. Ik houd van jullie!
